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ABSTRACT
In Vitro Molecular Modification of Human Cultured and Primary Cells
Using Lance Array Nanoinjection
John W. Sessions
Department of Mechanical Engineering, BYU
Doctor of Philosophy
Fundamentally altering cellular function at a genetic level is a major area of interest in the
biologic sciences and the medical community. By engineering transfectable constructs that can
be inserted to dysfunctional cellular systems, scientists can mitigate aberrant genetic behavior to
produce proper molecular function. While viral vectors have been a mainstay in the past, there are
many limitations, particularly related to safety, that have changed the focus of genome editing to
incorporate alternative methods for gene delivery.
Lance Array Nanoinjection (LAN), a second-generation microfabricated transfection biotechnology, is one of these alternative technologies. LAN works by utilizing both simultaneous electrostatic interaction with molecular loads and physical lancing of hundreds of thousands of target
cell membranes. The purpose of this work is to demonstrate LAN in the context of in vitro transfection of immortalized culture cells and primary cells. As part of that exploration, three distinct areas
of investigation are considered, which include: characterizing environmental factors that impact
LAN transfection, demonstrating LAN genetic modification of immortalized HeLa 229 culture
cells using an indicator marker, and lastly, investigating the effects of LAN on human primary,
neonatal fibroblasts.

Keywords: Lance Array Nanoinjection, saline solution, lance geometry, carbon coating, transient
low temperature, injection speed, serial injection, propidium iodide, CRISPR-Cas9, primary fibroblast, PDGFR-β , wound healing
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CHAPTER 1.

1.1

INTRODUCTION TO GENE THERAPY AND GENE MEDICINE

Motivation
Gene therapy and gene medicine approaches to correcting disease represent a major paradigm

shift in how clinicians are able to help patients, moving from a framework of reactionary treatment
of disease manifestations to fundamental, proactive prevention of disease when genetic alterations
are causative [1–3]. While still in a relatively early stage of development, medical approaches designed to engineer genetic outcomes have had promising results in terms of both monogenic [4–11]
and polygenic [12–17] disease corrections.
Unfortunately, the actual method for transmission of the genetic loads to target cells remains a challenge [18–21]. Many biotechnologies have been created to help address this issue
(with mixed results) [22]. The primary goal of all of these methods is to site-direct genetic loads
into cells without harming the host systemically or the target cell locally [18]. Key features frequently noted as critical design requirements for these biotechnologies include:
• High transfection efficiency
• Effective in a wide range of cell types
• Flexible pay load capacity
• No immunologic response
• No insertional mutagenesis

1.2

Problem Statement/Hypothesis
One non-viral transfection biotechnology, known as Lance Array Nanoinjection (LAN),

has been created with these design requirements in mind. LAN works by using a combination of
1

physical penetration of target cell membranes and electrical delivery of molecular loads using a
microfabricated silicon etched array of lances [23, 24]. Lance arrays contain 10 µm length lances
spaced 10 µm from center to center in a grid pattern, ultimately forming 4 million lances on a 2
cm by 2 cm chip.
Procedurally, nanoinjection works in a series of four major steps which include: staging the
lance in the solution containing the desired molecular load, electrical attraction of the molecular
load onto the lance, physical penetration of the cell membrane of target cells and electrical repulsion of the molecular load into the cytoplasmic space, and finally removal of the lance [25–27].
There are several attractive features of LAN relative to other transfection methods. First, it
does not rely on delivery agents that can cross-react with the immune system (such is the case with
several viruses [28–32]), nor does it create cytotoxic effects in target cells (such is the case with
many chemical based methods [22, 28]). Second, because the lances are 1-2.5 µm in diameter, the
resulting pores created during the injection event are relatively large, making it possible for large
molecules to transiently pass into the cell. Even though the pores are relatively large, the trauma
induced during the process is relatively minimal, as evidenced by high cell viability rates (78% to
91%) previously noted [24]. This latter feature of cell viability is an issue in some instrumentation
based transfection methods, such as electroporation [33] and microinjection [25].
The research here presents the results of in vitro molecular modification of culture and primary cells by Lance Array Nanoinjection (LAN). Formally stated, the hypothesis of this research
is:
It is hypothesized that using an array of silicon etched lances in a process known as nanoinjection, molecular loads, such as propidium iodide and DNA, can be placed into the intracellular
space of both cultured and primary cell types via electrical interaction. Furthermore, it is also
hypothesized that these modifications will be both non-threatening to target cells viability as well
as efficient in terms of expression.
In an effort to explore this hypothesis, three major objectives have been created which include:
1. Characterize environmental factors that impact transfection efficiency
2. Demonstrate LAN genetic modification of immortalized HeLa culture cells using an indicator marker
2

3. Investigate the effects of LAN genetic modification of human primary, neonatal fibroblasts
This chapter provides background information on transfection technologies and also gives
a brief overview of the approaches used to support these research objectives and the contributions
made in the form of publications.

1.3
1.3.1

Background
LAN in the Context of Transfection Technologies
Traditionally, viruses have been the benchmark for which transfection efficiency is mea-

sured. However, they fall short of meeting critical design requirements for robust transfection
(as detailed above), particularly in preparation for clinical application. Adenoviruses, Adenoassociated viruses, and lentiviruses are all considered to have high transfection rates in a wide range
of cell types [30, 34–42]. Unfortunately, adenoviruses are immunologically inflammatory which
can be life-threatening [29, 43], adeno-associated viruses can cause insertional mutagenesis which
can be cytotoxic [35,36], and lentiviruses cause immunologic responses and insertional mutagenesis [30–32, 44]. While retroviruses are useful in CNS (central nervous system) targets [37, 45], the
risk of insertional mutagenesis is quite high [37,46]. Furthermore, viruses in general are limited in
their effectiveness because of the limited payload capacity (≤ 10 kilo base pairs (kbp)) [37].
In contrast, LAN is able to by-pass many of these short-comings. First, LAN does not
utilize protein vehicles which could cross-react with the immune system, thereby removing immunologic response issues. Second, LAN creates relatively large pores in target cells (1-2 µm
diameter), allowing for large molecular loads to enter, thus reducing the concern of not having sufficient payload capacity. Third, LAN is compatible with gene editing tools such as CRISPR-Cas9
that mitigate concerns regarding insertional mutagenesis. While the same can be said of viruses
if re-programmed to remove self-insertional mechanisms, LAN does not have the same rigor of
testing to go through prior to use as viral delivery because insertional mutagenesis in the context of
LAN is only an element directly related to the molecular load type, not LAN as a delivery method.
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1.3.2

Previous Nanoinjection Works
In order to place context to the proposed LAN based research for culture and primary cells,

a brief overview of previous foundational works is presented.

Single Lance Nanoinjection
Initial development of the Nanoinjection concept began at Brigham Young University in
2007 where researchers developed a method for exogenous DNA delivery to mouse embryonic
cells via a solid, microfabricated lance. This process became known as ‘nanoinjection’ and is
described as electrical attraction of molecular elements such as DNA onto a micron-sized needle
structure, inserting the needle through the target cell membrane, and then electrically repelling the
molecular load into the pronucleus to be integrated during pro-nuclei disintegration and nuclear
formation events [25, 47]. Subsequent work showed effects of voltage pulsing while the lance is
inserted in the embryo, allowing for a phenomena known as intracellular electroporetic nanoinjection, which is a localized transient pore formation event in the pronucleus allowing molecular
loads to enter [27].

Lance Array Nanoinjection
More recently, researchers have modified the single lance nanoinjector to be an array of
10 micron-length lances capable of nanoinjecting hundreds of thousands of cells simultaneously
[24, 25, 48]. The biologic application for the design change reflects the fact that these lance arrays
can molecularly modify somatic, adherent cell types–a critical distinction from the embryonic
target cells used previously.

Electrical Modelling
Previous research involving the Single Lance Nanoinjector helped to characterize and model
the electrostatic attraction and repulsion of DNA to the device [26, 49, 50] and an extension of this
work has been conducted for LAN [51, 52]. The rationale behind this effort deals with the need
to model molecular load delivery based on electrical pulse levels. Based on conclusions derived
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from these works, it has been theorized that much lower voltages (i.e. 1.5V) are required to provide molecular delivery than traditional electroporation transfection protocols (typical kV), which
suffer from low cell viability rates as a result of high voltage exposure.

Early Biologic Testing
Mechanistic evaluation of LAN has also been performed, with initial testing with propidium iodide (PI), a dye normally impermeable to the cell membrane [24, 53]. In these experiments,
it has been shown that following LAN that HeLa target cells have elevated levels of propidium
iodide, manifested by increase fluorescence during flow cytometry.

Current Status of LAN
As mentioned previously, LAN development hinges upon in vitro transfection of target
cells. While previous work has provided key foundational elements to this end, full investigation
of in vitro modification of both immortalized culture cells and primary cells is the focus of this
work.

1.4

Research Approach/Literature Contributions
The sequential approach to establishing LAN in culture and primary cells can be compart-

mentalized broadly into the three major objectives outlined in this chapter. Discussed briefly here
are supporting research topics that explore these objectives.

1.4.1

Objective 1: Characterize environmental factors that impact molecular load delivery
Chapter 2 investigates the effects of three different saline solutions on propidium iodide up-

take in nanoinjected HeLa cells. The body of this chapter comes from a conference paper presented
at the 2014 International Design Engineering Technical Conference in Buffalo, NY.
Chapter 3 investigates the effect of lance geometry and carbon coating of silicon lances
on propidium iodide uptake in Lance Array Nanoinjection of HeLa 229 cells. The body of this
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chapter comes from a journal article accepted for publication in the Journal of Micromechanics
and Microengineering.
Chapter 4 investigates the effects of transient low temperature on propidium iodide uptake
in Lance Array Nanoinjected HeLa cells. The body of this chapter comes from a journal article
submitted to the Journal of Nanotechnology in Engineering and Medicine.
Chapter 5 investigates the effect of injection speed and serial injection on propidium iodide
entry into cultured HeLa and primary neonatal fibroblast cells using Lance Array Nanoinjection.
The body of this chapter comes from a journal article submitted to SpringerPlus.

1.4.2

Objective 2: Demonstrate LAN genetic modification of immortalized HeLa culture
cells using an indicator marker
Chapter 6 investigates the effect of a CRISPR-Cas9 plasmid designed to knock-out consti-

tutively expressed GFP in HeLa cells using Lance Array Nanoinjection. The body of this chapter
comes from a journal article submitted to SpringerPlus.

1.4.3

Objective 3: Investigate the effects of LAN genetic modification of human primary,
neonatal fibroblasts
Chapter 7 comprises a combination of two review journal articles that is included to provide

a context to chronic wound healing, particularly in regards to the platelet derived growth factor
receptor β (PDGFR-β ) and genetic engineering. The first portion of the chapter was derived from
a paper published in the Journal of Diabetes Science and Technology. The second portion of the
chapter was derived from a paper submitted to Experimental Dermatology.
Chapter 8 investigates the ability of LAN to deliver a CRISPR-Cas9 plasmid to primary,
neonatal fibroblasts using Lance Array Nanoinjection. This plasmid is designed to up-regulate
PDGFR-β in the fibroblasts. This work is designed as a proof-of-concept work that demonstrates
a clinically relevant application of LAN in conjunction with chronic wound healing. The body of
this chapter comes from a journal article submitted to PLoS ONE.
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1.5

Summary of Presented Research
The final chapter, Chapter 9, provides a brief survey of salient results of the research pre-

sented. As part of this chapter, a short discussion will be devoted to highlighting why these findings
are important as well as provide a context for potential future work.
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CHAPTER 2.

SALINE SOLUTION EFFECTS ON PROPIDIUM IODIDE UPTAKE

The following chapter was constructed from a conference paper that was presented at the 2014
International Design Engineering Technical Conference (Buffalo, NY) and is entitled “Saline Solution Effects on Propidium Iodide Uptake in Nanoinjected HeLa Cells” [54]. As a result, there
may be some material that is contained elsewhere in this dissertation but is presented here as a
representation of this original conference article.

2.1

Introduction
Genetic engineering of various mammalian target cells has become a new frontier in medicine.

Researchers are actively investigating the efficacy of modifying disease states that include but are
not limited to: joint erosive arthritis [55], intervertebral disc degeneration [55], aseptic orthopedic
implant loosening [55–57], osteoporosis [55], soft tissue repair (cartilage, tendon, ligament) [55],
bone healing [55, 58–60], ventricular arrhythmia [61], congestive heart failure [62], chronic diabetic wounds [63–68], incisional scar formation [69, 70], psoriatic skin disorders [71], hereditary
blood disorders [72], etc. Because genetic engineering aims to control aberrant function or improve existing function at the fundamental cellular level, there is potential to significantly impact
patient healthcare by improving genetic engineering technologies.
However, the process of introducing exogenous genetic material into a mammalian cell is
not trivial but rather multi-step and highly complex [73,74]. One of the initial barriers to exogenous
molecular load delivery is introducing molecular loads into the cytoplasm without compromising
the structural and functional integrity of the cell.
Traditionally, genetic reprogramming techniques have sought to penetrate and integrate
molecular loads into target cells using one of two major methods: viral [75, 76] and non-viral
[71, 77, 78]. Viral methodologies generally consist of using a viral vector programmed with a
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specific genetic sequence. Once engineered, these viral particles are allowed to infect targeted
tissues.
Unfortunately, viral gene therapy techniques have several challenges that limit clinical use.
These limitations to viral gene therapy include issues related to immunologic safety, virus containment to targeted tissues, vector production costs, limits to the amount of genetic load capacity of
the virus, and production containment and safety [59]. Furthermore, within the medical culture,
major barriers exist for viral method acceptance (despite their benchmark efficiencies) because of
a tainted safety history. For example, French clinical trials in treating X-linked Severe Combined
Immunodeficiency with a murine viral vector initially proved successful in creating functional immune systems in nine of ten treated patients. However, 3 of the ten developed leukemia and one
died [79].
Because of these limitations with viral based genetic engineering, researchers have put
considerable effort into generating alternate, non-viral methods for gene delivery. Currently, there
are several combinations of physical delivery applications practiced. Characteristically, physical
methods of exogenous genetic delivery use either physical or chemical approaches for delivery.
Two of those most common approaches include lipofection [77] and some form of electroporation
[74, 78, 80]. Lipofection, in short, consists of lipophilic molecules that encapsulate a molecular
load, such as DNA, in the extra-cellular space and transport the load to the intracellular space
because of the cell membrane’s permeability to lipophilic molecules. Electroporation operates by
applying an external electrical field to the cell and consequently causing formation of transient
pores that allows for extracellular molecules to pass into the cell. Both techniques have intrinsic
limitations that can be tied to the fact that they can cause significant compromise to the cell and
consequently produce lower cell viability, an undesired outcome for clinical use.
Recently, researchers have demonstrated an alternative, non-viral technique for molecular
load delivery called nanoinjection [26]. Nanoinjection is a process described as electrical attraction
of a molecular loads onto a micron-sized needle structure, inserting the needle through the cell
membrane, and then electrically repulsing the molecular load into the cytoplasm. This process,
using a single lance nanoinjector, has been used successfully in transgenic mice generation [25].
More recent modifications to the nanoinjection process include modifying the single lance
injector to be an array of 10 µm-length nanoinjector needles capable of nanoinjecting thousands
9

of cells simultaneously [81]. HeLa cell studies have illustrated that nanoinjection can effectively
deliver propidium iodide into target cells without compromising cell viability [24].
The present research seeks to extend previous work related to nanoinjection by examining two environmental factors, namely saline injection solution type and peak pulse amplitude,
that contribute to propidium iodide delivery into HeLa cells. Previous examination by other researchers [82] have demonstrated in electroporation studies, that solutions with increasing potassium (K+ ) require higher electrical field strengths to induce electroporation, a transient biological
response where pores form in the cell membrane. The rationale for this finding is that when a
cell, which has a transmembrane potential (Vm ), is exposed to an electrical field, the anodic side
of the cell membrane is first to reach a Vm = 0, at which point pores can begin to form. If the extracellular environment contains increasing amounts of K+ , then the voltage magnitudes at which
this behavior can initiate are greater. Since cell viability decreases with higher voltage application in electroporation, it is desirable to know in the context of nanoinjection if at lower voltages
comparable PI uptake can occur by simply using a different injection solution.

2.2
2.2.1

Methods
Lance Array Fabrication and Injection Device
Silicon lance arrays were photolithographically defined and etched using DRIE (deep re-

active ion etching). Following etching, the silicon was coated in a 0.5 µm thick layer of carbon
using chemical vapor deposition (CVD). Lances measure 1-1.5 µm in diameter and 8-10 µm in
length and are spaced at 10 µm. The silicon wafer is then cut into 2 cm by 2 cm square chips, each
containing roughly 4 million lances [81] (see Figure 2.1).
The injection device consists of an orthoplanar spring [83,84], fabricated with acrylonitrile
butadiene styrene (ABS) plastic using rapid prototyping, that has attached at its base with double
sided carbon tape the carbon coated silicon chip described above. Two electrical components are
housed within the orthoplanar device: gold contacts located at the interface between the orthoplanar spring and the carbon coated silicon chip, and the stainless steel wire extending from the gold
contacts to the outer surface of the injection device (see Figure 2.2).
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Figure 2.1: SEM image of lance array. Lances measure 1-1.5 µm in diameter and 8-10 µm in
length and are spaced at 10 µm in a grid pattern. Contained on a 2 cm by 2 cm lance array chip are
approximately 4 million lances, making it possible for each HeLa cell to be injected approximately
2-3 times in one injection event

Carbon-coatedmSilicon
LancemArray

Voltage
Source

Carbon-coatedmSilicon
LancemArray

InjectionmSolution
withm0.02mmg/mLmPI

Well

HeLamCellm
Mono-Layer
StainlessmSteel
Electrode

GlassmSlip

GlassmSlip
StainlessmSteel
Electrode

Figure 2.2: Illustrates a cross-sectional view of the manual injection device (left) and a zoomed
in view of the lance array interacting with the HeLa cell culture adhered to the glass slip (right).
During the injection process, the cell culture and the bottom portion of the injection device is
submerged in HBSS containing PI

2.2.2

Propidium Iodide
In treatment samples, propidium iodide (PI) was used as an indicator of delivery efficacy.

PI is a positively charged (2+) molecule that cannot penetrate the cell membrane of living cells
[85–87]. Traditionally used to label dead cells that have had their cell membranes compromised,
PI operates as a red fluorescing dye that intercalates between base pairs of both RNA and DNA.
This association with genetic material increases the fluorescent nature of PI 20 to 30 times, making
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the appropriately exposed cell identifiable with flow cytometry [88]. Because nanoinjection is
supposed to create transient pores via lancing action, the PI identified in living cells is characterized
as a good indication that PI indeed entered the cell and that the cell survived.

2.2.3

Nanoinjection Technique
The mechanics of nanoinjection can be separated into two major components, the second

being used for samples treated with pulsed voltage protocols. The first component includes the
physical lancing of the cell membrane by pressing downward on the injection device. This consequently causes the carbon coated silicon chip attached to the lower side of the injection device to
lance/penetrate the cell membrane of the target cell. The second component includes using electrical attraction of particles, such as PI, to the lance and then electrically repulsing the particle (with
a reversal of voltage) once the lance has penetrated the cell membrane. Shown is Figure 2.3 is a
step-wise process of how these two components operate during the injection process.

2.2.4

Testing Methods

Testing Plate Preparation
HeLa 229 cancer cells were cultured in Dulbeccos Modified Eagles Medium (DMEM)
with 10% Fetal Bovine Serum (FBS) and Gentamicin and then, incubated at 37C with 5% carbon
dioxide. Once cells had matured, six well plates were prepared with roughly 106 cells per well,
which were allowed to adhere to a 22 mm by 22 mm glass slide over a 24 hr period, creating a
confluent mono-layer. For experiments to be performed with voltage application, a stainless steel
electrode plate was added to each well beneath the glass slide.
After allowing the cells to adhere to the glass slide for 24 hr in the incubator, the six well
plates had the DMEM removed and then each well was rinsed with Hanks Balanced Salt Solution
(HBSS). Then, depending on the particular saline being tested, the wells were supplied with 2 mL
of either Hanks Balanced Salt Solution (HBSS), Phosphate Buffered Solution with K+ (PBS+K+ ),
or Phosphate Buffered Solution without K+ (PBS-K+ ). These salines represent the injection saline

12

Figure 2.3: The nanoinjection process consists of four major steps. Step 1 (Top Left) involves
placing the injection device into the test well on the 6-well plate and applying -1.5VDC. Step 2
(Top Right) involves pressing the lance array downward into the HeLa cell culture. Step 3 (Bottom
Left) involves application of a series of square wave pulses. Step 4 (Bottome Right) involves
removal of the lance array from the cell culture

solution. Following the placement of the injection saline, PI was added to the well bringing the
concentration of PI in the well to 0.02 mg of PI/mL of injection saline solution.
The injection process, which can be seen in Figure 2.3, consisted of lowering the injection
device with carbon coated silicon chip attached into a treatment well. The well, now containing the
specific injection saline (either HBSS, PBS+K+ , or PBS-K+ ), completely covers the carbon coated
silicon chip, glass slip with HeLa cells attached, and the stainless steel electrode.
At this point, one of eight treatment protocols was followed for each saline type and includes:
1. Negative Control - No applied voltage, No Lancing, and No PI
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2. Positive Control - No applied voltage, No Lancing, and +PI (0.02 mg/mL solution)
3. Treatment Protocol: Lancing Only - No applied voltage or PI, +Lancing
4. Treatment Protocol: Lancing and PI - Lance assisted Diffusion: No applied voltage,
+Lancing, and +PI (0.02 mg/mL solution)
5. Treatment Protocol: Pulsed 3V - 20 s application of -1.5VDC for PI attraction followed
by 5 s square wave voltage repulsion pulse of 1.5V to 3V with a 2ms period; +Lancing, and
+PI (0.02 mg/mL solution)
6. Treatment Protocol: Pulsed 5V - 20 s application of -1.5VDC for PI attraction followed
by 5 s square wave voltage repulsion pulse of 1.5V to 5V with a 2ms period; +Lancing, and
+PI (0.02 mg/mL solution)
7. Treatment Protocol: Pulsed 7V - 20 s application of -1.5VDC for PI attraction followed
by 5 s square wave voltage repulsion pulse of 1.5V to 7V with a 2ms period; +Lancing, and
+PI (0.02 mg/mL solution)
8. Treatment Protocol: Pulsed 9V - 20 s application of -1.5VDC for PI attraction followed
by 5 s square wave voltage repulsion pulse of 1.5V to 9V with a 2ms period; +Lancing, and
+PI (0.02 mg/mL solution)

Post Testing Flow Cytometry Preparation
All samples, following specific testing protocols, were treated with 0.5 mL of 5x Trypsin
(Sigma) and incubated for 5 min to remove adherent HeLa cells from the glass slip. Following
incubation, wells were treated with 1 mL of DMEM to de-activate the trypsin and then transferred
to FACS tubes (BD Biosciences) for centrifugation for 10 min at 2000 rpm. Supernatants were
removed following centrifugation and re-suspended in 0.25 mL in HBSS for flow cytometry (BD
Biosciences).

14

2.2.5

Flow Cytometry and Statistical Analysis
Following post testing preparation, samples were analyzed using flow cytometry to quantify

cell viability and PI uptake in living and dead cells. For each sample examined, 10,000 events
were captured and characterized. Analysis software (BD FACSDiva, Dako Summit) allowed for
visualization of these data sets using forward and side scatter.
Statistical analysis was then employed to determine cell survival and PI uptake for each data
set. For cell survival, samples were normalized against the negative controls. This normalization
was performed in two steps. The first step consisted of representing the total number of living cells
in the sample divided by the total number of living and dead cells in the sample. That numerical
result was then divided by the ratio of the number of living cells in the control well divided by the
number of living and dead cells in the negative control particular to that six well plate.

a=

b=

Living Cells in Test Sample
Total Living and Dead Cells in Test Sample

Living Cells in Negative Control
Total Living and Dead Cells in Negative Control

Cell Survival =

a
b

For PI uptake, samples were normalized against the positive controls and represented in a
similar manner as previously described. The total number of living, PI positive cells in a sample
were divided by the total number of living cells in a sample. That numerical result was then divided
by the total number of living, PI positive cells in the positive control divided by the total number
of living cells in the positive control particular to that six well plate.

c=

d=

Living and PI+ Cells in Test Sample
Total Living Cells in Test Sample

Living and PI+ Cells in Positive Control
Total Living Cells in Positive Control
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Table 2.1: Normalized PI Uptake Efficiency P-Values
Comparisons
HBSS vs PBS+K+
HBSS vs PBS-K+
PBS+K+ vs PBS-K+

Lance
0.0125
0.0005
0.0125

Lance+PI 1.5-3 V
0.0163
0.0352
0.4804
0.1014
0.1017
0.0010

1.5-5 V
0.0095
0.0415
0.0000

1.5-7 V
0.0184
0.4625
0.0159

1.5-9 V
0.1536
0.3861
0.1027

1.5-7 V
0.0155
0.0038
0.2068

1.5-9 V
0.0919
0.2895
0.0448

Table 2.2: Normalized Cell Survival P-Values
Comparisons
HBSS vs PBS+K+
HBSS vs PBS-K+
PBS+K+ vs PBS-K+

Lance
0.3892
0.0074
0.0244

Lance+PI 1.5-3 V
0.0652
0.0630
0.0270
0.1995
0.0029
0.3986

PI U ptake =

1.5-5 V
0.2614
0.0016
0.0257

c
d

Following normalization, sample populations were examined for outliers using a modified
Thompson Tau test and then statistically evaluated using a students t-test for statistical significance
between populations, with p-values less than 0.05 considered statistically significant.

2.3
2.3.1

Results and Discussion
PI Uptake Efficiency
Figure 2.4 shows the relative efficiency of PI uptake in living HeLa cells for the three

different salines (HBSS, PBS+K+ , and PBS-K+ ) at two different non-voltage protocols and four
different voltage pulsing protocols. Table 2.1 shows relative p-values (significance measured as
p<0.05) for comparisons between the different sample groups.
The overall behavior of the PI uptake can be categorized into three major findings. First
and most notable is that PBS+K+ sample groups are significantly better than the other two salines
at PI delivery at all voltages, except at the 9V pulsed voltage. While not significantly higher at 9V,
PBS+K+ samples appear to be modestly higher than the other salines. Peak efficiency for PBS+K+
occurs at 7V pulsed voltage, reaching a ratio of 3.352.
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Figure 2.4: Relative efficiency of PI uptake in living HeLa cells for different salines and LAN
injection protocols.

A second finding illustrated in the PI Uptake efficiency is seen by comparing the Lance/PI
group and the four different voltage groups. It is noted that there is only a significant increase in
PI uptake in PBS+K+ at 5V (p=0.0422) and 7V (p=0.0148) pulsed voltages. The other two saline
groups exhibit no significant increase in PI uptake when voltage applied and in fact, PBS-K+
actually experiences a reduction in PI uptake at 3V and 5V pulsed voltage compared to Lance/PI
group. For 9V pulsed voltages, none of the salines types exhibited significance increases over the
Lance-PI treatment group.
A third finding can be seen in context of comparing the saline types to themselves at the
four pulsed voltages. In comparing 3V against 5V, only PBS+K+ is significantly higher (p=0.0220)
among the three salines. At 5V to 7V, only PBS-K+ is significantly higher (p=0.0159). At 7V to
9V, only +K+ is significantly lower (p=0.011).
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2.3.2

Cell Survival
Figure 2.5 shows the relative cell survival of HeLa cells as a result of nanoinjection for the

three different salines (HBSS, PBS with potassium, and PBS without potassium) at two different
non-voltage protocols and four different voltage pulsing protocols. Table 2.2 shows relative pvalues (significance measured as p<0.05) for comparison between the different sample groups.
Lancing Only

HBSS

PBS+K+

PBS-K+

HBSS

PBS+K+

PBS-K+

PBS-K+

PBS+K+

PBS-K+

Pulsed: 1.5 to 9

Normalized Cell Viability

Normalized Cell Viability

Normalized Cell Viability

PBS+K+

HBSS

Pulsed: 1.5 to 7

Pulsed: 1.5 to 5

HBSS

Pulsed: 1.5 to 3

Normalized Cell Viability

Normalized Cell Viability

Normalized Cell Viability

Lancing and PI

HBSS

PBS+K+

PBS-K+

HBSS

PBS+K+

PBS-K+

Figure 2.5: Relative cell survival of HeLa cells for different salines and LAN injection protocols.

Of particular note is the relative behavior exhibited between the Lance/PI group and the 3V
pulsed voltage group. While there is no significant difference between the PI uptake when comparing Lance/PI to 3V pulsed voltage, there is a dramatic difference in cell survival between these two
groups (p = 0.0025, 0.0000, 0.0182 for HBSS, PBS+K+ , PBS-K+ respectively). Embedded in this
relationship though, is the fact that PI uptake efficiency is based upon cells that are both living and
PI positive. While it is true that there are comparable PI uptake efficiencies between the Lance/PI
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and 3V pulsed voltage groups, the 3V pulsed voltage group actually have more cells labeled with
PI initially but don’t survive the process and thereby reduces the PI uptake efficiency.
A second finding that is worth noting is that when comparing the cell survival of the Lance
sample group to the Lance/PI group, that in both cases PBS-K+ is significantly better than the other
two salines. While modest in degree, it appears that PBS-K+ offers approximately 3% increase
in cell survival. This finding suggests that potassium, which is present in HBSS and PBS+K+ ,
may destabilize the cell enough to prevent cellular recovery post-nanoinjection. This finding is
not as clearly defined when voltage protocols are used suggesting that the role of potassium is
complicated by voltage.

2.3.3

Potassium Effects
As mentioned previously, prior research indicates that the threshold voltage required for

electroporation of a cell membrane is reduced in low potassium extracellular solutions. Based
on the data represented in the context of nanoinjection, this finding in regard to potassium is not
supported. This suggests two possibilities that require further investigation. The first is that nanoinjection with the voltage protocols outlined above may not actually induce electroporation of the
cell membrane because it is not sufficiently large enough, despite the close proximity of the electrode to the cell membrane. Another possibility is that because the cell membrane is physically
lanced, the relative behavior of the cell in the potassium environments may react differently. Because there are micron-sized pores created by the lancing process, the cell membrane has no need
to create transient electroporation pores to re-establish homeostatic transmembrane potential.

2.4

Conclusion
In order to improve genetic engineering, researchers will need technologies that can facili-

tate molecular load delivery to the intracellular space without compromising cell survival. Nanoinjection is one such technology that appears to be a viable option.
In this study, PI uptake efficiency and cell survival are investigated in the context of using
different injection salines, non-voltage lancing protocols, and pulse voltage protocols. Shown here
is that PBS+K+ experiences higher overall PI uptake efficiencies than HBSS and PBS-K+ . Also,

19

cell survival is variable in degree for voltage treated samples, ranging primarily between 75% and
87%.
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CHAPTER 3.
THE EFFECT OF LANCE GEOMETRY AND CARBON COATING OF
SILICON LANCES

The following chapter was constructed from a journal article that has been accepted for publication
by the Journal of Micromechanics and Microengineering and is entitled “The Effect of Lance
Geometry and Carbon Coating of Silicon Lances on Propidium Iodide Uptake in Lance Array
Nanoinjection of HeLa 229 Cells”. As a result, there may be some material that is contained
elsewhere in this dissertation but is presented here as a representation of this original journal article.

3.1

Introduction
Correcting disease at a fundamental cellular level has been and continues to be a promising

medical research area [56, 89, 90]. Because of advancements in both creation and manipulation of
relevant target cells, such as induced pluripotent stem cells [91–94], as well as enhancements in
site-directed gene modification tools, such as CRISPR/Cas9 [95–97], there is an intensified need
to develop methods for combining these tool types into meaningful biotechnologies [98–100].
Unfortunately, placing gene editing constructs into useful target cells types is complicated by the
delivery process, both in terms of effectively getting genetic pay-loads to the intracellular space of
target cells and maintaining cell viability following treatment.
Many methods have been developed to help address the need to facilitate molecular load
delivery and can categorically be separated into four areas, which include viral [101–103], particlebased [104–106], reagent-based [77, 107], or instrumentation-based methods [74, 107, 108]. Engineered viruses are the most common biologic carrier method for molecular delivery largely because of the self-promotional features associated with the viral life-cycle [109, 110]. Once reprogrammed with the desired genetic pay-load, viruses can infect specific surface marker carrying
cells [111–114] and manufacture the desired effect, using the viruses’ own re-purposed machinery
if necessary [115].

21

Unfortunately, even though viral transfection methods often exhibit benchmark efficiencies
for molecular delivery, there are clinically-limiting drawbacks to using viral transfection, which
include: immunologic safety, viral containment to target tissues, limits to genetic load capacity, and insertional mutagenesis [116]. Essentially, these “procedural limitations” of viral vectors
have caused researchers to investigate alternative non-viral methods, particularly particle-based
and instrumentation-based, for transfection [117].
In terms of instrumentation-based biotechnologies, several researchers have created high
throughput nanowire biomolecule delivery and sensing systems which have demonstrated utility
in terms of transfection applications [118–122]. This work contributes to this group of work by
focusing on a non-viral, instrumentation-based transfection technology, known as nanoinjection,
that uses nanowire-like silicon lance structures to electrically interact and deliver biomolecules to
target cells [25].
The first generation nanoinjection device was originally designed as a six-bar microelectromechanical device designed to modify single mouse embryos with foreign transgenes [25–27].
Since that time, the scope of nanoinjection has been extended to be used for simultaneous modification of hundreds of thousands of somatic cells using an array of silicon etched lances, a process
known as Lance Array Nanoinjection (LAN) [23, 24, 54].
Procedurally, LAN works in four major steps which combine physical penetration of the
cell membrane and electrical delivery of molecular loads. Figure 3.1 shows these four steps which
include the following: staging–electrical attraction of molecular loads, injection–physical penetration of target cell membranes, delivery–electrical repulsion of molecular loads, and finally,
removal–withdrawal of the lances from the target cells’ intracellular space [24].
This work presents two major fabrication alterations to the silicon lance array typically
used for LAN, which include: lance geometry (lance tip shape and shaft diameter), and presence
of a carbon coating. The purpose of lance geometry testing is to evaluate how cells respond to cell
membrane damage when injections are performed by different lance geometries. Because cellular
trauma is a concern in regards to preserving cell viability, lance geometry is an important investigative factor in terms of LAN. The purpose for the lance coating test is to evaluate how carbon
coating presence can impact the electrical events that occur during LAN, a parameter important
for molecular load delivery in both in terms of the attraction and repulsion of molecular loads [26].
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Staging: Electrical Attraction
of Molecular Load to Silicon Lances

Figure 3.1: Illustrates the general process of Lance Array Nanoinjection with notes specific to the
delivery of Propidium Iodide molecular load used for the biological testing portion of the presented
work.

In an effort to create a lance array that both conducts electricity easily and thereby allows for a
low applied voltage for LAN, silicon lances were constructed with a thin (<100 nm thick) carbon
coating. To help evaluate the effects of these alterations, biologic testing results are presented,
which explore the performance with which propidium iodide (PI), a cell membrane impermeable
dye, can be delivered to HeLa 229 cells via LAN.
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3.2
3.2.1

Materials and Methods
Lance Array Fabrication
Microfabrication of the silicon lance arrays have been previously described in the litera-

ture [23] and is noted briefly here only for convenience in regards to the alternations or additions
made for the lances tested in this work. Silicon lance array construction consists of photolithographic definition of positive photoresist (AZ330F) in an array of circular features spaced at 10 µm
followed by deep reactive ion etching (DRIE). In order to create pointed lances, a sulfur hexafluoride (SF6) isotropic plasma etch undercuts the photoresist features, resulting in a conical shape that
supports the photoresist dot. This etch is typically in the range of 30 to 60 seconds, depending on
the desired undercut depth. Following SF6 etching, the photoresist dots are stripped using acetone
and then exposed for 2 minutes in an oxygen plasma etch. The final lance array consists of a 2 cm
by 2 cm chip etched with an array of 10 µm length solid lances which are spaced every 10 µm in
both planar directions (see Figure 3.2).

Lance Geometry Fabrication
Silicon lance arrays construction for lance geometry testing can be categorized into three
different groups and include: Flat, Narrow (FN, 1 µm diameter); Flat, Wide (FW, 2-2.5 µm diameter); and Pointed (P, 1 µm diameter) (see Figure 3.2). The lance microfabrication used the same
process as what is described in Lance Array Fabrication with two alterations. First, only the P
lances underwent the sulfur hexafluoride etch to create a pointed tip. Second, the relative diameter
of the lance was controlled by altering the length of photoresist exposure – the shorter exposure
times yielded a larger diameter dot, which resulted in larger diameter lances.

Lance Carbon Coating Fabrication
Silicon lance array construction for carbon coated testing followed the same process as
what is described in Lance Array Fabrication with one additional step. Following the oxygen
plasma etch, the lances were coated in a <100 nm thick layer of carbon using chemical vapor
deposition (ethylene at 230 sccm, hydrogen at 218-220 sccm, at 900C for 5 min) (see Figure 3.3)
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Figure 3.2: SEM images of the three different shaped silicon lance arrays. (Top) Shows rows of
Flat, Narrow (FN) lance tips, measuring 1 µm in diameter. (Middle) Shows rows of Flat, Wide
(FW) lance tips, measuring 2 to 2.5 µm in diameter. (Bottom) Shows rows of Pointed (P) lance
tips, measuring 1 µm in diameter.

Though the angle of the lances in Figure 3.3 makes them look flat, these lances were fabricated
using the pointed protocol.
As mentioned previously, coating the silicon lances in a thin layer of carbon is hypothesized
to alter the performance of PI delivery during LAN. Experimental investigation of the electrical
performance of the two lance array types (Si and CC) demonstrate that non-coated silicon lance
arrays (Si) have a resistance of 1364 Ω and the carbon coated silicon lance arrays (CC) have a
resistance of 395 Ω.

3.2.2

Nanoinjection Device
Figure 3.4 provides a side-view schematic of the LAN device seated in a six well plate

filled with an injection solution containing the molecular load to be injected. Noted are three major elements making up the LAN device, which includes: the orthoplanar spring (with electrical
connection), the silicon lance array, and the glass slide/counter electrode. The orthoplanar spring
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Figure 3.3: SEM images of carbon coated silicon lance array. (Left) Shows arrangement of lances
post-carbon coating treatment. (Right) Close up image of a single carbon coated lance.

Figure 3.4: Nanoinjector device used for both Lance Geometry testing and Carbon Coating testing.

design has been described previously in the literature [23,84] and contains compliant flexural members that inhibit transverse and rotational motions during vertical actuation. The silicon lance array
adheres to the inferior portion of the orthoplanar spring using double-sided carbon tape, thereby
electrically connecting the lance array to a switch box that provides the appropriate electrical inputs according to the treatment sample type. Shown below the lance array is a glass slide sitting
atop a stainless steel counter-electrode (serves as ground). The glass slide contains the cell culture.
Operation of the nanoinjection device occurs as manual force is applied to the superior surface of the orthoplanar spring, allowing the attached lance array (with lances oriented downward)
to move in a vertical direction towards the cell culture atop the glass slide. Manual force is applied until the lance array contacts the glass slide substrate, thereby ensuring target cells have been
injected.
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3.2.3

Biologic Testing

Testing Preparation
HeLa 229 culture cells were incubated on glass slides contained in six well plates (Sarstedt)
at 37C and 5% carbon dioxide cultured in Dulbeccos Modified Eagles Medium (DMEM, Gibco)
with 10% Fetal Bovine Serum (FBS, Denville Scientific) and Gentamicin (Sigma-Aldrich). Cells
were allowed to adhere to a glass slide over a 24 hour period prior to testing. At the time of testing,
the cell cultures had formed a mono-layer of approximately 70% confluency or cell density across
a 1 cm diameter area centrally located on the glass slide
Following the 24 hr incubation test prep period, the six well plates containing the cultured
cells were removed from the incubator and had DMEM/FBS growth media removed and then cells
were rinsed in 1 mL per well of Hanks Balance Saline Solution (HBSS, Gibco). The respective
treatment protocols detail specific treatments applied to the wells from this point forward.

Lance Geometry Experimental Design
The following describes the various well types:
• Non-Treated Control (NTC): Following the addition of HBSS, no treatment was performed
on this well.

• Background PI Control (BC): Received 80 µL of PI solution (concentration: 500 µg of
PI powder per mL PBS) per 1 mL of HBSS in injection well, no lancing, and no further
treatment.

• Treatment Protocol Lancing (FN, FW, or P): Received 80 µL of PI solution (concentration: 500 µg of PI powder per mL PBS) per 1 mL of HBSS in injection well, lanced using
a either a Flat, Narrow (FN); Flat, Wide (FW); or Pointed (P) lance array using the injection device described above. The injection device was inserted into each well and manual
force was applied for five seconds to depress the lance array into the cell culture. Following
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the lancing, the injection device was removed from the well. No voltage was used, so that
random diffusion was responsible for transporting PI through the opened pores into the cells.

Lance Coating Experimental Design
As noted in the Test Preparation, HeLa 229 cells were cultured on a glass slide 24 hrs before
testing. Additionally, these glass samples were placed on top of a stainless steel flat plate during
this incubation process. This plate serves as the counter-electrode during testing. Each six well
plate had one non-treated control well, a background PI control well, and four treatment wells.
Directly following incubation, media was removed from the wells, each well was washed
with HBSS solution, and 2 mL HBSS solution was added to each well as an injection medium
preparatory to LAN.
The following describes the various well types. Note that each treatment protocol was
performed on both carbon coated lance arrays (CC) and non-coated silicon lance arrays (Si).
• Non-Treated Control (NTC): Received no PI in injection solution, no lancing, and no voltage.

• Background PI Control (BC): Received 40 µL of PI solution (concentration: 500 µg of PI
powder per mL PBS) per 1 mL of HBSS in injection well, no lancing, and no voltage.

• Treatment Protocol (CC/0V or Si/0V): Received 40 µL of PI solution (concentration: 500
µg of PI powder per mL PBS) per 1 mL of HBSS in injection well, lanced for 5 seconds,
and no voltage applied. These treatment samples were used to evaluate the diffusion rate of
PI through the patent cell membrane.

• Treatment Protocol: +1.5V DC (CC/1.5V DC or Si/1.5V DC) Received 40 µL of PI
solution (concentration: 500 µg of PI powder per mL PBS) per 1 mL of HBSS in injection
well. Injection process occured as: lances lowered into six-well plate with −1.5V applied
for 20 seconds to attract PI to lances, physical lancing of cell membranes, +1.5V applied for
5 seconds to repulse PI from the lances, and then removal of lances from cell.
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• Treatment Protocol: +5V Pulsed (CC/5V Pul or Si/5V Pul) Received 40 µL of PI solution
(concentration: 500 µg of PI powder per mL PBS) per 1 mL of HBSS in injection well.
Injection process occured as: lances lowered into six-well plate with −1.5V applied for 20
seconds to attract PI to lances, physical lancing of cell membranes, followed by ten pulses
between +1.5V and +5V applied within 20 ms, +1.5V DC applied for 5 seconds to repulse
PI from the lances, and then removed from cells.

3.2.4

Propidium Iodide
In designated treatment wells, propidium iodide (PI, Sigma-Aldrich), a dye that is both

impermeable to an intact cell membrane and fluoresces 20 to 30 times greater when intercalating
with nucleic acid base pairs, was used as an indicator for nanoinjection efficacy. Because the
nanoinjection process induces a physical pore to form as a result of being lanced, PI positive,
living cells are qualified as successful transfection events. Quantification of test wells using PI (as
well as control samples) is handled using flow cytometry.
For both experiments, a PI solution was prepared at a concentration of 500 µg of propidium
iodide powder per 1 mL of PBS. Because large differences in PI+ uptake were desired for the
Lance Geometry experimentation, because PI+ uptake is dependent only on diffusion, 80 µL of PI
solution was placed in each 1 mL of HBSS prior to injection. For Lance Coating experimentation,
an equivalent of 40 µL of PI solution was placed in each 1 mL of HBSS prior to injection, half
the concentration used in the Lance Geometry experiment because other factors are believed to
contribute to PI+ uptake.

3.2.5

Post Testing Flow Cytometry Preparation
After specific testing protocols were run, all samples were treated with 0.5 mL of 5X

Trypsin (Gibco) and incubated for 5 min to remove the cells from the glass slide after which each
well was treated with 1 mL of DMEM/FBS media to deactivate the trypsin. The samples were then
transferred to FACS tubes (BD BioSciences) for centrifugation for 10 min at 2000 rpm. Following
centrifugation, supernatants were removed and remaining cells were re-suspended in 0.25 mL of
PBS for final preparation prior to flow cytometry.
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3.2.6

Flow Cytometry
Following flow cytometry preparation, the samples were qualified using flow cytometry

(BDCanto) to determine the cell viability (living vs dead cells) and PI uptake (fluorescing vs nonfluorescing cells). Each sample examined had approximately 10,000 events counted and characterized. Post flow processing occurred in respective analysis softwares (BD FACS Diva-Dako
Summit) to visualize samples.

3.2.7

Statistical Analysis
Data gathered from the post flow analysis in Summit was used to calculate the percentage

and cell count of living cells contained in the total cell population, also referred to as cell viability,
as well as the percentage and cell count of the PI+ cells contained in the living cell population, also
referred to as PI+ uptake.
Following this post processing, data sets were compared statistically initially using ANOVA
testing to characterize presence of statistically significant relationships [123] followed by twosided student t-tests (α = 0.05) using JMP (SAS).

3.3
3.3.1

Results and Discussion
Lance Geometry Experimentation
Figure 3.5 shows a box-and-whisker plot of the percent of living cells in the total cell

populations, or cell viability, for the Lance Geometry experiment. Accompanying this figure is
Table 3.1, which provides statistically significant p-values for the comparision of the associated
sample types. Among treatment groups, FN had a significantly higher cell viability than FW and
P groups, albeit the difference in mean viabilities is <3% (see Table 3.2). For all comparisons
involving the treatment groups vs. both NTC and BC controls, statistically significant differences
are noted.
Figure 3.6 shows a plot of the percent of PI+ cells found in the living cell populations, or
PI+ uptake, for the Lance Geometry experiment. Table 3.1 also shows the associated p-values. For
treatment group comparisons, the FN group was significantly lower than both FW and P groups,
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Table 3.1: Lance Geometry Experimentation: P-values for comparing percentage of living
cells in total cell population and PI+ cells in living cell population
Comparisons
NTC vs BC
NTC vs FN
NTC vs FW
NTC vs P
BC vs FN
BC vs FW
BC vs P
FN vs P
FN vs FW
FW vs P

% Total Cell Pop. that is Living
0.8682
<0.0000
<0.0000
<0.0000
<0.0000
<0.0000
<0.0000
<0.0000
0.0087
0.3422

% Living Cell Pop. that is PI+
<0.0000
<0.0000
<0.0000
<0.0000
<0.0000
<0.0000
<0.0000
<0.0000
<0.0000
0.5441

having a difference in mean PI+ uptake between P group of nearly 15% (see Table 3.2). Similar to
cell viability for Lance Geometry experimentation, the PI+ uptake for all treatment groups vs both

Percent
of Total
Cell Populat
that
is Living
Percent
of Living
Cells inion
Total
Cell
Pop.

NTC and BC controls are stastically significant.

Non-Treated
Control

Background PI
Control

Flat, Narrow Lance Flat, Wide Lance
(1 micron diameter) (2 to 2.5 micron dia.)

Pointed Lance
(1 micron diameter)

Figure 3.5: Cell Viability results for Lance Geometry Experimentation are represented as the percent of living cells in the total cell population for respective sample types. Table 3.1 shows statistically significant relationships for comparison between sample types.

31

N

li

d PI U t k

Percent
of Living
Population
PI+
Percent
of PI+Cell
Cells
in Living that
Cell is
Pop.

Non-Treated
Control

Background PI
Control

Flat, Narrow Lance Flat, Wide Lance
(1 micron diameter) (2 to 2.5 micron dia.)

Pointed Lance
(1 micron diameter)

Figure 3.6: PI Uptake results for Lance Geometry Experimentation are represented as the percent
of PI positive cells in the living cell population for respective sample types. Table 3.1 shows
statistically significant relationships for comparison between sample types.

Table 3.2: Lance Geometry Experimentation: Sample Size and Mean Value Summary
Sample Type
NTC
BC
FN
FW
P

n
15
17
40
40
80

% Cell Viability (CV) CV Cell Count % PI Uptake (PI) PI Cell Count
95.52%
167,166
0.33%
583
95.69%
167,452
26.71%
46,735
91.73%
160,529
60.11%
105,195
90.08%
157,640
73.50%
129,213
89.57%
156,745
75.08%
131,996

The Lance Geometry findings in regards to cell viability are suggestive of how the cell
membrane reacts to surface defects. In reference [124], it was shown that a blunt tip AFM probe
measuring 800 nm in diameter required more than three times less force to penetrate human epidermal melanocytes as opposed to a probe with the same diameter but with a pointed tip (Penetration
Force for Blunt tip: 0.67 nN, Penetration Force for Pointed tip: 1.90 nN). Furthermore, it was
shown that an AFM tip measuring 200 nm in diameter with a blunt tip required a penetration force
of 0.65 nN, suggesting that penetration force is less dependent upon diameter of probe and more
dependent upon the tip being blunt or pointed. By comparison, we have previously shown [125]
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using lance array nanoinjection that an average of 2.3 µN per lance is required to puncture HeLa
cell membranes using pointed lances. In our study, we quantified the force per lance required to
maximize PI delivery into the cells, which may be different than the force required for a single
lance to pierce the cell membrane
Given this basis, it was anticipated that with FW and FN lance types a lower amount of
cellular disruption would occur because less force would be required to penetrate, resulting in
higher cell viability rates. However, in this experiment, cell viability rates were only significantly
higher for the FN vs FW and P cases. Even so, the cell viability differences for FN and FW were
<3% different than P samples.
A possible explanation for the difference between reference [124] and this work deals with
the fact that the AFM experimental results were force controlled. The LAN process used in this
study was not force-controlled (particularly on the order of nN), and therefore membrane penetration mechanics and cell viability may be irrelevant in regards to geometry when there is such a
difference in force magnitude application.
In terms of PI+ uptake, the findings demonstrate that PI uptake is greatest in P treatment
samples (75.08%), followed closely by FW treatment samples (73.50%). The rationale for this
outcome is not clear. It was anticipated that the FW samples would have a larger PI+ uptake rate
than both the FN and P samples because the effective surface defect area created from FW lances
would be between 4 to 6.25 times greater. However, despite this fact, the comparison between FW
and P is not significant.
It is possible, in terms of the PI+ uptake for FW and P lances, that even though the P
shaft is smaller than the FW, that perhaps the way the cell membrane and underlying structures are
disrupted following injection with the pointed lance tip makes it more difficult for the cell to heal
the surface defect allowing more diffusion of PI across the membrane.

3.3.2

Lance Coating Experimentation
Figure 3.7 shows a plot of cell viability for the Lance Coating experiment and is further

summarized in Table 3.3 and Table 3.5 for statistical comparison. Noted in this comparison study
between the non-coated and the carbon-coated silicon lances is the lack of statistically significant difference between the lance type groups when comparing similar testing conditions. One
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Table 3.3: Lance Coating Experimentation: P-values for comparing different sample types
in terms of Percentage of Living Cells in Total Cell Population
Sample Type
BC
CC/0V
Si/0V
CC/1.5V DC
Si/1.5V DC
CC/5V Pul
Si/5V Pul

NTC
BC
CC/0V
Si/0V
0.6436
0.0308
0.0613
0.0201
0.0399
0.8644
<0.0000 <0.0000 <0.0000 <0.0000
<0.0000 <0.0000 <0.0000 <0.0000
<0.0000 <0.0000 <0.0000 <0.0000
<0.0000 <0.0000 <0.0000 <0.0000

CC/1.5V DC

Si/1.5V DC

CC/5 V Pul

0.2006
0.0806
0.0358

0.7116
0.4487

0.0077

exception to this observation is the comparison of CC/5V Pul to Si/5V Pul, where CC/5V Pul is
significantly higher by 5%. It is not clear why the CC/5V Pul has a higher cell viability rate in this
situation. It is possible that the difference is a function of the electrical exposure, and requires further investigation. Also seen in these results is the gradual decrease in cell viability as the amount
of electrical exposure increases when referenced by NTC and BC controls, regardless of lance
type.
Figure 3.8, Table 3.3, and Table 3.5 present the PI+ uptake for the two lance coating types.
Notably, there are no statistically significant relationships between the CC and Si lance array types
when similar testing conditions exist, suggesting no advantage is gained by carbon coating the
lance array.
Although not the focus of the lance coating experimentation, also shown in these results is that electrical application can increase significantly PI+ uptake (ie. see comparison of
CC/0V:CC/1.5V DC and Si/0V:Si/1.5V DC) as well as cause a decrease in PI+ uptake (ie. see
comparison of CC/1.5V DC:CC/5V Pul and Si/1.5V DC:Si/5V Pul). The later comparison suggests that perhaps electrically pulsing the lances once inserted into the cell has an adverse effect
either in terms of PI+ release directly and/or cell viability, which in turn reduces the number of PI+
living cells.

3.4

Conclusion
Improving the delivery of molecular loads to target cells is a critical part of integrating

meaningful biologic discovery with clinical and benchtop application. The primary goal for LAN
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Figure 3.7: Cell Viability results for Lance Coating Experimentation are represented as the percent
of living cells in the total cell population for respective sample types. Table 3.3 shows statistically
significant relationships for comparison between sample types.

Table 3.4: Lance Coating Experimentation: P-values for comparing different sample types
in terms of Percentage of PI+ Cells in Living Cell Population
Sample Type
BC
CC/0V
Si/0V
CC/1.5V DC
Si/1.5V DC
CC/5V Pul
Si/5V Pul

NTC
BC
CC/0V
<0.0000
<0.0000 0.0186
<0.0000 0.0242
0.8980
<0.0000 <0.0000 <0.0000
<0.0000 <0.0000 <0.0000
<0.0000 <0.0000 <0.0000
<0.0000 <0.0000 <0.0000

Si/0V

CC/1.5V DC

Si/1.5V DC

CC/5 V Pul

<0.0000
<0.0000
<0.0000
<0.0000

0.8613
0.0060
0.1716

0.0112
0.2399

0.1619

as a transfection technology is to effectively deliver molecular loads without compromising cell
viability. Since LAN relies both on physical and electrical interactions with target cells, structural
design and function of the microfabricated silicon lances are closely wrapped together.
Investigated in this work are two parameters, lance geometry (tip shape and shaft diameter)
and coating, believed to impact the ability of a non-viral transfection technology, known as Lance
Array Nanoinjection, to deliver propidium iodide to the intracellular space of HeLa 229 cells.
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Figure 3.8: PI Uptake results for Lance Coating Experimentation are represented as the percent
of PI positive cells in the living cell population for respective sample types. Table 3.4 shows
statistically significant relationships for comparison between sample types.

Table 3.5: Lance Coating Experimentation: Sample Size and Mean Value Summary
Sample Type
NTC
BC
CC/0V
Si/0V
CC/1.5V DC
Si/1.5V DC
CC/5V Pul
Si/5V Pul

n % Cell Viability (CV) CV Cell Count % PI Uptake
28
95.84%
167,726
0.17%
40
94.85%
165,985
24.84%
52
91.29%
158,836
31.24%
48
90.98%
158,400
30.91%
35
81.15%
147,297
51.29%
33
78.42%
143,154
50.75%
48
81.87%
144,076
43.57%
43
76.86%
136,697
47.31%

PI Uptake Cell Count
295
43,466
77,886
81,329
64,581
65,668
88,583
87,540

Findings indicate two major items in terms of lance geometry. First, FN lances produce a
slightly higher cell viability rate (91.73%) than the other two lance geometries (FW: 90.08%, P:
89.57%). Second, P lances produce the highest PI uptake rate of 75.08%.
Lastly, findings related to the carbon coating of the silicon lances (CC) demonstrate that
neither cell viability or PI uptake rates are increased when comparing to non-coated lances (Si)
during both non-voltage and voltage injection events.
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Given the fact that cell viability rates of all lance geometries are nearly 90% and that greater
PI uptake was seen with P lances, it appears that using P shaped lances would be the recommended
geometry for future nanoinjection experiments. Noted earlier was the fact that lance shape does
not necessarily translate to degree of cellular trauma detectable in post-injection flow cytometry
analysis. Future histological investigation of cellular structures post-injection may be warranted in
the context of lance geometry to determine if lance shapes influence cellular damage and/or cell
viability.
While the electrical effects of the carbon coating on the silicon lances proved to be inconsequential, it is still of interest to characterize other microfabricated lances in terms of the effects
of electrical behavior during LAN. Future investigation in this area may include similar testing
protocols with alternative materials used for lance arrays, such as carbon nanotubes.
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CHAPTER 4.

TRANSIENT LOW TEMPERATURE

The following chapter has been submitted as a journal article to the Journal of Nanotechnology in
Engineering and Medicine and is currently in review. The title of this journal article is “Transient
Low Temperature Effects on Propidium Iodide Uptake in Lance Array Nanoinjected HeLa Cells”.
As a result, there may be some material that is contained elsewhere in this dissertation but is
presented here as a representation of this original journal article.

4.1

Introduction
Biologic engineering applications utilizing specific cell lines and/or entire organisms have

been accelerated by the use of programmable endonucleases such as zinc-fingers (ZFNs) [126],
transcription activator-like effector nucleases (TALENs), and clustered interspaced short palindromic repeats and associated cas9 (CRISPR-Cas9) [127–129]. These tools present researchers
with a large degree of freedom in designing site-specific modifications to the genome. The ability
to directly insert [130, 131], activate [132–134], repress [132, 135], and/or knock-out [97] genes at
multiple sites, even in a single transfection event [136–138], is now possible.
Further fueling excitement in regards to genetic engineering is the ability to direct these and
related technologies towards mitigating and controlling disease processes. Specifically, therapies
are being directed at treating both human monogenic diseases such as lipoprotein lipase deficiency
(LPLD) [4], leber cogenital amaurosis (LCA) [5–9], and hemophilia B [10, 11] as well as more
genetically complex diseases such as heart failure [12–15], B-cell malignancies [16], and neurodegenerative diseases [17] using exogenously deliverd genetic material to alter aberrent cellular
behaviors.
While the ability to modify target cells has dramatically improved, the ability to physically
deliver these effector molecules to target cells is still constrained in many ways. What makes it
challenging for transfection methods to achieve successful transformation is that there are barriers
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that inhibit molecular delivery and can be described as barriers related either to physical or physiological elements of cellular targets. In the context of physical barriers, molecular loads must cross
both the cell membrane and cell nucleus before genomic modification can be achieved.
In the past, engineered viruses have been an attractive option for overcoming genetic delivery to target cells because viruses have cell adhesion proteins that help transport the virus across
the cell membrane [111–114]. When coupled with the tropic ability of viruses to target specific cell
types within a mixed population such as blood, researchers have been able to achieve benchmark
transfection rates.
Despite these strengths, viral transfection methods have limitations that make widespread
application difficult, especially in the clinical setting. Weaknesses in regards to viral transfection
include: immunologic safety, viral containment to target tissues, limits to genetic load capacity,
and potential insertional mutagenesis [116]. Because of these drawbacks researchers have sought
alternative, non-viral modalities for molecular delivery [117].

4.1.1

Nanoinjection
One of these non-viral transfection technologies has been described in the literature as a

process called nanoinjection [25, 26]. Originally designed to facilitate transgenic mouse embyro
modification, a second generation of nanoinjection technology has been developed that is designed
to modify hundreds of thousands of somatic cells simultaneously [24]. This second generation
nanoinjection process is called lance array nanoinjection (LAN) because it utilizes an array of microfabricated silicon lances measuring 10 microns in length, spaced every 10 microns to facilitate
both the physical piercing and electrical manipulations required for LAN (see Figure 4.1).
Procedurally, LAN occurs in four major steps, which include: staging the lance array in
an injection solution containing the molecular load of choice, electrical attraction of the molecular
load onto the lance structure, physically lancing of the cell culture–effectively placing the molecular load attached to the lance in the cells’ cytoplasm and electrically repulsing the molecular load
into the intracellular space of the cell, and retraction of lances from cell culture [24].
Prior nanoinjection research has focussed on intrinsic variables specific to nanoinjection in
terms of both modelling and experimentation of electrical parameters effecting delivery of molec-
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ular loads, particularly DNA [50, 139, 140]. This work seeks to expand that perspective by investigating the thermal environmental effects on target cells undergoing LAN.

4.1.2

Cell Membrane in Response to Transient Low Temperature
Because LAN, like all other non-viral transfection methods, relies on cell membrane me-

chanics for molecular transport into the cell’s cytoplasm, it is critical that factors related to the cell
membrane behavior be well understood. One particularly important environmental stressor that
alters membrane function is sub-physiologic temperature (i.e., <37◦ C) [141–154].

4.1.3

Cell Membrane Stiffening at Low Temperature
In general terms, the mammalian cell membrane is constructed of a phospholipid bilayer

containing protein aggregates and carbohydrates with regions of cholesterol rich domains, which
play an important part in membrane transport as it relates to temperature [142, 143]. Al-Fageeh
et al. [141] notes that with in vitro reduction in temperature, rigidity of the membrane increases
as internal hydrophobic portions of the phospholipids begin to pack more closely, increasing the
stiffness of the membrane structure [143].
In order to mitigate this effect, many cellular systems will attempt to maintain a constant
degree of membrane fluidity in the face of reduced temperature, an idea known as homeoviscous
adaptation. In order to facilitate this goal during cold stress, the cell initiates activity of fatty
acid desaturase and dehydrases to convert saturated fatty acids to poly-unsaturated fatty acids,
effectively reducing the length of the chain and increasing fluidity of the membrane [141,144–148].
Although these measures do attempt to mitigate the stiffening of the cell membrane, it does not
altogether prevent stiffening when exposed to reduced temperature [143].

4.1.4

Diminished Cytoskeleton at Low Temperature
While the cell membrane itself is structurally stiffer with reduced temperature, atomic force

microscopy studies indicate that the overall integrity of the cell decreases in stiffness as temperature
decreases [149–151]. This behavior is caused by the disassembly of the underlying cytoskeleton
which serves as a structural scaffold that runs throughout the intracellular space of the cell.
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Figure 4.1: SEM image of Lance Array Silicon chip. Lances measure 10 microns in height, 1-2.5
microns in diameter, with a 10 micron spacing

This fact becomes relevant in terms of LAN because the cytoskeleton plays a critical role
in cell membrane wound healing. When surface damage occurs to the cell membrane, the cytoskeleton facilitates actinomyosin contraction and recruiting of repair machinery to the damaged
site [152–154], a function that is hypothesized to be impaired at low temperature because of reduced cytoskeleton presence.
The purpose of this work is to characterize the behavior of HeLa 229 cells in response to
transient low temperature (3◦ C) relative to warmer samples (23◦ C) following lance array nanoinjection (LAN). It is hypothesized that because the cell membrane is stiffer and the cytoskeleton is
compromised (and thereby functionally impaired) at low temperature, that pores created by LAN
will remain patent longer for samples treated at 3◦ C than samples treated at 23◦ C. To help characterize this hypothesized thermal-dependent pore formation event, propidium iodide (PI, SigmaAldrich), a dye impermeable to the cell membrane that fluoresces when interacting with nucleic
acids, will be added to injected cell cultures at various intervals post-injection. When the cells have
pores still present at the time of PI introduction into the sample solution, PI should pass through
the cell membranes of living HeLa cells, interact with nucleic acids, and fluoresce during flow
cytometry. Figure 4.2 illustrates this process, which is a variant to nanoinjection processes used in
the past [24].
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Staging: Injection Solution
set at 3C or 23C

Figure 4.2: Lance Array Nanoinjection Stepwise Process. 1: Staging lance array into injection
solution maintained at either 3◦ C or 23◦ C. 2: Injection of cell culture, consisting of both physical
penetration of the cell membrane and electrical treatment. 3: Staining of cell culture by introduction of PI into the extracellular solution at 0, 3, 6, and 9 minutes post-injection. 4: Induced pores
from injection event eventually close and PI molecules in the intracellular space of injected cells
interact with nucleic acids, increasing PI fluorescence.

4.2
4.2.1

Methods
Lance Array Fabrication
Microfabrication of the silicon lance array consists of four major steps, which include pat-

terning with positive photoresist (AZ330F), deep reactive ion etching (DRIE), a sulfur hexafluoride
(SF6) isotropic plasma etch, and a final cleaning step. More details of the microfabrication are contained in prior work [23].
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4.2.2

Injection Set-Up

Nanoinjection Device and Electrical Switch Box
The nanoinjection device consists of six major elements which include: stepper motor,
orthoplanar spring, coiled spring, lance array holder, lance array, and electrical connection. The
rapid-prototyped, ABS (acrylonitrile butadiene styrene) orthoplanar spring has a stepper motor
attached superiorly that presses against a coiled spring that acts to move the orthoplanar spring
upward and downward. Attached to the orthoplanar spring apparatus at the inferior end is a lance
array holder that allows for the insertion and removal of the silicon-etched lance array. Gold contacts were used to electrically connect the lance array to an electrical switch box (see Figure 4.3).
The electrical switch box, which is connected to the injection device, operates by receiving
2 input signals and switching between these at specific times. Treatment samples receiving electrical treatment experience an initial −1.5V for 20 seconds, followed by insertion of the lances into
the cells, followed by a 20 ms interval of positive pulsed voltage (2 ms period, 50 percent duty
cycle), followed lastly by a 5 second interval of +1.5V.
During injection events typically performed using LAN, the initial negative voltage attracts
the molecular load to the lances and the positive pulses repel the PI into the cells [24]. For this
study the PI was added into solution after injection to help elucidate molecular mechanisms in
response to LAN. The electrical treatment was kept the same as what has been reported in the past
to allow for comparison [24].

Cell Culture Platform
The 3D printed Cell Culture Platform (MakerBot Replicator 2) consists of three parts—the
PLA (polylactic acid) base, glass slide, and the PLA top clip. The glass slide was used to provide
a flat, uniform culturing surface for the HeLa cells. This glass slide snap-fitted into the PLA
base. Once snapped into place, the top PLA clip was placed on the assembly to provide a uniform
base for the Nanoinjection Device described above to rest on during nanoinjection. In addition to
allowing for the glass slide to attach, the base also contains an exposed wire coil that serves as an
electrical ground. The addition of the 3D printed Platform was to help facilitate better alignment
of individual components that proved to be of value in preliminary testing (see Figure 4.4).
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Figure 4.3: Diagram of Nanoinjection Device. Components shown (top to bottom) include: Stepper motor mounted to ABS orthoplanar spring, threaded screw acting to actuate silicon lance array
mounted above 3D printed Cell Culture Platform, and associated electrical connections (ground
connected to Cell Culture Platform).

Figure 4.4: Cell Culture Platform assembly. Glass slide containing cell culture secured between
the bottom PLA base and top PLA clip to provide proper alignment during injection.
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Electrical Inputs from WaveForm
Generator and Power Supply
Electrical Outputs to
Nanoinjection Device

Thermocouple
Nanoinjection Device
Six-Well Plate
LAN Experimental
Set-Up

LabView Program monitoring Electrical
Signals during Injection Process

Figure 4.5: Experimental set-up illustrating injections performed for 3◦ C treatment samples. A
thermocouple was used to verify surrounding fluid temperature of ice/water bath of 3◦ C prior to
treatment. LabView program was used to verify proper electrical signals delivered to Nanoinjection
Device. Six well plate containing Cell Culture Platforms and associated cell cultures were aligned
to Nanoinjection Device.

4.2.3

Propidium Iodide
In designated treatment wells, propidium iodide (PI, Sigma-Aldrich), a dye that is both

impermeable to an intact cell membrane and fluoresces 20 to 30 times greater when associated with
genetic material, was used as an indicator for nanoinjection efficacy. Because the nanoinjection
process induces a physical pore to form as a result of being lanced, PI positive, living cells are
qualified as successful modification events. Quantification of test wells using PI (as well as control
samples) is handled using flow cytometry.

4.2.4

Testing Preparation
HeLa 229 culture cells were incubated at 37C and 5% carbon dioxide cultured in Dul-

beccos Modified Eagles Medium (DMEM, Gibco) with 10% Fetal Bovine Serum (FBS, Denville
Scientific) and streptomycin/penicillin (Gibco). Six well plates were seeded with cell cultures and
allowed to adhere to a glass slide in conjunction with the 3D printed Cell Culture Platform over a
24 hour period, producing an approximately 70% confluent mono-layer of cells.
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Following the 24 hr incubation, the six well plates containing the cultured cells were removed from the incubator and had growth media removed and then cells were rinsed in 1 mL
per well of phosphate buffered solution (PBS). The respective treatment protocols detail specific
treatments applied to the wells from this point forward.
As noted previously, cultured samples were prepared in the 3D printed PLA platform and
top clip components. Typical six well plates were organized to have a non-treatment control (no
voltage, no lancing, no PI), a backgroung PI control (only PI added), and the remaining wells for
treatments at two different test temperatures, room (23◦ C) and ice (3◦ C), at two different voltage
protocols.
In order to ensure the exposure of the cells to the different temperatures, six well plates were
given 20 min to come to temperature. For test samples exposed to ice temperatures, the six well
plates were placed in ice baths. This time frame was selected for the cold exposure because it was
determined that was the amount of time required to get the sample to 3◦ C and longer-term exposure
to cold temperatures has been shown to induce cell cycle arrest, reduced energy production, and
activation of apoptosis [151, 155–157].
Figure 4.5 shows the experimental set-up used for injections. Equipment include a thermocouple (Fluke 51 K/J Thermometer) used for verifying amibent temperature of the injection fluid,
a waverform generator (Agilent 33220A) and power supply (Keithley 2400 Sourcemeter) for providing electrical input signals, an electrical switch box for controlling electrical signal delivery to
the nanoinjection device, a LabView VI (National Instruments) program used to monitor electrical
signal inputs, and the nanoinjection device with the associated six-well plate (Sarstedt) and cell
culture platforms.

Treatment Protocols
The following describes the various well types:
• Non-Treatment Control (NTC): Received no lancing, no applied voltage, and no PI. Nontreated controls were generated for each temperature (23◦ C and 3◦ C).
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• Background Control for PI (BC): Received no lancing, no applied voltage. Received 0.02
mg/mL PI. Background PI controls were generated for each temperature (23◦ C and 3◦ C).

• Treatment Protocol +5V Pulsed: Lanced, and received applied voltage which consisted
of: 20 second application of −1.5 DC voltage, followed by 10 squarewaves pulsed between
+1.5V to +5V with a 2 ms period, followed by 5 seconds of a +1.5 DC voltage. These
treatment samples were generated for each temperature (23◦ C and 3◦ C). PI was finally added
at four different time intervals (0, 3, 6, and 9 min) measured from the time the when lances
were removed from the cells.

• Treatment Protocol +7V Pulsed: Lanced, and received applied voltage which consisted
of: 20 second application of −1.5 DC voltage, followed by 10 squarewaves pulsed between
+1.5V to +7V with a 2 ms period, followed by 5 seconds of a +1.5 DC voltage. These
treatment samples were generated for each temperature (23◦ C and 3◦ C). PI was finally added
at four different time intervals (0, 3, 6, and 9 min) measured from the time the when lances
were removed from the cells.
For convenience, specific treatment sample types will be referred to by temperature of
injection solution, pulsed voltage protocol used, and if requisite, the time interval at which PI was
introduced. For example, 3◦ C/7V/T3 means a treatment sample that was injected in a solution at
3◦ C using a 7V pulsed voltage protocol and the specific time PI was added was 3 minutes postinjection.

4.2.5

Post Testing Flow Cytometry Preparation
After specific testing protocols were run, all samples were treated with 0.5 mL of 5X

Trypsin (Gibco) and incubated for 5 minutes for removal of cells from the glass slide. Once the
HeLa cells were removed, each well was treated with 1 mL of DMEM/FBS media to deactivate
the trypsin. The samples were then transferred to FACS tubes (BD BioSciences) for centrifugation
for 10 min at 2000 rpm. Following centrifugation, supernatants were removed and remaining cells
were re-suspended in 0.25 mL of PBS for final preparation prior to flow cytometry.
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a. FSC/SSC with Gating

b. Non-Treatment Control

c. Background Control for PI

f. 7V Pulsed, 23C Treatment

d. 5V Pulsed, 23C Treatment

g. 7V Pulsed, 3C Treatment

e. 5V Pulsed, 3C Treatment

Figure 4.6: Flow cytometry examples of six different sample types explored in this experiment.
a) Demonstrates how cells were gated for Living Cells from forward and side-scatter signals. bg) Represents gating of living cells based on signal intensity of samples from blue-laser 2 sensor
(BL-2). Note: The threshold for PI+ signals was determined from non-treated control samples and
is used globally to determine PI+ cells in treatment samples.

4.2.6

Flow Cytometry
Following flow cytometry preparation, the samples were qualified using flow cytometry

(Attune Acoustic Focusing Flow Cytometer, Life Technologies) to determine the cell viability and
PI uptake. Each sample examined had approximately 10,000 events counted and characterized.
Post flow analysis occurred in Attune Cytometric 2.1 (Applied Biosystems, Life Technologies) to
visualize, gate desired cell populations, and develop primary level data for each sample. Figure 4.6
helps to demonstrate how these cell populations were gated and quantified.
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4.2.7

Statistical Analysis
Data gathered from the post flow analysis in Attune was statistically analyzed in JMP

(SAS). Prior to analyses, treatment samples were normalized relative to both non-treated control
and background PI control samples at room temperature. Specifically, normalized cell viability
and propidium iodide (PI) uptake was calculated according to:

a=

b=

Living Cells in Test Sample
Total Living and Dead Cells in Test Sample

Living Cells in Non − Treated Control
Total Living and Dead Cells in Non − Treated Control

Normalized Cell Survival =

c=

d=

a
b

Living and PI+ Cells in Test Sample
Total Living Cells in Test Sample

Living and PI+ Cells in Backgroun PI Control
Total Living Cells in Backgroun PI Control

Normalized PI Uptake =
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c
d

This normalization step was used to help control for confounding variables particular to
individual six-well plates.
Following both PI Uptake and Cell Viability Normalizations, data sets were compared statistically using ANOVA and student t-tests. Further analysis was conducted to evaluate statistical
significance using the more conservative methods by using the permutation testing in JMP (1000
iterations, two-sided p-value) [158]. Additionally, linear combinations statistical methods were
used to examine whether 3◦ C samples as a whole were statistically different from 23◦ C samples.
Using the same criteria, sample sets were also contrasted using linear combinations for examining
whether 5V samples as a whole were statistically different from 7V samples.

4.3
4.3.1

Results and Discussion
Normalized PI Uptake
Figure 4.7 shows a collection of box-plots showing the respective data for each sample

set and relative statistically significant relationships following permutation analysis. Analysis of
the 3◦ C/7V Pulsed samples shows a statistically significant difference (two-sided p-value) with
both 23◦ C/5V Pulsed and 23◦ C/7V Pulsed samples at all times, with the exception of the 6 min
comparison between 3◦ C/7V Pulsed and the 23◦ C/5V Pulsed. Furthermore, in both the 3 and 9
minute comparisons, 3◦ C/7V sample sets are significantly different from 3◦ C/5V Pulsed samples.
Shown in the Table 4.1 and Table 4.2 are corresponding values for the two-sided p-values attached
to the comparison of samples at each time interval for both PI uptake and cell viability. (See
Figure 4.7)
Shown in Figure 4.8 are sample population means for each sample type relative to the time
post-injection when the samples had PI added. Figure 4.8 illustrates three key findings. First, all
treatent samples demonstrate an increase in normalized PI uptake for samples from 0 minutes to
3 minutes followed by a decrease from 3 minutes to 6 minutes. With the exception of the 3◦ C/5V
Pulsed samples, all samples measured a more minor secondary increase in normalized PI uptake
from 6 minutes to 9 minutes.
Second, both colder samples have higher degrees of normalized PI uptake than the 23◦ C
sample types, with the 3◦ C/7V Pulsed samples having the highest overall magnitude of PI uptake
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a. Normalized PI Uptake, t = 0 min Post-Injection
3C/7V/T0

23C/5V/T0

3C/5V/T3

3C/7V/T3

23C/5V/T3

Normalized PI Uptake

Normalized PI Uptake

3C/5V/T0

b. Normalized PI Uptake, t = 3 min Post-Injection

c. Normalized PI Uptake, t = 6 min Post-Injection
3C/7V/T6

23C/5V/T6

3C/5V/T9

3C/7V/T9

23C/5V/T9

Normalized PI Uptake

Normalized PI Uptake

3C/5V/T6

d. Normalized PI Uptake, t = 9 min Post-Injection

Figure 4.7: Box Plots of Normalized Propidium Iodide Uptake for all sample types, grouped according to post-injection time when PI was added. Statistically significant relationships based on
the permutation testing are indicated with a star.
with the exception of the nearly comparable value it shares with the 3◦ C/5V Pulsed samples at 6
minutes.
Lastly, the ordering of the sample types by degree of PI uptake indicates that the 3◦ C/7V
Pulsed samples had the greatest PI delivery efficiency, while the 23◦ C/7V Pulsed samples had the
lowest PI delivery efficiency.(See Figure 4.8)
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Figure 4.8: Mean Normalized PI Uptake for all sample types through time.
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Figure 4.9: Mean Normalized Cell Viability for all sample types through time.
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Table 4.1: Normalized PI Uptake Efficiency P-Values for Thermal Testing
Comparisons
0 Min Delay
◦
vs 23 C/7V
0.109
◦
◦
23 C/5V vs 3 C/5V
0.512
23◦ C/5V vs 3◦ C/7V
0.207
◦
◦
23 C/7V vs 3 C/5V
0.003
◦
◦
23 C/7V vs 3 C/7V
0.001
3◦ C/5V vs 3◦ C/7V
0.402

23◦ C/5V

3 Min Delay
0.145
0.168
0.001
0.006
0.000
0.005

6 Min Delay
0.235
0.192
0.297
0.005
0.014
0.932

9 Min Delay
0.321
0.648
0.031
0.123
0.005
0.026

Table 4.2: Normalized Cell Viability Efficiency P-Values for Thermal Testing
Comparisons
0 Min Delay
◦
vs 23 C/7V
0.087
◦
◦
23 C/5V vs 3 C/5V
0.055
23◦ C/5V vs 3◦ C/7V
0.868
◦
◦
23 C/7V vs 3 C/5V
0.000
◦
◦
23 C/7V vs 3 C/7V
0.012
3◦ C/5V vs 3◦ C/7V
0.025

23◦ C/5V

4.3.2

3 Min Delay
0.000
0.086
0.923
0.000
0.000
0.084

6 Min Delay
0.599
0.397
0.655
0.037
0.941
0.099

9 Min Delay
0.173
0.859
0.739
0.048
0.011
0.467

Normalized Cell Viability
Figure 4.9 are sample population means for the normalized cell viability for each sample

type at the different times post-injection. This graph demonstrates an effective range of cell viability of 63% (3◦ C/5V Pulsed at t = 3 min) to 99% (23◦ C/7V Pulsed at t = 3 min). With the
exception of 23◦ C/7V Pulsed samples, it appears that cell viability decreases from 0 to 3 minutes
post-injection, followed by an increase during 3 to 6 minutes.

4.3.3

Temperature and Pulsed Voltage Contrasts
Table 4.3 illustrates p-values related to the linear combinations of temperature contrast.

First, in the context of temperature contrast between 23◦ C and 3◦ C samples, it appears that cell
viability is significantly different during the first two sample intervals (T0 and T3), favoring samples exposed to warmer conditions. The PI uptake for this same comparison also indicates that the
colder samples had significantly higher levels for all time intervals investigated.
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Table 4.3: Linear Combination P-Values for Temperature Contrast
Comparisons
Cell Viability: 23◦ C vs 3◦ C
PI Uptake: 23◦ C vs 3◦ C

0 Min Delay
0.002
0.003

3 Min Delay
0.000
0.000

6 Min Delay
0.462
0.005

9 Min Delay
0.198
0.004

Table 4.4: Linear Combination P-Values for Voltage Contrast
Comparisons
Cell Viability: 5V vs 7V
PI Uptake: 5V vs 7V

0 Min Delay
0.002
0.730

3 Min Delay
0.000
0.357

6 Min Delay
0.066
0.819

9 Min Delay
0.241
0.199

Table 4.4 shows pulsed voltage comparison using the same method. It appears that there
is a significant difference for the first two time intervals (T0 and T3) in terms of cell viability,
favoring the samples that experienced higher pulse voltages. PI uptake is not significantly different
for the voltage comparison criteria at all time intervals investigated.
The results suggest several cellular response mechanics in regards to concomitant thermal
stress and surface structural dysruption. Discussed earlier were the effects that lower physiological temperature has on target cells in regards to the cell membrane/material stiffening as well as
diminished cytoskeletal support leading to reduced surface defect healing.

4.3.4

Surface Defect Healing
In the context of surface defect healing, Figure 4.8 shows a decrease in PI uptake between

3 and 6 minutes post-injection for all treatment sample types. This suggests that large numbers of
induced pores are closing in some degree during this time period. Notably, because the lance arrays
are designed to create approximately the same number of pores in each injected well, it is suggested
by the larger decrease in PI uptake for the 3◦ C samples over this interval that surface defect healing
rate is greater during cold stress. However, it also suggests that while the magnitude of induced
pore closure rate may be greater in the 3◦ C samples during 3 to 6 minutes post-injection, that the
23◦ C samples have a lower number of pores still patent after this event. In the initial hypothesis,
it was believed that colder samples would have stiffer membrane material properties and therefore

54

have a greater number of pores patent for a longer period of time. Statistically, this relative behavior
between temperatures can be viewed in Table 4.3.
To help corroborate the conclusion that the major pore closing event occurs between 3 to
6 minutes post-injection, Figure 4.9 illustrates that over the same time period, cell viability levels
increase, with the exception of the 23◦ C/7V Pulsed sample which experiences a modest decrease
in cell viability (approximately 5%). A likely explanation is that as induced pores begin to close,
manifested in terms of reduced PI uptake, the transmembrane ion gradients that were dysrupted by
the injection event begin to stabilize and thereby improve cell survival.
Returning to Figure 4.8 and the suggested pore-closure events occurring in all sample types
between 3 to 6 minutes post-injection, it is worth noting these findings in terms of the original hypothesis regarding cytoskeletal function in surface defect healing. It was originally hypothesized
that at the reduced temperature, cytoskeletal integrity would be diminished and thereby the functional ability of the cell to repair surface defects would be reduced. However, that behavior is not
seen in Figure 4.8 in terms of a lag time in pore closure with the 3◦ C samples. A possible reason
that behavior is not found may deal with the fact that reduced temperature exposure to treatment
samples was transient enough to not adversely diminish cytoskeletal structure/function.

4.3.5

Temperature-Dependent Ion Re-Balancing
One particular behavior that is also suggested in Figure 4.8 is a temperature-dependent re-

balancing of ion gradients during the post-injection period. Early in the experimentation of this
work, it was anticipated that the cell would experience a temperature-dependent re-balancing due
to the decreased production of ATP at lower temperature, a behavior noted in other mammalian cell
types at approximately 3◦ C [159]. The propidium iodide molecular load used post-injection was
thought to be actively removed via membrane bound ATP-driven pumps [160]. When PI is added
to the post-injected solution, while the target cells are still re-establishing ion gradients due to the
multiple (2-4 pores per cell) 1-2.5 micron-sized pores, it is believed that the PI and transiently
mis-placed ions would be removed from the intracellular space via ATP-pumps. Demonstrated in
Figure 4.8 is that the 3◦ C samples at all time periods post-injection, had greater levels of PI still
present in the intracellular space, suggesting that ATP production is reduced with lower temperature, therefore reducing PI removal from the cell as well.
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In context of the two voltage protocols used during the LAN event, there appears to be
no clear pattern as far as PI uptake is concerned as noted in Table 4.4. In terms of the injection
process, this finding is not surprising since because PI was not yet added to the solution until after
the injection process.

4.3.6

Minor PI Uptake Rebound
Figure 4.8 shows during 6 to 9 minutes post-injection, that all samples (except 3◦ C/5V

Pulsed samples) experience a rebound in the degree of PI uptake. Treatment sample 3◦ C/7V Pulsed
experience the greatest rebound in PI while 23◦ C/5V and 23◦ C/7V Pulsed samples experience a
more comparable level of PI uptake rebound. The timing and degree for this behavior is not clear.

4.3.7

Cell Survival with Large Surface Defect
To the authors’ knowledge, this is the first time pores formed with such a large diameter

(approximately 2.5 microns in diameter, 2-4 per cell) in the presence of the thermal stress has
been conducted in context of cell survival. Remarkedly, even in the presence of such relatively
large compromises to the cell structure, these cell cultures still maintain an average cell viability
of 78.08% for 3◦ C samples and 89.61% for 23◦ C samples.

4.4

Conclusion
Characterizing cell culture environmental factors and the role they play in alterations to

structural and functional behavior of target cells is a critical foundational research topic for enhancing non-viral transfection technologies. Presented here is a non-viral transfection technology
known as Lance Array Nanoinjection (LAN), a method that relies on both physical penetration
of the cell membrane and electrical delivery of charged molecular loads. Experimentally, it was
shown that LAN in the presence of thermal variation delivers greater amounts of propidium iodide
to target cells when samples are cooled to 3◦ C rather than maintained at 23◦ C. Furthermore, it is
suggested in this work that HeLa cells respond uniquely in regards to pore closure 3 to 6 minutes
post-injection and that despite the surface damage from the injection, they maintain average cell
viability rates between 78.08% and 89.61% for 3◦ C and 23◦ C treated samples, respectively.
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CHAPTER 5.

INJECTION SPEED AND SERIAL INJECTION

The following chapter has been submitted as a journal article to SpringerPlus and is currently in
review. The title of this journal article is “The Effect of Injection Speed and Serial Injection on
Propidium Iodide entry into Cultured HeLa and Primary Neonatal Fibroblast Cells using Lance
Array Nanoinjection”. As a result, there may be some material that is contained elsewhere in this
dissertation but is presented here as a representation of this original journal article.

5.1

Introduction
Gene therapy and gene medicine approaches to correcting disease represent a major paradigm

shift in how clinicians are able to help patients, moving from a framework of reactionary treatment
of disease manifestations to fundamental, proactive prevention of genetic alterations causing the
disease [1–3]. While still in a relatively early stage of development, medical approaches designed
to engineer genetic outcomes have had promising results in terms of both monogenic [4–11] and
polygenic [12–17] disease corrections.
Unfortunately, the actual method for transmission of the genetic loads to target cells remains a challenge [18–21]. Many biotechnologies have been created to help address this issue
(with mixed results) [22, 161–165]. The primary goal of all of these methods is to site-direct genetic loads into cells without harming the host systemically or the target cell locally [18]. Key
features frequently noted as critical design requirements for these biotechnologies include:
• High transfection efficiency
• Effective in a wide range of cell types
• Flexible pay load capacity
• No immunologic response
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Figure 5.1: SEM image of two rows of lances contained on the Lance Array Silicon chip. Lances
measure 10 µm in length, 1-2.5 microns in diameter, and spaced 10 µm from center to center

• No insertional mutagenesis
One non-viral transfection biotechnology, known as Lance Array Nanoinjection (LAN),
has been created with these design requirements in mind. LAN works by using a combination of
physical penetration of target cell membranes and electrical delivery of molecular loads using a
microfabricated silicon etched array of lances [23, 24]. Figure 5.1 shows an SEM image of a lance
array which contains 10 µm length lances spaced 10 µm from center to center in a grid pattern,
ultimately forming 4 million lances on a 2 cm by 2 cm chip.
Procedurally, nanoinjection works in a series of four major steps which include: staging the
lance in the solution containing the desired molecular load, electrical attraction of the molecular
load onto the lance, physical penetration of the cell membrane of target cells and electrical repulsion of the molecular load into the cytoplasmic space, and finally removal of the lance [25–27]
(See Figure 5.2 for illustration of LAN process).
There are several attractive features of LAN relative to other transfection methods. First, it
does not rely on delivery agents that can cross-react with the immune system (such is the case with
several viruses [28–32]), nor does it create cytotoxic effects in target cells (such is the case with
many chemical based methods [22, 28]). Second, because the lances are 1-2.5 µm in diameter, the
resulting pores created during the injection event are relatively large, making it possible for large
molecules to transiently pass into the cell. Even though the pores are relatively large, the trauma
58

Figure 5.2: Lance Array Nanoinjection Stepwise Process. 1: Staging the lance array in the solution
containing the desired molecular load. 2: Electrical attraction of the molecular load onto the lances.
3: Physically penetrating the cell membrane of target cells and electrical repulsion of the molecular
load into the cytoplasmic space. 4: Removal of the lance array, leaving the molecular load in the
intracellular space of target cells

induced during the process is relatively minimal, as evidenced by high cell viability rates (78% to
91%) previously noted [24]. This latter feature of cell viability is an issue in some instrumentation
based transfection methods, such as electroporation [33] and microinjection [25].
Despite these attractive features of LAN, one short-coming that LAN as well as all nonviral transfection technologies encounter is that transfection rates are lower than what can be
achieved with viral modalities [28]. This work seeks to directly address this challenge related
to efficient molecular delivery by considering two intertwined procedural variables unique to LAN
59

which include: the speed of injection and serial injection of the same sample. In prior testing, it
has been noted that following a single injection event, many cells do not stay adherent to the glass
slide used for staging the injection process. The purpose of investigating the effect of speed of
injection is to determine the extent that cell removal can be minimized such that serial injection
protocols can be investigated.
Indeed, it is shown in this work that by slowing the speed of the injection process that target
cells are able to remain adherent to the glass slide using for staging the injection. Because the cells
remain post-injection, it is possible to inject multiple times and thereby increase the amount of
molecular load delivered to the cell.
To help establish the robustness of this procedural investigation, as part of the serial injection testing, two different cell types, immortalized HeLa culture and primary neonatal fibroblast
cells, were used to determine how the different cell types respond. To demonstrate molecular load
delivery, propidium iodide (PI), a dye typically impermeable to the cell membrane, was used in
conjunction with flow cytometry to quantify the injection-dose response.
Because the speed of injection experimentation led to serial injection experimentation, the
following will be compartmentalized to consider the speed of injection work first, followed immediately by the serial injection work.

5.2

General Methods
This work consists of two major experiments – the speed of injection and serial injection

experiments. The speed of injection work, which is presented first, is a precursor experiment that
led to further exploration that makes up the serial injection experiment. Both used common experimental elements which are detailed in this general methods section. For experimental elements
unique to the specific experiment, separate descriptions are provided.

5.2.1

Lance Array Fabrication
Reference [23] provides a complete description of the microfabrication process used for

creating the silicon lance array and is presented here simply for convenience. The lance array
microfabrication process consisted of using positive photoresist (AZ330F) to pattern a grid of
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circles that became pillar-like structures following deep reactive ion etching (DRIE). These pillars
were then treated with a sulfur hexafluoride (SF6) isotropic plasma etch, which serves to form a
pointed tip on the pillars, resulting in lances (see Figure 5.1).

5.2.2

Injection Set-Up
Figure 5.3 shows a schematic, cross-sectional view of the injection device and contains

eight major components which include: stepper motor, threaded rod, coiled spring, orthoplanar
spring, electrical connections, silicon lance array, glass slide for the cell culture, and cell culture
platform. The stepper motor and electrical connections receive input signals from the electrical
control box (see Figure 5.4). During the injection process, the stepper motor causes the threaded
rod to vertically displace the coiled and orthoplanar springs. The lance array is attached to the
inferior surface of the orthoplanar spring and interacts with the cell culture contained on the glass
slide according the process outlined in Figure 5.2. The cell culture platform serves to facilitate
alignment with the orthoplanar spring and also helps fix the glass slide, preventing it from adhering
to the silicon lance array.

5.2.3

Electrical Control Box
The electrical control box, which provides electrical input to the injection device, operates

by receiving three inputs from three separate power supplies (2400 SourceMeter, Keithley) (see
Figure 5.4). Figure 5.5 is a full electrical schematic of the electrical control box where it illustrates
electrical inputs from the power supplies running through two relays arranged in series. The first
relay was used to allow either Input 1 or 2 to pass, while the second relay was used to allow the
input from the previous relay or Input 3 to pass. This allowed one input at a time to pass using two
digital pins (one to control each relay, using 5V or GND).
The output signals from the electrical control box used for the serial injection testing can
be described as the following: Output 1, current controlled of either 1.5 or 3.0 mA for 20 seconds;
Output 2, 10 intermittent pulsing events between 0V and +7V for 20 ms (2 ms period); Output 3,
5 second interval of +1.5V. In addition to these actions, the electrical control box also operates the
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Figure 5.3: Cross-sectional schematic of LAN injection device relative to cell culture platform.
Components include (top to bottom): stepper motor, threaded rod, coiled and orthoplanar springs,
electrical connections, silicon lance array, glass slide for cell culture, and cell culture platform

stepper motor attached to the superior end of the injection device. It should be noted, Outputs 2
and 3 occur when the lances are inserted into the cells.

5.3
5.3.1

Methods: Speed of Injection Experimentation
Stepper Motors
Two separate stepper motors (28BYJ-48-5V, Rohs; TSFNA25-150-17-023-LW4, Anaheim

Automation (AA)) were used to for the speed of injection testing in order to achieve the speeds
needed and still ensure that the stepper motors would not skip steps by being driven too quickly.
Five different speeds were used for this experiment, which include 0.08, 0.16, 0.60, 1.80, 3.00
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Injection Device

Electrical Control Box

Electrical Outputs
to Injection Device
Six Well Plate with
Cell Culture Platforms

Electrical Inputs
from Power Supplies

Figure 5.4: Experimental set-up showing the electrical control box receiving three separate input
signals coming from three power supplies (not shown) and outputing appropriately timed output
signals to the injection device mounted above the prepared six-well plate. Cell culture platforms
with the prepared cell cultures are seen as white and red circular components resting in the wells
of the six-well plate

mm/sec. For the slower speeds of 0.08 and 0.16 mm/sec, the Rohs stepper motor was used and for
0.60, 1.80, and 3.00 mm/sec speeds, the AA stepper motor was used. The injection device was the
same for all sets of injection tests, with the exception of the stepper motor being changed to match
speed conditions.

5.3.2

Cell Culture Preparation
HeLa 229 cells were plated on glass slides within six-well plates (Sarstedt) and incubated

at 37C and 5% carbon dioxide. Culture media contained Dulbeccos Modified Eagles Medium
(DMEM, Gibco) with 10% Fetal Bovine Serum (FBS, Denville Scientific) and streptomycin/penicillin
(Gibco). Cell cultures were allowed to incubate for 24 hrs following the plating process to ensure
adequate adherence to the glass slide. Following the 24 hrs, a mono-layer of HeLa cells, which
were approximately 70% confluent, had their growth media removed and were re-supplied with 2
mL of phosphate buffered solution (PBS, Gibco) in final preparation for injection.
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Figure 5.5: Electrical schematic for the current control box. An Arduino was used to control two
relays and a stepper motor driver for the injection process. Five LEDs are used as indicators for
power, output, and which input being passed through the box
5.3.3

Treatment Protocols
The following describes the various sample types used in the speed of injection testing:

• Non-Treatment Control (NTC): Received no lancing.

• Treatment Protocol for Different Speeds: Samples were lanced a single time and received
no applied voltage during the injection process. Five different injection speeds were applied
during the injection event and include: 0.08, 0.16, 0.60, 1.80, 3.00 mm/sec.

As a convention, specific treatment sample types will be designated by the speed of injection. For example, HeLa/0.08 refers to a treatment sample that was lanced a single time at 0.08
mm/sec.
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5.3.4

Post-Treatment Analysis
After the injections were completed, all samples were given 0.5 mL of 5X trypsin (Gibco)

and incubated 5 minutes at 37C to facilitate removal of the cells from the glass slides. After the
5 minutes, samples were treated with 1.5 mL of DMEM/FBS media to deactivate the trypsin and
then centrifuged at 2000 rpm for 10 minutes. The supernatant was then removed, 0.25 mL of PBS
was added to each sample, and each sample was then vortexed to prepare them for hemocytometry. Quantification of the number of cells were performed according to standard hemocytometry
methods using trypan blue [166].

5.3.5

Statistical Analysis
After cell counts were obtained using hemocytometry, data for treatment samples were

normalized relative to the Non-Treatment Controls according to the following formula.
Cell Count in Treatment Sample
Cell Count in Non − Treated Control

This normalized data was then statistically analyzed in JMP (SAS), using initially an
ANOVA test to screen for statistically significant relationships (F-Ratio: 16.5426) followed by
individual student t-tests (α = 0.05).

5.4

Results and Discussion: Speed of Injection Experimentation
Figure 5.6 shows a set of box plot results for the data generated for the five different injec-

tion speeds. The left-most two box plots were obtained by using the slower stepper motor (Rohs),
while the other three box plots were obtained from the slightly faster stepper motor (AA). It can
be seen that statistically significant relationships exist in all cases between the slower and faster
stepper motors (<0.0001) (see Table 5.1).
Table 5.2 provides a summary of the results showing that for both the 0.08 and 0.16 mm/sec
speeds, that the mean normalized cell count is more than double the highest normalized mean
obtained with the faster stepper motor.
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Normlaized Cell Count Percentage

0.08

0.16

0.60

1.80

3.00

Speed of Injection (mm/sec)

Figure 5.6: Injection Speed Box Plot. The two left-most box plots were the result of the slower
stepper motor (Rohs) whereas the three right-most box plots were the result of the faster stepper
motor (AA). Statistically significant relationships are noted with an asterisk
Table 5.1: P-Values for Speed of Injection Experiment
Comparison
HeLa/0.08 vs HeLa/0.16
HeLa/0.08 vs HeLa/0.60
HeLa/0.08 vs HeLa/1.80
HeLa/0.08 vs HeLa/3.00
HeLa/0.16 vs HeLa/0.60

P-Value
Comparison
P-Value
0.6466 HeLa/0.16 vs HeLa/1.80 <0.0001
<0.0001 HeLa/0.16 vs HeLa/3.00 <0.0001
<0.0001 HeLa/0.60 vs HeLa/1.80 0.7180
<0.0001 HeLa/0.60 vs HeLa/3.00 0.4362
<0.0001 HeLa/1.80 vs HeLa/3.00 0.2566

Table 5.2: Statistical Summary for Injection Speed Experiment
Injection Speed (mm/sec)
HeLa/0.08
HeLa/0.16
HeLa/0.60
HeLa/1.80
HeLa/3.00

Sample Size (n)
10
10
10
10
10
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Mean Normalized Cell Count
0.993
0.946
0.427
0.390
0.507

Suggested in these results is that the cultured cells are able to adhere better to the glass
surface used for staging the injection when using injection speeds of 0.08 to 0.16 mm/sec. These
findings are consistent with atomic force microscopy (AFM)-based single-cell force spectroscopy
(SCFS) studies [167–173]. Friedrichs et al [174] demonstrated with a single cell adhered to an
AFM probe by cell adhesion molecules (CAMs), that when placed in contact with a substrate
surface, the speed with which the AFM probe was removed was directly related to the viscous
forces created between the substrate surface and the cell. If sufficiently strong viscous forces
were generated by removing the AFM probe (with the attached cell) fast enough, the cell would
experience a series of five major events which include:
1. Shrinking of the surface area contact between the cell and substrate surface.
2. Cell body removal from the substrate with only membrane nanotubes linking the cell and
substrate.
3. Stressing of the CAM linkages between the cell and AFM probe – reaching a non-linear
maximum level as cytoskeletal structures are strained in the direction of motion.
4. Peripheral rupture of the CAM structures leading to a rapid decrease in adhesion force between the cell and the AFM probe.
5. Cell removal from the AFM probe as the viscous effects from the substrate-cell interface
overcome the cellular adhesion to the AFM probe.
Returning to the context of LAN, it is suggested that for the majority of cells present on the
glass slides that experience injection speeds of ≤0.16 mm/sec, that the viscous forces created by
the removal of the silicon lance array does not exceed the strength with which the cells are adhered
to the glass slide. For treatment samples experiencing greater speeds of lance array removal, it
appears that fewer cells are able to withstand these removal forces and are pulled away from the
glass.

5.5

Methods: Serial Injection Experimentation
Using the fact that slowing the injection process results in an increase in cell number re-

maining on the glass slide substrate used for staging the injection process, it was proposed to
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investigate whether or not target cells could be injected multiple times and exhibit an increase
in molecular load delivery. Furthermore, it was also proposed to determine whether a difference
exists in molecular delivery when using different cell types. To explore this latter item, two cell
types were selected which include HeLa 229 cells (commonly used in basic research) and primary,
human neonatal fibroblasts (BJ(ATCC® CRL-2522TM )) (used in wound healing applications).
For convenience, the injection speed of 0.16 mm/sec was used for the serial injection testing
because it was twice as fast as the 0.08 mm/sec speed setting and still had a high mean number of
cells still adherent to the glass slide following injection (i.e. 94.6%).

5.5.1

Cell Culture Preparation
For both cell types, test preparation began with seeding glass slides contained within six-

well plates with 2 mL of a growth media, which consisted of: Dulbeccos Modified Eagles Medium
(DMEM, Gibco), 10% Fetal Bovine Serum (FBS, Denville Scientific), and streptomycin/penicillin
(Gibco). Cells were incubated overnight prior to injection at standard conditions of 37C and 5%
carbon dioxide.
Following this process, glass slides were transferred to new six-well plates and snapped
into 3D printed cell culture platforms (used to help align the injection device). Cells, now staged
for the injection process, were given 2 mL of phosphate buffered solution (PBS, Gibco) per well.
At this point, both cell types had formed a mono-layer of approximately 70% confluency.

5.5.2

Propidium Iodide
Propidium iodide (Sigma-Aldrich) was used as a molecular marker in this experiment be-

cause it is typically impermeable to the cell membrane. Because the lances used in LAN penetrate
target cells and then deliver PI to the intracellular space of these target cells, it is an indicator
of successful delivery. Once in the cell, PI can intercalate will nucleic acids, which results in
fluorescent activity 20 to 30 times greater than normal, thereby providing a detectable means of
transfection rates during flow cytometry.

68

5.5.3

Treatment Protocols
Treatment samples were generated using the following protocols for both HeLa and Fi-

broblast cells which include:
• Non-Treatment Control (NTC): Received no lancing, no applied voltage, and no PI.

• Background Control for PI (BC): Received no lancing, no applied voltage. Received 0.02
mg/mL PI.

• Treatment Protocol 1.5 or 3.0 mA, injected 1, 2, or 3 times: Lanced, receive 0.02 mg/mL
PI, and received current control which consisted of: 20 second application of either 1.5 or
3.0 mA, followed by 10 intermittent pulsing events between 0V and +7V for 20 ms (2 ms
period), followed by 5 seconds of a +1.5 DC voltage.

Those treatment samples that were injected more than once were incubated for one hour
before the sample was injected again. This refractory period has been shown in previous
testing to prevent excessive stress to target cells.

As a convention, specific treatment sample types will be designated by cell type, current
control setting used during injection, and the number of times the sample was injected. For instance, Fibro 1.5 mA, x2 refers to a fibroblast treatment sample that was injected with 1.5 mA
(used for Input 1), two times.

5.5.4

Post Testing Flow Cytometry Preparation
Following injections, all samples were incubated for 2 hrs prior to being treated with 0.5

mL of 5X Trypsin (Gibco) and incubated for 5 minutes for removal of cells from the glass slide.
Following treatment with trypsin, samples were given 1.5 mL of DMEM/FBS to deactivate the
trypsin. After transferring individual samples to FACS tubes, the samples were centrifuged for 10
min at 2000 rpm. Final preparation for flow cytometry of the samples include decanting supernatants and re-suspending cell pellets in 0.5 mL of PBS.
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5.5.5

Flow Cytometry
Quantification of samples was performed using flow cytometry (Attune Acoustic Focusing

Flow Cytometer, Life Technologies). Approximately 20,000 events were captured and characterized for each sample. Data extraction was performed using Attune Cytometric 2.1 software (Applied Biosystems, Life Technologies) by facilitating visualization of events, gating of appropriate
cell populations, and developing primary level data usable for JMP (SAS) statistical analysis.

5.5.6

Statistical Analysis
Primary level data generated from post-flow analysis in Attune Cytometric software was

evaluated in a two part process. First, the percentage of living, PI positive cells in each sample
were calculated according to the following formula:
Number of Living PI Positive Cells in Sample
Number of Living Cells in Sample

Second, data was then screened in JMP for statistical signficance using ANOVA test (FRatio for HeLa study: 21.0098; F-Ratio for Fibroblast study: 49.1873) followed by individual
student t-tests (α = 0.05).

5.6

Results and Discussion: Serial Injection Experimentation
Figure 5.7 shows box plot results of the HeLa cell serial injection experiment. Three find-

ings can be seen in these plots and quantitatively represented in Table 5.3 and Table 5.4. First,
the samples receiving 3.0 mA during Input 1 had a higher mean number of modified cells than
samples receiving 1.5 mA. The relative maximum for the 3.0 mA samples reached a mean value
of 60.47%, which is nearly four times greater than the relative maximum achieved for the 1.5 mA
group. Second, within groups receiving the same current control during Input 1 of the injection
process, samples that were injected twice had a higher mean number of modified cells than those
samples injected one or three times. Third, within the current control groups, both groups receiving
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Percentage of Living/Propidium Iodide Positive HeLa Cells
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Control
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Figure 5.7: Mean Percentage of Living/Propidium Iodide Positive HeLa Cells for all sample types.
Because of the number of statistical relationships that were derived, statistically significant relationships are not noted on the box plot figure. For statistical significant relationships, reference
Table 5.3

three injections had mean values for PI uptake that were intermediate levels for the current control
group.
Figure 5.8 shows the box plot results for the serial injection of primary, fibroblasts using
the two different current control settings. Two main features are observed in the results. First, the
Fibro 3.0 mA, x2 sample group had the highest mean percent of modified cells for all samples
(i.e. 20.97%), being more than three times greater than the best mean percent in the 1.5 mA group.
Second, similar to the behavior seen in the HeLa samples for serial injection, the fibroblasts treated
with 3.0 mA also had a relative maximum mean value for the two times injected group.
Table 5.5 and Table 5.6 provide both statistically significant relationship and summaries
for the experiment. Of note, the fibroblasts exhibit lower mean values for the PI delivery than
analogous HeLa samples. Also of note, the HeLa samples that were treated with 3.0 mA had a
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Table 5.3: P-Values for HeLa Serial Injection Experiment
Comparison
NTC vs BC
NTC vs 1.5mA,x1
NTC vs 1.5mA,x2
NTC vs 1.5mA,x3
NTC vs 3.0mA,x1
NTC vs 3.0mA,x2
NTC vs 3.0mA,x3
BC vs 1.5mA,x1
BC vs 1.5mA,x2
BC vs 1.5mA,x3
BC vs 3.0mA,x1
BC vs 3.0mA,x2
BC vs 3.0mA,x3
1.5mA,x1 vs 1.5mA,x2

P-Value
0.5813
0.2629
0.0114
0.0346
<0.0001
<0.0001
<0.0001
0.5299
0.0402
0.1032
<0.0001
<0.0001
<0.0001
0.1903

Comparison
1.5mA,x1 vs 1.5mA,x3
1.5mA,x1 vs 3.0mA,x1
1.5mA,x1 vs 3.0mA,x2
1.5mA,x1 vs 3.0mA,x3
1.5mA,x2 vs 1.5mA,x3
1.5mA,x2 vs 3.0mA,x1
1.5mA,x2 vs 3.0mA,x2
1.5mA,x2 vs 3.0mA,x3
1.5mA,x3 vs 3.0mA,x1
1.5mA,x3 vs 3.0mA,x2
1.5mA,x3 vs 3.0mA,x3
3.0mA,x1 vs 3.0mA,x2
3.0mA,x1 vs 3.0mA,x3
3.0mA,x2 vs 3.0mA,x3

P-Value
0.3578
0.0009
<0.0001
<0.0001
0.6946
0.0381
<0.0001
<0.0001
0.0141
<0.0001
<0.0001
<0.0001
0.0274
0.0574

Table 5.4: Statistical Summary for HeLa Cell Serial Injection Experiment
Comparisons
Sample Size (n)
HeLa, NTC
24
HeLa, BC
24
HeLa 1.5mA, x1
16
HeLa 1.5mA, x2
16
HeLa 1.5mA, x3
16
HeLa 3.0mA, x1
16
HeLa 3.0mA, x2
15
HeLa 3.0mA, x3
15

Mean (%)
0.1996
3.3325
7.3231
16.4594
13.7281
30.9944
60.4720
46.7300

much larger variability in the grouping of data points when compared to the fibroblast 3.0 mA
treatment groups.
Key elements shown in the results of both HeLa and fibroblast cells is that the cells respond
to the series of injections by having an increase in PI introduction, with the exception of the samples
injected 3 times. Two possibilities to explain the decrease in PI observed in three times injected
samples are related to physiologic responses to LAN. One possibility is that the 1 hr rest period
given to the cells following injection is not long enough for cellular structures to recover from
the injection event. Even though LAN has been shown to be mild in terms of cell viability after
a single injection event [24], it is possible that after three injections, that a longer rest period is
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Figure 5.8: Mean Percentage of Living/Propidium Iodide Positive Fibroblast Cells for all sample
types. Because of the number of statistical relationships that were derived, statistically significant
relationships are not noted on the box plot figure. For statistical significant relationships, reference
Table 5.3

Table 5.5: P-Values for Fibroblast Serial Injection Experiment
Comparison
NTC vs BC
NTC vs 1.5mA,x1
NTC vs 1.5mA,x2
NTC vs 1.5mA,x3
NTC vs 3.0mA,x1
NTC vs 3.0mA,x2
NTC vs 3.0mA,x3
BC vs 1.5mA,x1
BC vs 1.5mA,x2
BC vs 1.5mA,x3
BC vs 3.0mA,x1
BC vs 3.0mA,x2
BC vs 3.0mA,x3
1.5mA,x1 vs 1.5mA,x2

P-Value
<0.0001
<0.0001
0.0028
0.0095
<0.0001
<0.0001
<0.0001
0.6775
0.5598
0.2826
<0.0001
<0.0001
<0.0001
0.3646

Comparison
1.5mA,x1 vs 1.5mA,x3
1.5mA,x1 vs 3.0mA,x1
1.5mA,x1 vs 3.0mA,x2
1.5mA,x1 vs 3.0mA,x3
1.5mA,x2 vs 1.5mA,x3
1.5mA,x2 vs 3.0mA,x1
1.5mA,x2 vs 3.0mA,x2
1.5mA,x2 vs 3.0mA,x3
1.5mA,x3 vs 3.0mA,x1
1.5mA,x3 vs 3.0mA,x2
1.5mA,x3 vs 3.0mA,x3
3.0mA,x1 vs 3.0mA,x2
3.0mA,x1 vs 3.0mA,x3
3.0mA,x2 vs 3.0mA,x3
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P-Value
0.1745
<0.0001
<0.0001
<0.0001
0.6654
<0.0001
<0.0001
<0.0001
<0.0001
<0.0001
<0.0001
0.0002
0.1438
0.0286

Table 5.6: Statistical Summary for Fibroblasts Cell Serial Injection Experiment
Comparisons
Sample Size (n)
Fibro, NTC
23
Fibro, BC
24
Fibro 1.5mA, x1
16
Fibro 1.5mA, x2
15
Fibro 1.5mA, x3
16
Fibro 3.0mA, x1
16
Fibro 3.0mA, x2
16
Fibro 3.0mA, x3
14

Mean (%)
0.5383
5.7713
6.3556
4.9353
4.2588
15.1175
20.9738
17.4550

required in order to reduce cellular stress and increase cell survival rates. A second possibility is
related to the effects on the cellular adhesion to the glass slide following injection. Perhaps even
though cells are able to maintain adhesion to the glass slide at high rates (as shown in the first
portion of this work), that residual strain collects in the CAM structures and after three times of
injection, the CAM can no longer adhere to the glass, resulting in a decreased observed number of
PI in the sample. Suggested here is further investigation into what effects the rest period duration
has on the ability of cultured cells to withstand multiple injection events.
Despite the decreases seen in the samples injected three times, the samples are still exhibiting relatively high levels of PI modification. For instance, the fact that the primary fibroblasts
had a lower number of cells modified than the HeLa cells is not unexpected, particularly given the
fact that BJ(ATCC® CRL-2522TM ) fibroblasts are difficult to modify [175–177]. Even so, nonoptimized delivery of PI still reached levels of 20.97%. Furthermore, it is clear that the magnitude
of the current control used in Input 1 has a dramatic impact on PI delivery and warrants further
exploration.

5.7

General Discussion
The combination of results obtained for the speed of injection and the serial injection testing

represent three major findings. First, cell cultures are able to adhere to the glass slide used for
staging the injection process much better (i.e. >94.6%) when the speed of injection is reduced
below 0.16 mm/sec. Second, during serial injection testing, samples treated with 3.0 mA during
Input 1 and injected twice appear to have the greatest mean percent of living, PI positive cells.
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Third, the cell type appears to have an effect on how well cells are modified by PI during the
injection process, with HeLa cells performing better than primary, neonatal fibroblasts.
All three of these findings are viewed as particularly important milestones in regards to
LAN because of how influential they are in establishing higher transfection rates. As noted earlier,
there are several biotechnologies that have attempted to address the challenge of molecular delivery
by non-viral means but are still plagued with transfection efficiency issues, which varying widely
because of intrinsic weaknesses that are part of the technology or because of the cell type being
transfected [28].
Traditionally, viruses have been the benchmark for which transfection efficiency is measured. However, they fall short of meeting critical design requirements for robust transfection,
particularly in preparation for clinical application. Adenoviruses, Adeno-associated viruses, and
lentiviruses are all considered to have high transfection rates in a wide range of cell types [30, 34–
42]. Unfortunately, adenoviruses are immunologically inflammatory which can be life-threatening
[29, 43], adeno-associated viruses can cause insertional mutagenesis which can be cytotoxic [35,
36], and lentiviruses cause immunologic responses and insertational mutagenesis [30–32, 44].
While retroviruses are useful in CNS (central nervous system) targets [37, 45], the risk of insertional mutagenesis is quite high [37, 46]. Furthermore, viruses in general are limited in their
effectiveness because of the limited pay load capacity (≤ 10 kbp) [37] (see Table 5.7).
In contrast, Lance Array Nanoinjection is able to by-pass many of these short-comings.
First, LAN does not utilize protein vehicles which could cross-react with the immune system,
thereby removing immunologic response issues. Second, LAN creates relatively large pores in target cells (1-2 µm diameter), allowing for large molecular loads to enter, thus reducing the concern
of not having sufficient pay load capacity. Third, LAN is compatible with gene editing tools such
as CRISPR-Cas9 that mitigate concerns regarding insertional mutagenesis. While the same can be
said of viruses if re-programmed to remove self-insertional mechanisms, LAN does not have the
same rigor of testing to go through prior to use as viral delivery because insertional mutangenesis
in the context of LAN is only an element directly related to the molecular load type, not LAN as a
delivery method.
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Table 5.7: Benchmark Comparison of Viral Transfection Technologies
Viral Vector

Load Capacity
Transduction
Wide Cell
(kbp)
Rate
Types Use
Adenovirus
8.5 [37]
[34]
[37, 38]
Adeno-Associated
4-5 [37]
[35, 36]
[39]
Retrovirus
10 [37]
[178]
[37, 45]
Lentivirus
10 [37]
[30]
[30, 40–42]
Key
High Degree Medium Degree Low Degree

5.8

Immune
Reaction
[29]
[37]
[43]
[30–32]

Insertational
Mutagenesis
N/A [38]
[35, 36]
[37, 46]
[30, 44]

Conclusion
Effectively placing molecular loads into target cells without threatening the cell’s survival

is the overall goal of transfection biotechnologies. One non-viral method presented in this work
is known as Lance Array Nanoinjection, a MEMS based device that relies on physical interaction
with target cells and electrical direction of molecular loads. Shown in two sequential experiments
is the effect that the speed of injection and the ability to inject cells repeatedly have on target
cells. In the speed of injection investigation, it was shown that slower injection speeds improve the
number of cells still adherent following injection, reaching a peak mean of 99.3% at 0.08 mm/sec
injection speed. Using these results, serial injection testing with HeLa 229 cells and BJ(ATCC®
CRL-2522TM ) cells (neonatal, primary fibroblasts) were conducted by injecting samples multiple
times (1, 2, and 3 times) at two different current control settings (1.5 and 3.0 mA). Results show
that HeLa cells treated with 3.0 mA and injected twice (x2) had the greatest mean PI uptake of
60.47% and that neonatal fibroblasts treated with the same protocol reached mean PI uptake rates
of 20.97%. Together these findings help to establish LAN as a method that can obtain modification
rates comparable to other transfection technologies.
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CHAPTER 6.
CRISPR-CAS9 DIRECTED KNOCK-OUT OF CONSTITUTIVELY EXPRESSED GFP IN HELA CELLS

The following chapter has been sumitted as a journal article to SpringerPlus and is currently in
review. The title of this article is “CRISPR-Cas9 Directed Knock-Out of Constitutively Expressed
GFP in HeLa Cells using Lance Array Nanoinjection”.1 As a result, there may be some material
that is contained elsewhere in this dissertation but is presented here as a representation of this
original journal article.

6.1

Introduction
The creativity and scale with which researchers are utilizing clustered regularly interspaced

short palindromic repeat (CRISPR) sequences and Cas9 (CRISPR-associated) proteins for genomic editing has led to an explosion of possibilities in both transgenic research and gene therapy
applications [127–129, 179–182]. Three major elements fueling this movement include the target
versatility and ease with which researchers can generate CRISPR-Cas plasmids [183], the ability
to modify multiple genomic locations in a single step [137, 138], and the ability to do so at rates
difficult to obtain using other editing methods such as transcription activator-like effector nucleases
(TALEN) [184, 185].
Despite the great potential CRISPR/Cas9 plasmids offer, there are limitations that make
delivering such molecular loads to target cells challenging for widespread application. Commonly
used viruses, such as adenoviruses, adeno-associated viruses, and lentiviruses, are known for having high transfection rates [30,35]. However, adenoviruses cause excessive immune reactions [29],
adeno-associated viruses can cause insertional mutagenesis [35], and lentiviruses can cause both
immune reactions and insertional mutagenesis [30–32, 186]. While CRISPR-Cas provides an ele1 This work was also presented at a poster presentation at the 2015 NanoEngineering for Medicine and Biology
(NEMB) annual meeting (St. Paul, MN) and has been accepted as part of an oral presentation at the 2016 International
Society for Transgenic Technologies (ISTT) annual meeting (Prague, Czech Republic).

77

gant method to by-pass many of the concerns related to insertional mutagenesis [187], viruses are
still constrained by pay load capacity, which can limit utility [37].
In an effort to address concerns raised with viral transduction, researchers have put emphasis on developing chemical, physical, and/or electrical transfection technologies aimed at producing a robust delivery method in terms of effective delivery and expression without compromising
cell viability [188–190]. Unfortunately, the trade-off for using non-viral approaches has resulted
in lower transfection rates [28] and additional challenges, such as genetic load transfer and preservation across both the cell and nuclear membranes [191–195]. Commonly used chemical methods
(such as cationic lipids and polymers) can be effective in transfection [196–198] (although not as
effective as viral modalities) [199–206] but are also potentially toxic to cells because of dosage requirements, usually require optimization experimentation for each cell type, and do not work in all
cell lines [22,28]. Physical methods like microinjection and electrical methods like electroporation
can be effective [207] but often are traumatic to the target cells, reducing cell viability [25, 28].
Recently, a new non-viral transfection technology, known as Lance Array Nanoinjection
(LAN) was introduced which was designed with many of these challenges in mind. LAN uses
a microfabricated silicon etched array of lances to physically penetrate hundreds of thousands of
cells simultaneously and electrically deliver attached molecular loads [23,24,208] (see Figure 6.1).
Built upon a first generation technology used to create transgenic mice [25–27], LAN interacts
directly with the molecular load via electrical interactions, thereby eliminating viral-induced immune responses and carrier-vehicle cytotoxicity issues. Furthermore, LAN creates transient pores
between 1-2.5 µm in diameter (making it possible to deliver large loads) and it has cell survival
rates of 78% to 91% post-injection [24].
In this report, we extend previous work by combining LAN with CRISPR-Cas9 technology.
To do this, a CRISPR-Cas9 plasmid was designed to knock-out (KO) constitutive green fluorescent protein (GFP) expression in HeLa cells via Non-Homologous End-Joining (NHEJ) repair.
Two major variables explored in this work included: the current-control setting used during the
initial attraction of DNA to the silicon lances prior to cell membrane penetration (1.5, 4.5, and 6.0
mA) and the number of times samples were injected (one time, x1; three times, x3). We report
that cells injected x3 had a significantly higher number of cells with GFP knocked-out when compared to samples x1 injected samples and that the injection-dose response was non-linear. Also, it
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Figure 6.1: Isometric projection of silicon etched lance array taken by scanning electron microscope. Lances measure 8 to 10 µm in length and 1 to 2.5 µm in diameter. Spacing of lances from
center-to-center measure 10 µm in both planar directions in a grid of 2000 by 2000 lances per chip

was observed that an intermediate current control setting (4.5 mA) used during the LAN process
produced the greatest percentage of living, GFP negative HeLa cells.

6.2
6.2.1

Materials and Methods
GFP+/FRT HeLa Cell Line
We generated an isogenic cell line containing a single copy of EGFP (enhanced green flu-

orescent protein) by cloning the code sequence of EGFP into pCDNA5/FRT and introducing this
plasmid into HeLa/FRT cells in the presence of Flip recombinase (Flp-In System, Life Technologies, Carlsbad, CA). Hygromycin selected HeLa cells expressed 99% GFP and were grown in
Dulbeccos Modified Eagles Medium (DMEM, Life Technologies, Carlsbad, CA) with 10% Fetal Bovine Serum (FBS, Denville Scientific, Holliston, MA) and streptomyocin/penicillin (Gibco,
Waltham, MA) and incubated at 37C and 5% carbon dioxide.
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Figure 6.2: Diagram of the LAN set-up. (Left) Describes the four Phases of the LAN process in
terms of electrical parameters and physical events. (Right) Illustrates the connection of the stepper
motor to the orthoplanar spring to the silicon lance array. With the lance array pointed downward,
during the injection process, the lances are inserted into cultured cells secured on the cell culture
platform

6.2.2

CRISPR Plasmid
In order to facilitate GFP knock-out in the GFP+/FRT HeLa cell line, a CRISPR-Cas9

plasmid was constructed using sgRNA primers directed towards the N-terminus of EGFP, which
would disrupt GFP production via NHEJ repair inaccuracies [183, 209].
The CRISPR-Cas9 GFP knock-out plasmid was created by preparing and ligating sgRNA
GFP oligos to a pSpCas9(BB)-2A-Puro (PX459) plasmid, a gift from Feng Zhang (Addgene plasmid 48139) [183]. The top and bottom oligos were prepared to be inserted into the pSpCas9(BB)2A-Puro plasmid using protocol previously described in the literature [183]. Plasmids were then

80

transformed into competent top10 cells using a standard transformation protocol. DNA was amplified and extracted from the top10 cells following the protocols of Qiagen Maxi and Mega prep
kits (Qiagen, Valencia, CA).

6.2.3

Injection Set-Up
The LAN device used for injections is comprised of five major components which include:

silicon-etched lance array, orthoplanar spring and mount, cell culture platform, stepper motor and
threaded screw, and electrical switch box. Figure 6.2 illustrates the interactions of these components and provides a context to the LAN process.

6.2.4

Silicon-Etched Lance, Orthoplanar Spring and Mount
The LAN device contains of a microfabricated silicon wafer containing the etched lances

(Figure 6.1) attached to an orthoplanar spring which has the stepper motor mounted on top (Figure 6.2). The lance array serves to physically penetrate cell membranes and also to electrically
interact with DNA. The orthoplanar spring has an attachment on its bottom surface for the silicon lance chip to be inserted, thereby providing vertical motion required for injection as well as
the electrical connections. Construction of both the lance array and the orthoplanar spring are
discussed in prior literature [23, 84].

6.2.5

Cell Culture Platform
The cell culture platform consists of three individual pieces: two PLA 3D printed platform

pieces (MakerBot Replicator 2, MakerBot, Brooklyn, NY) (snap-fit together) and the glass slide
(contains adhered cells). The system is designed such that the glass slide can be assembled into the
cell culture platform during injection, which helps with alignment of the orthoplanar spring/lance
array attachment. Following injection, the glass slide can be easily removed from the assembly for
incubation.
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6.2.6

Stepper Motor and Threaded Screw
The stepper motor is shown in Figure 6.2 as a component attached to the top surface of the

orthoplanar spring and serves as an actuator of the spring in orchestration with the electrical input
signals delivered to the silicon lances. The stepper motor is controlled by an Arduino Uno (Small
Projects, Somerville, MA) and has been calibrated to vertically operate the threaded screw insert
at 160 m/sec.

6.2.7

Electrical Box
The electrical box is designed to take electrical input signals from three different power

sources (Keithley 2400, Cleveland, OH) and to output them to the two electrical leads; one lead
passing through the upper portions of the injection device to supply charge to the lance array, and
another lead passing through the cell culture platform to act as a counter-electrode beneath the cell
culture. Figure 6.2 describes the electrical conditions supplied by the electrical box during the four
phases of the injection process. The timing of the electrical signal delivery to the nanoinjection
device is controlled by an Arduino Uno.

6.2.8

Testing Preparation
GFP Positive/FRT HeLa cells were prepared approximately 24 hrs in advance on 18 mm by

18 mm glass slides contained in six well plates. Cells were incubated during this period at 37C, 5%
carbon dioxide, and supplied with 2 mL of DMEM with 10% FBS and streptomyocin/penicillin.
Cells cultures on the glass slides were approximately 70% confluent.
Following this 24 hr incubation, the HeLa cells were snapped into the 3D-printed cell culture platforms. Following transfer to the platforms, cells were supplied with 2 mL of fresh DMEM
and 4 µL of 25 mM chloroquine and then incubated for an additional 15 minutes. After being pretreated with chloroquine, DMEM was removed and 2 mL of phosphate buffered solution (PBS,
Gibco, Waltham, MA) was added. Incubation for an addition 15 minutes followed. Immediately
prior to injection, treatment samples were supplied with the CRISPR-Cas9 plasmid at a concentration of 750 ng of DNA/mL of PBS injection solution.
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6.2.9

Post Testing Flow Cytometry Preparation
Following injection, all samples had their glass slides removed from 3D-printed cell culture

platforms and placed into six-well plates with 2 mL of DMEM. All treatment samples were then
incubated for a period of seven days to allow the existing GFP to be lost from cells. After seven
days of incubation, all samples were trypsinized with 0.5 mL of 5x trypsin (Sigma Aldrich, St.
Louis, MO) per well and incubated for 5 min. Trypsin was then deactivated with 1.5 mL of DMEM
per well and then transferred to FACS tubes for centrifugation for 10 min at 2000 rpm. Following
centrifugation, samples’ supernatant were removed and cells were re-suspended in 0.5 mL of PBS
with 80 L of propidium iodide (PI, 500 µg/mL; Sigma Aldrich, St. Louis, MO). The PI served as
a viability stain for selecting living cells from dead cells in post flow cytometry analysis.

6.2.10

Flow Cytometry
All samples were quantified using flow cytometry (Attune Acoustic Focusing Flow Cy-

tometer, Life Technologies, Carlsbad, CA). Prior to flow, appropriate single color samples were
generated for GFP and PI in order to compensate for signal cross-over. Each sample was then run
and had approximately 20,000 events counted and characterized.
Using Attune’s post-processing software, samples were gated based on PI signals for living
vs dead cells. Using only the living cell populations, samples were then gated based on the GFP
signal in order to characterize the efficacy of the CRISPR-Cas9/LAN knock-out of GFP. Figure 6.3
illustrates example flow cytometry results based on the gating procedure described.

6.2.11

Statistical Analysis
Data gathered from flow cytometry was analyzed statistically in JMP (SAS, Cary, NC)

using an ANOVA test (F-ratio = 48.0318) and Student t-tests (α = 0.05). The efficiency statistic
reported in the Results section is based on number of living GFP Negative cells in each sample.
Of note, based on the hypotheses that the samples injected three times will be greater than or equal
to the samples injected once, t-tests involving the comparison of the controls to treatment groups
or treatment groups against one another, a one-tailed p-value is reported. Because samples are
allowed to incubate for seven days post-injection, relative viability rates are not available. For
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Figure 6.3: Representative flow cytometry results from the ten different samples types. (Left Cluster) Illustrate controls from the experiment (a-d), which contain largely GFP positive populations.
(Right Cluster) Illustrate treatment samples that have been injected one time (e, g, i) and comparably treated samples that have been injected three times (f, h, j), with 1 hr rest periods between
injection events

context of viability rates following LAN, other works have reported viability rates post-injection
between approximately 75% to 90% [208].

6.3

Results
Ten groups of samples were created in order to characterize the effects that the number of

injection events and the current control settings used during LAN would have on GFP knock-out
in the GFP Positive/FRT HeLa cells. Four of these sample types were controls, which consisted
of: Non-Treated Controls (NTC) – received no injection, no applied current/voltage, and no DNA;
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Background Controls for nanoinjection (BC) – received DNA, but no applied electrical protocols
or physical injection; Negative Controls for electrical exposure (NC) – received physical injection,
but with no applied electrical protocols or DNA; and lastly Diffusion Controls (DC) received
physical injection and DNA, but no applied electrical protocol.
Treated samples make up the other six sample types. Single Injection (x1) samples were
physically injected only one time under the following conditions:
• Phase 1: 20 second application of 1.5 mA, 4.5 mA, or 6.0 mA across lance array (performed
with lances external to cell) for the purpose of DNA collection on the lance.
• Phase 2: Lance array inserted into cell culture and pulsed with 10 square-wave pulses of
amplitude between 0 to -7V for 20 ms.
• Phase 3: Directly following pulsing, a 5 second period of -1.5V DC is applied
• Phase 4: Lance array is removed from the cells.
Multiple Injection (x3) samples were Injected under the same conditions as described for
Single Injections (x1) with the exception that following the first injection, cell cultures were placed
back into the incubator for 1 hr before injecting again. This process was repeated for a total of 3
injection events into the same cell culture.
For convenience with treatment sample nomenclature, specific treatment sample types will
be referred to by the current control setting used during Phase 1 and the number of times the sample
was injected. For instance, 1.5 mA, x1 means that the sample received 1.5 mA during Phase 1 and
the samples were nanoinjected only once.

6.3.1

Multiple LAN injections are more effective at GFP Knock-Out
The construction of the HeLa cell line was noted earlier, and consisted of a pFRT/laczeo

HeLa cell line (Flp-In System, Life Technologies) which was purchased and transfected with a
pcDNA5/FRT expression vector containing both the gene of interest and means to facilitate its
production, which include: a green fluorescent protein (GFP) gene, a CMV promoter, and a FRT
site. The FRT site is situated right before the compliment ATG sequence for the hygromycin gene
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Table 6.1: LAN Statistical summary of the sample types and associated GFP KO rates
Sample Type
NTC
NC
BC
DC
1.5 mA,x1
4.5 mA,x1
6.0 mA,x1
1.5 mA,x3
4.5 mA,x3
6.0 mA,x3

Sample Size (n)
21
26
18
23
16
8
16
20
27
20

Mean GFP KO Percent
5.27%
3.92%
5.96%
4.04%
6.92%
21.63%
22.65%
66.79%
79.56%
70.01%

Median GFP KO Percent
5.37%
3.62%
5.37%
3.82%
6.11%
17.37%
8.45%
72.78%
93.77%
70.32%

found in the Flp-In host HeLa cell line. Co-transfection with the pOG44 vector expresses the
flip recombinase machinery that allows the pcDNA5/FRT to flip into the pFRT/laczeo HeLa cell
line, thereby making the hygromycin gene in the HeLa cells functionally complete. Once both
transfection events were accomplished, HeLa cells that successfully had flipped-in the GFP gene
at the FRT site could be selected by hygromycin.
The construction of the CRISPR-Cas9 plasmid was noted earlier, and consisted of a
pSpCas9(BB)-2A-Puro (PX459) plasmid, a gift from Feng Zhang (Addgene plasmid 48139) [183]
that was modified with oligos that code for sgRNA that directs Cas9 to the FRT site to disrupt GFP
production via NHEJ. If the CRISPR-Cas9 GFP knock-out plasmid is successful in disrupting the
GFP gene at the targeted FRT site, the HeLa cells will become GFP negative because these HeLa
cells only have a single GFP gene.
Table 6.1 shows the statistical summary of the flow cytometry results of the respective
sample groups demonstrating the disruption of the GFP gene. Two key findings were noted in
regards to the number of injections and transfection rates. First, the transfection rates for the
x3 injected samples are significantly higher than the x1 injected samples, with the 4.5 mA, x3
treatment samples achieving a median GFP knock-out efficiency of 93.77% (see Table 2). The box
plots in Figure 6.4 and Figure 6.5 box plots show that the collection of data points representing the
4.5 mA, x3 treatment group is relatively closely grouped, with 75% of observations having greater
than 65% transfection rates.
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Table 6.2: One-Sided T-test Results from Comparisons of
Multiple (x3) vs Single (x1) Injected Samples
Multiple Injections (1) vs Single Injections (2) P-Value
1.5 mA,x3 vs 1.5 mA,x1
<0.0001
4.5 mA,x3 vs 4.5 mA,x1
<0.0001
6.0 mA,x3 vs 6.0 mA,x1
<0.0001

Difference in Mean GFP KO (1-2)
59.87%
57.93%
47.36%

Data collected from flow cytometry and analyzed in JMP represents mean and median GFP
KO rates for the respective sample types. Percentage of cells successfully transfected is calculated
as the number of living and GFP negative cells divided by the number of living cells in each sample.
Second, Table 6.2 demonstrates that a large difference was observed between mean values
for all treatment group comparisons when examining the effect of number of injections. The largest
difference was observed in the 1.5 mA samples, exhibiting a change of 59.87% when comparing
x1 to x3 injected samples. When viewed in context of Table 6.1, it is noted that the injectiondose response of all treatment samples is non-linear, meaning the rate of GFP knock-out did not
follow a linear scale with the number of times cells were injected. In the case of the 1.5 mA
current controlled samples, the single injection mean transfection rate is 6.11%. On a linear scale,
the predicted value for samples injected three times should be roughly 18.33%. Instead, for 1.5
mA, x3 treatment samples the transfection rate is 72.78%, nearly 4 times greater than the linear
predicted value. Similar but less pronounced observations were made in the case of the 4.5 mA
and 6.0 mA samples, resulting in differences in linear predictions and observed mean transfection
rates of 14.67% and 2.06%, respectively.
Represented data was initially screened in JMP using ANOVA test to determine presence of
statistically significance relationships followed by one-sided t-test (α = 0.05) evaluation of specific
comparisons. Default minimum p-value reported is 0.0001. Note: All represented relationships
are statistically different.

6.3.2

Mid-range current control most effective at GFP Knock-Out
Table 6.3 shows the results from statistical comparisons between sample types, grouped

according to the number of times the samples were injected. While it is of note that there were no
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Figure 6.4: Combined box plot results for controls and single injection (x1) treatment samples.
Statistically significant relationships are noted Table 6.2 and Table 6.3

NTC

BC

NC

DC

1.5 mA, x3 4.5 mA, x3 6.0 mA, x3

Figure 6.5: Combined box plot results for controls and multiple injection (x3) treatment samples.
Statistically significant relationships are noted Table 6.2 and Table 6.3
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Table 6.3: One-sided T-test Results from Intra-Group Comparisons
(by Number of Times Injected)
Single (x1) Injected Comparisons
1.5 mA,x1 vs 4.5 mA,x1
1.5 mA,x1 vs 6.0 mA,x1
4.5 mA,x1 vs 6.0 mA,x1

P-Value
0.0684
0.0093
0.4621

Multiple (x3) Injected Comparisons
1.5 mA,x3 vs 4.5 mA,x3
1.5 mA,x3 vs 6.0 mA,x3
4.5 mA,x3 vs 6.0 mA,x3

P-Values
0.0985
0.3454
0.8895

intra-group comparisons that were statistically significant in regards to current control effects on
GFP knock-out (with the exception of 1.5 mA, x1 vs 6.0 mA, x1 injections), it should be observed
that the relative position of the median values for both the single and multiple injection groups
appears to follow a pattern, favoring the 4.5 mA treated samples (see Fig. 4 and Fig. 5). The
data suggests that using an intermediate current control setting of 4.5 mA during Phase 1 that
may improve transfection efficiency. This observed behavior is shown numerically in Table 6.1
and graphically in Figure 6.4 and Figure 6.5. Notably, 4.5 mA, x1 out performs the other single
injection sample groups in terms of the median KO percent by at least 8% and the 4.5 mA, x3
behaves the same by exceeding the other x3 injected sample groups by at least 20%.
Represented data was initially screened in JMP using ANOVA test to determine presence of
statistically significance relationships followed by one-sided t-test (α = 0.05) evaluation of specific
comparisons. Default minimum p-value reported is 0.0001. Note: Only one statistically significant
relationship was identified between the 1.5 mA, x1 and 6.0 mA, x1.

6.4

Discussion
Much like other transfection methods, the designed intent of LAN is to direct genetic loads

into target cells without threatening their survival. Noted earlier, viruses have been a mainstay
in transfection protocols because of the higher transfection rates that can be achieved relative to
non-viral modalities [28]. LAN is a non-viral method designed to address this short-coming by
generically delivering any electrically charged molecular load by electrostatic attraction and release
into the intracellular space of target cells via small micron-sized lance structures.
This process of electrical interaction with molecular loads and physical penetration of the
cell membrane was originally created for mouse embryonic transgenic research using a microelec-
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tromechanical system (MEMS)-based single silicon lance [210]. Using this device, it was shown
that nanoinjection had comparable transfection rates to microinjection but increased embryo survival rates [25]. This delivery system was particularly useful because genetic delivery merely
needed to be cytoplasmic due to the localized electroporative effect the lance had on the pronuclei
an event termed intracellular electroporetic nanoinjection (IEN) [27].
Later, nanoinjection was extended to somatic cell targets by utilizing an array of silicon
etched lances, a design used in this work. Electrostatic principles used to initially determine DNA
behavior with the single lance injector [26, 140] have been also applied in LAN, both structurally
[23, 84] and procedurally [24, 208].
Initial experimentation with LAN was designed to show the effectiveness with which small
molecular loads (such as propidium iodide, PI) could be delivered to cultured cells and what impact
that would have on survival. Results showed a voltage-dependent relationship for PI delivery, while
maintaining viability rates between 78% to 91% [24]. Similar results were obtained using LAN
in experimentation designed to assess the effects of different saline solution types used during
injection [208].
This current work marks the first LAN proof-of-concept results regarding the use of CRIPSRCas9 plasmids to knock-out gene function. Table 1 indicates that the maximum median GFP KO
efficiencies of 70.32% to 93.77% can be achieved using LAN after injecting HeLa cells three times.
Contextually, these LAN efficiencies are encouraging because high-throughput screening
of the human genome using CRISPR-Cas9 plasmids designed to knock-out (KO) gene function
have proven to be critical to understanding gene function [187]. Maggio et al. [211] recently
demonstrated the KO behavior of CRISPR-Cas9 using adenoviral vector delivery of gRNA and
Cas9 in two separate vectors. Designed to target the AAVS1 safe harbor locus in a panel of human
cells types which include: cervix carcinoma HeLa cells, osteosarcoma U2OS cells, hMSCs, and
myoblasts, this team showed relative gene KO when increasing amounts of the two vectors were
applied. In the case of HeLa cell experimentation, Maggio et al. achieved maximum gene KO
of 31% when 100 TU/cell of both vectors, an efficiency rate less than a third of the maximum
efficiency reported here using LAN in the same cell type. While it can be said that this study
targeted a different locus and therefore had altered efficiency rates, there is no clear indication that
this experiments gene target was easier to alter.
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In addition to exhibiting high knock-out efficiency rates, this work also shows in Figure 6.4
and Figure 6.5 the non-linear difference between the x1 and x3 injected samples, a behavior not
previously noted in LAN. For example, 1.5 mA, x1 samples had a median KO rate of 6.11%, while
1.5 mA, x3 samples had a median KO rate of 72.78%, a rate nearly 12 times higher. While the
magnitudes are not as high for the other sample comparisons, the non-linear trend is still present.
One possible explanation for this behavior is related to cellular response to cell membrane
defects, such as defects created by lance induced pores. When a surface defect occurs in a cell
membrane, the cell responds by attempting to mobilize and remodel structural elements such as
actinomyosin, microtubules, and the cell membrane by contracting around the wound and allowing
repair machinery to close membrane gaps [153, 154]. In LAN samples that experience multiple
injections, one possible explanation for increased GFP KO is that repair mechanisms may be delayed because of prior insults still being repaired. If true, saturation of repair mechanisms would
permit longer periods of time for CRISPR-Cas9 plasmid movement into the cell following multiple
injection treatments, and thereby allowing greater GFP KO. While this idea potentially explains
why greater plasmid delivery may be possible, it does assume that diffusion is a major factor in
plasmid motion across a cell membrane following LAN, a behavior that is not supported by the
diffusion controls (DC) used in this study.
Another explanation for the increased GFP KO with samples injected x3 is related to how
quickly the target cells remove the delivered plasmid. Prior to injection, samples are pre-treated
with chloroquine, an agent designed to inhibit lysosomal action, to increase the half-life of the
plasmid in the cytoplasm of target cells. It is possible that initial dosing of plasmids into target cells
during the first injection event is enough to saturate functional lysosomes such that when additional
plasmids are delivered in subsequent injection events, higher levels of functional CRISPR-Cas9
plasmids are available to disrupt GFP gene function. Again, this idea has not been defined in prior
work and requires further investigation.
Another behavior noted in regards to non-linear KO rates deals with the current control
exposure during Phase 1. Noted in Table 6.1 is the fact that 1.5 mA samples experience the greatest increase in GFP KO from x1 injection treatment to x3 injection treatment (mean difference
of 59.87%). It has been noted in previous work that lower applied electrical conditions during
LAN contribute to higher cell viability rates [208]. It is believed that the because the 1.5 mA, x3
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treatment samples received a reduced electrical exposure during injection, that more successfully
transfected cells survived to be GFP negative than the 4.5 mA and 6.0 mA treated samples. If that
were the case, samples exposed to 1.5 mA would more likely survive the injection process and
thereby potentially increase the transfection rate.
Intertwined in the discussion of the non-linear behavior of the GFP KO rates when comparing x1 injections to x3 injections is the fact that mid-range current controlled samples had the
best median GFP KO. It is observed in Table 6.2 that the 1.5 mA samples experience the greatest
change in GFP KO from x1 to x3 injected samples (a difference of 59.87%), while overall the 4.5
mA samples experience the greatest magnitude in GFP KO, reaching a median value of 93.77% for
the x3 injected treatment group. A possible explanation for this behavior is that 4.5 mA protocols
offers the best balance between effective electrical attraction/release of the DNA during the LAN
process, while being a mild stressor in terms of cell viability. Even though the 1.5 mA protocol
is milder in terms of cellular stress, a feature seen in electroporation studies to improve cell viability [212], perhaps the 4.5 mA protocol is better at balancing the cellular stress with effective
attraction and release of the DNA, a parameter shown to increase DNA motion when done at higher
magnitudes in processes like electrophoresis [50, 139, 140].
Having demonstrated the ability to effectively KO gene function using CRISPR-Cas9 plasmids, future work regarding LAN may aim to either optimize this reported process or explore other
genomic mechanisms that CRISPR-Cas9 can perform, such as transcriptional activation/repression
or gene insertion [130–135], in terms of other cell types, such as primary cell lines or stem cells.
Primary cell line targets are of interest because of the potential therapeutic options it creates in
regards to gene medicine and gene therapy applications, such as enhancing chronic wound healing [178, 213–216]. Stem cells are also of interest because of similar gene therapy potentials as
well as applications related to transgenic animal generation. Specifically, a common method for
creating chimeric transgenic animals involves genetic modification of stem cells prior to introduction to the blastocyst [217–220]. The methods used to genetically modify these stem cells (i.e.
electroporation, liposomal reagents) are characteristically threatening to cell survivability and/or
have lower transfection rates [28, 221, 222]. As discussed, LAN could provide a viable alternative
in this area given the fact that genetic modifications and cell survival can occur at high rates, and
therefore requires further investigation.
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CHAPTER 7.

CHRONIC WOUND HEALING AND GENE MEDICINE

The following chapter was constructed from two journal articles. The first portion of the chapter
provides a general overview of chronic wounds. Part of the information for this section comes from
an article entitled “Biologic Basis of Nerve Decompression Surgery for Focal Entrapment Diabetic
Peripheral Neuropathy”, which was published in the Journal of Diabetes Science and Technology
in 2014 [208], presented at the Association of Extremity Nerve Surgeons (AENS) annual meeting,
and winner of the Scott Nickerson Award (Houston, TX, 2013).
The second portion of this chapter is a review of transduction and transfection technologies
that have been used in chronic wound healing and highlights emerging concepts that could bridge
current challenges. The information for this section comes from an article entitled “A Review of
Biotechnologies for Enhanced Chronic Wound Healing”, which was submitted to Experimental
Dermatology and is currently under review.
It is intended that the reader can use the information from this chapter as a context for
the work presented in Chapter 8. While some of the material that is presented here is discussed
elsewhere in this dissertation, this chapter provides a much more comprehensive context to the
subject material of chronic wounds and genetic engineering technologies.

7.1

General Chronic Wounds Overview
Chronic wounds globally affect an estimated 50 million patients causing a huge social and

economic impact on patients and communities. The cost of general wound care is estimated to
be $25 billion annually in the US alone and rapidly growing, mainly due to aging populations,
increasing rates of obesity, and the increased occurrence of diabetes [223, 224]. Just in terms of
diabetes, the International Diabetes Federation reports that 415 million adults have diabetes and
this will rise to 642 million by 2040 [225]. When these data are married with an anticipated 25%
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lifetime risk for ulceration for people with diabetes, the need for effective wound healing takes on
a palpable sense of urgency [226–228].
Chronic wounds are complex micro-environments because they can be caused by a variety
of mechanisms. Common factors involved with wound creation include: metabolic disfunction,
vascular disfunction, peripheral neuropathy, tissue insult (through blunt and/or repetitive microtrauma), drugs and medications, poor nutrition, etc. [226, 229–232]. The intertwined nature of
these factors makes treating each patient uniquely difficult. Yet despite many of these challenges,
modern medicine has delivered critically important therapies.
For instance, diabetic patients frequently experience foot ulcerations. These ulcers are
regularly a result of metabolic disfunction creating focal entrapment peripheral neuropathy in the
distal limbs and the patient unknowingly creating tissue damage through biomechanical over-load,
burns, blunt trauma, etc. Moreover, compromised vascular supply to the region due to vascular
calcification secondary to diabetes and/or autonomic disfuction in smaller vessels makes healing
these ulcers difficult without intervention. Furthermore, wounds can harbor and foster bacterial
colonies and/or foreign bodies, which can inflame surrounding tissue and add to delays in healing.
Fortunately, intervention therapies exist. In terms of focal entrapment neuropathy, Dellon
is credited for extending carpal tunnel surgical release of constrainted anatomic locals to lower
extremity entrapment sites, leading to neuropathic reversals [208]. In terms of vascular re-supply,
it is common practice to re-purpose the great saphenous vein for arterial by-pass to the lower limb,
thus facilitating better nutrient and immune cell supply to affected limbs. In terms of bacterial
management, antibiotics exist that can attack a variety of organisms, although the emergence of
antibiotic resistant bacteria is a rising concern.
Despite these critical therapuetic advances, one element that still is difficult in terms of
healing an open wound is actually getting resident wound bed cells to quickly close the wound.
While there are many techniques that use environmental controls to get the wound to initiate
healing, such as debridement (surgical or agent-based) of non-viable tissues that can both surround and be contained in the wound bed, reduction of inflammation and/or infection with antiinflammatories and antibiotics, moisture correction with wound dressings, and re-epithelialization
and granulation of the wound bed by promotional adjuvants [233, 234], there are still wounds that
are recalcitrant to these methods and do not close.
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7.2

Wound Closure Technologies
In response to this immense chronic wound challenge, researchers have explored and con-

tinue to explore novel alternative approaches to enhance healing processes by genetically engineering wound beds. The purpose of this review is to highlight two key aspects of research involving the
genetic modification of chronic wound beds for enhanced healing outcomes. First, this review will
survey both viral transduction and non-viral transfection technologies that have been employed in
wound healing, spotlighting animal experimentation, relative strengths and weaknesses associated
with each, and general mechanisms. Second, this review will also consider emerging concepts
related to the transfection process specifically, genomic targeting with CRISPR-Cas9 and new
delivery methods. Further exploration of wound characterization technologies that help guide decisions regarding molecular targets, including wound diagnostics (i.e. bar coding) and molecular
targets for improved healing, will be briefly discussed.

7.2.1

Viral Transduction
Re-purposing viral vectors with the desired therapeutic molecular load is a classical ap-

proach to genetic modification of cutaneous target cells. While this has been done with several
virus types in other areas of gene medicine, primarily three virus types have been used specifically in wound healing applications, which include: adenovirus, adeno-associated virus, and the
retroviridae family (retrovirus and lentivirus).

Adenoviruses
Adenoviruses (ADV) are non-enveloped viruses containing double-stranded DNA and are
prominently used in wound healing literature. Mechanistically, ADV enters the host cell via receptor mediated endocytosis, transported and then escaped from an endosome, and then has its capsid
bind to the nuclear pore complex of the nucleus and deliver its DNA into the nuclear space where
it is not integrated into the host genome (thus not a risk of insertional mutagenesis) [38,235]. Once
in the nucleus, the DNA can be processed to eventually be expressed as a protein (see Figure 7.1
for more information about ADV function).
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Figure 7.1: Adenovirus transduction occurs as the non-enveloped virus containing double-stranded
DNA binds to coxsackievirus and adenovirus receptors (CAR) and are internalized into the host
cell. Once inside, the virus is contained in an endosome, from which it can escape and then bind
to the nuclear pore complex on the nuclear membrane. The capsid then disassembles and the viral
DNA is imported into the nucleus where it can be transcribed and later translated in the cytosol to
an effector protein
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Advantages of ADV in context of wound healing include: transduction rates of 70-80%
in fibroblasts and keratinocytes [236], transient expression [178], no insertional mutagenesis [38],
and the ability to infect target cells regardless of cell cycle stage [237]. Unfortunately, ADV
also can cause acute inflammatory responses (likely due to capsid proteins) [29], has commonly
infected roughly 90% of people (thus patients may have antibodies developed to the virus making
it difficult to be effective), and has a modest pay load capacity of 8.5 kb [37].
Experimentally the utility of ADV has been shown by its ability to effect production of
several key proteins (such as platelet-derived growth factor-B (PDGF-B), inducible nitric oxide
synthase (iNOS), and vascular endothelial growth factor (VEGF)) [238–242] and in one case, a
receptor (i.e. ErbB3 receptor) [243] for wound healing. In regards to VEGF, a key angiogenic
protein used to increase blood flow to wounds, two investigators have explored using adenoviruses
for VEGF delivery. Romano Di Peppe et al. demonstrated with a topical application of the vector
in healing impaired diabetic mice, that a 3.7-fold increase in blood vessel density was noted 7
days post-treatment [240]. A companion study was attempted in porcine, using a micro-needling
delivery of VEGF-carrying adenovirus in which higher levels of VEGF were noted in the wound
environment but unfortunately did not lead to an associated elevation in neovascularization [241].
More recently, Okwueze et al. demonstrated using a recombinant ADV re-programmed with an
ErbB3 receptor gene, a receptor that produces a cascade leading to re-epithelialization, that significant improvements in wound healing maturity could be achieved [243]. This work is of particular
note because it demonstrated that EGF-like ligand could initiate/control healing by topical application an attractive clinical feature.
As mentioned earlier, ADV have also shown the ability to successfully modify human
primary keratinocytes and fibroblasts at rates as high as 79% [236]. While encouraging in terms
of efficiency, this study unfortunately also highlights the fact that cytotoxic effects were observed
after 10 days post-treatment. These cytotoxic effects, coupled with the fact that adenovirus capsid
proteins can produce acute inflammatory reactions which can disrupt healing in itself [29, 239],
have influenced exploration of other viral vectors.
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Adeno-associated Viruses
Adeno-associated viruses (AAV) are non-enveloped viruses containing single-stranded DNA.
Functionally, AAV generally operate similar to ADV with the main exception being that once the
DNA of the AAV enters the nucleus, it forms either an episomal structure or in rare cases, can
integrate into the host genome (thus carrying a low risk of insertional mutagenesis [244]). Once in
the nucleus, the DNA can be expressed to eventually produce a protein (see Figure 7.2 for more
information about AAV function).
The advantages of AAV include: being highly stable, particularly resistant to heat inactivation [245], low immunogenicity [237], able to target non-proliferating cells [237], mostly nonpathogenic to humans [178], and have broad tissue tropism [178]. The downside of AAV use is that
they can require high MOI (multiplicity of infection) to transduce cells [237] and have a relative
low pay load capacity of 4 to 5 kb [37].
In companion studies using AAV to express VEGF-A in mice and rat models, it was shown
histologically that more consistent wound healing (in comparison to ADV) has been noted in terms
of angiogenesis, re-epithelialization, and extracellular matrix deposition [215, 246]. Additional
work involving AAV has shown that AAV2/5 and AAV2/8 exhibit affinity for epidermal and dermal
cell targets which can be engineered to be enhanced further by modifying capsid proteins, making
it a useful vehicle even if skin tissues are missed when placing the viral-load [247, 248].

Other Viruses
Lesser used wound modifying viruses include members of the retroviridae family. Retroviruses have larger load capacity than AAV AVD (10 kb), albeit it is still fairly modest [37] and
can integrate into the host genome [237]. Retroviruses are characteristically more instable, cannot
transduce non-dividing cells (with the exception of lentiviruses, a genus in the retroviridae family), and have lower modification rates [245]. In experimentation, it was shown that retroviruses
containing a PDGF-AA gene facilitated a 300-fold increase in in vitro levels of PDGF-AA after 7
days, producing thickened connective tissue as well as an increase in regional blood vessels [249].
More recently, lentivirus transfection with stromal cell derived factor 1 alpha (SDF-1alpha) has
been shown in diabetic mice models to enhance granulation tissue formation, which is attributed
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Figure 7.2: Adeno-associated virus transduction occurs as the non-enveloped virus containing
single-stranded DNA binds to the host cell and is internalized. Once inside, the virus is contained
in an endosome, from which it can escape, collects around the nucleus, and then bind to the nuclear
pore complex on the nuclear membrane. The exact mechanism for entry is not clearly understood,
but it terms of transduction, nuclear entry represents the rate limiting step for successful transduction. Once the viral DNA is in the nucleus, it can form into an episome or in rare cases integrate into
the host genome. DNA is then transcribed, followed by mRNA translation for protein production
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Figure 7.3: General differences between viral transduction and non-viral transfection. Note: Green
plus signs are features viewed as positive characteristics while red ”x” marks are viewed as negative
characteristics

to increased cell mobilization and recruitment [216]. While this group of viral vectors are useful,
there is concern that with integration capabilities that insertional mutagenesis is a problem and
therefore limits potential clinical use as a solo technology [46, 186].

7.2.2

Non-Viral Transfection
Some clinical challenges exist that make using viral vectors difficult to use (i.e. limits on

payload capacity, cytotoxic effects, immune reactions, difficulty containing viral particles to tissue
specific locations, etc.) [30–32, 35, 37, 43, 46, 178, 186] and have caused researchers to explore
alternative non-viral modalities for gene transfection of wounds. Figure 7.3 presents general differences between viral and non-viral methods in the context of wound healing and provides an idea
of the current limitations of each.
Non-viral transfection technologies have undergone an evolutionary development as both
the understanding of biologic systems has improved and the ability to use that knowledge has
increased. Early works with non-viral transfection in the field of wound healing began with naked
DNA injections and micro-seeding, a process of naked DNA introduction via a modified tattoo
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machine [214, 250, 251]. While novel in approach, many of these direct insertion approaches had
little success in terms of molecular expression or wound healing mainly because of the inability
to keep the DNA intact in the extracellular environment as well as the poor delivery of the DNA
across the target cells outer membrane.
In an effort to more specifically deliver genetic loads across the cell membrane of target
cells, more sophisticated methods began to be used, which include reagent-based methods like liposomal agents and instrumentation-based methods like the gene gun. One of the first studies to
report both gene expression and functional improvements using non-viral transfection was a team
that used liposomal agents to deliver a plasmid for acidic fibroblast growth factor (aFGF) [252].
Encapsulated in a cationic liposome, the plasmid was topically applied to both incisional and excisional wounds in diabetic mice. Both immunohistologic assays and mechanical testing showed
that treated wounds responded significantly better. Follow-up work using a similar premise showed
that using liposomes filled with multiple genes was significantly more effective at achieving biologic effects in wound healing than single gene filled liposomes [253], a result that is useful given
that robust healing employs multiple factors.
The instrumentation-based method called the gene gun, also known as particle bombardment, is another method for plasmid transfer to target cells that has seen functional success. Typically, gene guns use either gold or tungsten particles with plasmids attached. These particles are
propelled towards target cells, penetrate the cell membrane, and are then able to have the plasmid
removed for molecular effect. Two studies have demonstrated functional results of using plasmids
coding for PDGF and EGF [249, 254]. In the case of the PDGF, it was noted that an increase in
tensile strength occurred, whereas the EFG study showed an improvement in epithelialization and
granulation tissue.
In addition to the gene gun, various forms of electroporation have also been employed for
several cutaneous disorders generally [255] and wound healing specifically [67, 256–259]. Functionally, electroporation generally consists of brief, high pulses of voltage across target cell membranes and causes transient formation of pores in the membrane, allowing passage of molecular
loads. Although designed to address slightly different elements of the healing cascade, much of the
electroporation work has shown functional results ranging from increased regional angiogenesis to
enhanced re-epithelialization. While effective in many cell types, electroporation has disadvan101

Figure 7.4: General mechanisms for non-viral transfections methods

tages related to the transient indiscriminate movement of molecules across the cell membrane and
the permanent membrane damage that can follow the high voltage pulses that can lead to cell
death [260, 261] (see Figure 7.4 for more information about non-viral transfection mechanisms).
Shown in Table 7.1 and Table 7.2 is a summary of both viral and non-viral animal-wound
studies that show how these methods have been applied to wound healing and the outcomes of
those studies. (Note: Direct injection refers to the placement of the viral particles directly into
the wound bed via injection with a syringe; indirect injection refers to in vitro transduction of
cultured cells using viral particles and then placement of these modified cells into the wound bed
via injection with a syringe.)

7.2.3

Emerging Concepts
While many of the methods discussed up to this point have shown encouraging improve-

ments in wound healing outcomes, there still is no transduction/transfection method that robustly
solves the chronic wound healing problem. Illustrated in Figure 7.5 is a list of criteria that have
helped form technologies aimed at wound healing up to this point and now guide emerging concepts in the field.
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Table 7.1: Animal Experimentation involving Viral Transduction of Wounds
Method of Transfet
Adenovirus by
Direct Injection

Gene
PDGF-B

Animal Model
Mouse

Effect
Diabetic treated mice experienced
significant reductions in epithelial gaps
(50%) and increases in granulation tissue
area (3.2 fold) 7 days post-treatment.

Source
[238]

Adenovirus by
Direct Injection

PDGF-B

Rabbit

Treated samples have increased granulation
tissue volume in ischemic wounds.

[239]

Adenovirus by
Needle Array Direct Injection

VEGF

Porcine

Increased expression of VEGF in wound
beds. No associated elevation in
neovascularization or re-epithelialization.

[241]

Adenovirus by
Gene Gun

ErbB3 Receptor

Porcine

Following treatment, wounds were given
topically applied EGF-like ligands to
stimulate ErbB3 receptor. Significant wound
re-surfacing and granulation tissue thickness
were observed 5 days post-treatment.

[243]

Adenovirus by
Indirect Injection

eGFP

Rat

Used as a proof-of-concept of adenoviral
delivery to burn wounds. Transfection rates
were significantly elevated 10% to 40% in
human fibroblasts and keratinocytes.

[236]

Adenovirus by
Topical Application

iNOS

Mouse

Wounds treated at the time of wounding
were able to overcome iNOS deficient states
allowing for faster wound closure times.

[242]

Adenovirus by
Topical Application

VEGF

Mouse

Treated wounds experienced significant
wound closure between 3 and 9 days posttreatment. Length density of arterioles
were also significantly increased ( 2 fold).

[240]

Adeno-Associated Virus by
Indirect Injection

N/A

Mouse

Demonstrated that AAV2/5 and AAV2/8
exhibit dermal and epidermal tropism when
placed deep to the skin surface and offers a
potentially useful mechanism for wound
healing.

[247]

Adeno-Associated Virus by
Indirect Injection

VEGF

Mouse

Increased angiogenesis, re-epithelialization,
and extracellular matrix production resulting
in increased wound breaking strength.

[215]

Adeno-Associated Virus by
Indirect Injection

VEGF

Rat

Statistically significant histological scores
obtained 18 days post-treatments in terms
of epidermal and dermal regeneration,
granulation tissue thickness, and
angiogenesis.

[246]

Retrovirus by
Indirect Injection

Beta-galactosidase and hGH

Porcine

Increased hGH protein concentrations
observed for 8 days post-treatment,
leading to significantly increased healing
time.

[262]

Retrovirus by
Indirect Injection

PDGF-AA

Mouse

Modified in vitro keratinocytes exhibit 300fold increase in PDGF-AA levels.

[213]

Lentivirus by
Direction Injection

SDF-1alpha

Mouse

Treatments exhibited significantly increased
granulation tissue at 7 days, while wound
surface area did not decrease differently
from controls, they did experience greater
epithelialization.

[216]
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Table 7.2: Animal Experimentation involving Non-Viral Transfection of Wounds
Method of Transfet
Direct Injection

Gene
IL-8

Animal Model
Porcine

Effect
Used to show neutrophil recruitment posttreatment.

Source
[251]

Electroporation

HIF-1alpha

Mouse

Treated mice express 10-fold increase in
circulating angiogenic cells with increased
local treatment site levels of VEGF, PLFGF,
PDGF-B, and ANGPT2.

[67]

Electroporation

KGF-1

Mouse

Demonstrated that 90% of treated wounds
healed in 12 days versus only 40% in
controls.

[259]

Electroporation

KGF-1

Rat

Increased re-epithelialization of wound by
60% over control after 12 days.

[258]

Electroporation

TGF-beta1

Mouse

Showed that 5 to 7 days post-treatment that
wounds showed increased re-epithelization,
collagen synthesis, and angiogenesis. Also
demonstrated that diabetic skin is more
sensitive to electroporative damage.

[257]

Electroporation

VEGF

Rat

Significantly increased skin flap perfusion 10
and 14 days post-treatment.

[256]

Gene Gun

EGF-R

Porcine

Increased EGF-R 24 to 48 hrs. posttreatment at different levels of skin based
on varied pressures used to propel gene
carrying particle.

[254]

Gene Gun

PDGF-A and -B

Rat

Transient increases in wound tensile
strength over controls as high as 3.5-fold
increase at 7 days.

[249]

Injection of
Cationic Dendrimer

VEGF

Mouse

Increased VEGF expression and healing of
wound 6 days post-treatment.

[263]

Liposomal Formation

FGF

Mouse

Increased FGF expression and wound break
strength post-treatment.

[252]

Liposomal Formation

IGF-1/KGF

Rat

Increased skin regeneration of wound 250%
over control.

[253]

Micro-Seeding

EGF

Porcine

Increased EGF expression 2 days posttreatment, reaching four to seven fold times
greater than single injected skin samples
and two to three times higher expression
over particle-mediated gene transfer.

[214]
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Key Criteria for Exogenous Genetic
Modification of Chronic Wounds

Transfection Mechanics
1. Able to transfect multiple cell types at high rates
2. Does not cause insertional mutagenesis
3. Does not cause immune reaction response
4. Able to facilitate various molecular load sizes and types
5. Able to treat target cells without threatening the cell's
survival

Cutaneous Specific Mechanics
6. Able to have a transient activity of the molecular effector
as opposed to permanent integration.
7. Able to keep the treatment localized to target tissues.

Controlled Molecular Healing
8. Able to induce activation of molecular effector in order to
sequentially match the molecular result with the appropriate
stage of healing
9. Able to modify multiple genomic targets in a single transfection
event
10. Able to up-regulate target cells' surface receptors

Figure 7.5: Presents key criteria used to develop transduction/transfection technologies for wound
healing applications

One of the most important ideas that has and continues to promise enhancements to genetic methods in wounds is the combination of approaching the wound in terms of characterizing
the wound system (i.e. wound diagnostics via bar coding and identification of molecular targets
that play an important role in healing) and then matching those characterizations with appropriate
methods (i.e. site-directed genomic enhancement, new delivery methods). Presented briefly here is
a discussion of wound system characterization followed by method improvements (see Figure 7.6).
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Figure 7.6: Illustrates the interplay between wound system characterization and new method developments that create meaningful emerging technologies

Wound Diagnostics
Bar coding is an advanced wound diagnostic concept that is designed to monitor the molecular dysfunction in wounds. It consists of a taking samples of tissue or fluid from patients wounds
to characterize levels of molecular markers present to help determine the state of the wound and
identify key missing elements related to healing [264]. Demidova-Rice et al. [233] notes that by
using bar coding, providers are able to hone in on specific growth factors and potential receptors
that are absent or expressed at diminished levels.
To help illustrate the utility that can come from bar coding, it is critical to understand that
in a chronic wound there are a variety of dysfunctional activities that can be occurring and that
correctly identifying the problems can greatly increase the potential for healing. For instance, fibroblasts found in chronic wounds have a lower growth factor receptor density and consequently,
have a lower mitogenic responses to ligands such as platelet derived growth factor-AB (PDGFAB), insulin growth factor (IGF), fibroblast growth factor-basic (bFGF), and epidermal growth
factor (EGF) [265–267]. The believed underlying cause of lower receptor density is directly related to elevated levels of interstitial proteases, that damage surface receptors on the resident cells.
Complicating the situation further, if high levels of bacteria (greater than 105 ) or bacterial tox-
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ins are present, excessive inflammatory responses can also occur, further degrading extracellular
growth factors and receptors [233].
This marks a salient point in regards to why genetic approaches to wound healing are necessary. Without properly functioning surface receptors on resident wound cells, it is less effective or
ineffective to attempt to control molecular behavior via application of exogenous ligands. This behavior is evidenced by disappointing clinical results achieved with becaplermin (rPDGF-BB), the
only FDA approved topically applied growth factor ligand commercial available. Genetic modification to resident wound bed cells provide a means whereby cells can both locally produce essential
growth factors and up-regulate necessary surface receptors that facilitate intracellular biochemical
healing cascades (see Figure 7.7)
The utility of bar coding for pin-pointing molecular dysfunction in regards to chronic
wounds cannot be overstated. Unfortunately, the current practice of bar coding is not widely
adopted.

Molecular Target Identification
Behm et al. [268] offers a well written compilation of mediators that play a significant role
in wound healing. Listed are several traditionally accepted mediators, sources from which these
mediators and natively derived, cell types and receptor types upon which these mediators will act,
and key functions that the mediators initiate.
In addition to these mediators, the reader may also consider other molecular targets that
have more recently been identified in the literature and include: HIF-2α, Toll-like receptor 3
(TLR3) agonist polyriboinosinic-polyribocytidlylic acid (Poly(I:C)), IL-22, adiponectin [269–273].
Additionally, as mentioned earlier, the value of surface receptors initiating local cellular
response towards healing continues to be investigated as noted by findings supporting the effects
of Toll-like receptor 4 (TLR4), CD9, and the cross talk between insulin growth factor receptor 1
(IGF-1R) and estrogen receptors (ERα) receptors on wound closure [273–275].
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Figure 7.7: Illustration of receptor during normal healing and stalled healing secondary to degradation in chronic wounds

CRISPR-Cas9 Genomic Target Modification
A critical interplay occurs between the logistical delivery of genetic pay loads and the
native biologic mechanisms in target cells required to promote exogenous DNA expression. In the
case of viral transfection, this interplay is clearly integrated because the virus is involved in the
delivery as well as the expression of the desired gene. In the case of non-viral transfection, this
interplay is not integrated, and historically been a major source for reduced efficiency in expression
rates relative to viral methods [18, 20–22].
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Fortunately, a relatively new nuclease editing tool, known as CRISPR-Cas9, has been developed which can facilitate meeting many of the stated wound healing criteria when coupled with
an efficient physical delivery modality. CRISPR-Cas9 nuclease editing systems work with essentially two elements, the gRNA and the Cas9 protein. gRNA sequences are short programmable
sequences that provide a genomic address for the associated generic Cas9 protein to locate target
loci and modify it [96, 183]. Once bound to the target, Cas9 can initiate a variety of effects which
include: direct gene insertion (permanent effect) [130, 131], direct gene knock-out (permanent
effect) [97], transcriptional activation (transient effect) [132–134], or transcriptional repression
(transient effect) [132,135]. Furthermore, since the gRNA and Cas9 protein operate in two distinct
roles, by providing multiple different gRNA sequences, multiple genomic modifications can occur
in a single transfection event [136–138, 209].
The multiple functions of CRISPR-Cas9 are potentially very useful for chronic wounds.
First, CRISPR-Cas9 constructs are relatively simple to construct and are small. Second, CRISPRCas9 can specifically modify nearly any genomic target (making insertional mutagenesis much
less of a concern) and can use the gene library already found in the host genome rather than having
to consistently rely on inserting exogenous DNA. This is particularly useful for wounds because
enhanced performance on a transient basis is useful for matching healing stage to the gene therapy.
Third, if using non-viral methods, the risk of an immune response is near absent. Fourth, CRISPRCas9 can modify multiple genomic targets in a single event making it possible to leverage and
mobilize many of the known molecular effectors for healing as opposed to only one or two as
demonstrated by Table 7.1 and Table 7.2.
Further demonstration of CRISPR-Cas9s potential in wound healing is that CRISPR-Cas9
has been used already in many other related applications including: Duchenne Muscular Dystrophy
[138], following the progression of disease phenotype expression in diseases such as Friedreichs
ataxia [276], development of novel HIV therapies [277], use as in situ functional assays [278], and
transgenic plant breeding [279]. Given the promising results of many of the studies, it is only a
matter of time before CRISPR-Cas9 plasmids are applied to chronic wound healing.
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New Delivery Systems
Tied closely to the promising biologic mechanisms of CRISPR-Cas9 is the idea of combining CRISPR-Cas9 with transfection methods specifically designed to interface with skin conditions. Two existing methods that could be easily employed if dosed in a way to mitigate cell
death: 1) topically applied liposomal reagents or 2) optimized electroporation. As discussed earlier, both of these methods have been shown to deliver at relatively efficient rates to cutaneous
targets [253, 255].
Other technologies that have not yet been used in animal experimentation but have demonstrated good results in proof-of-concept cell culture conditions include conjugated nanoparticles
[280], microfabricated needles [281, 282], microfabricated nanowires [119], and multi-electrode
arrays [283]. Additionally, another technology that leverages both physical and electrical actions
to modify target cells is an in vitro instrumentation-based method called nanoinjection. First generation nanoinjection consisted of a micro-electromechanical system (MEMS) that used electrostatic
attraction of DNA onto a silicon micro-sized solid lance that was then inserted into mouse embryos
before electrically releasing exogenous DNA into the host [25–27,210]. This same technology has
been modified in its second generation to consist of a micro-fabricated silicon wafer that has been
etched to create a grid of four million 10 micron length lances spaced every 10 microns that allow
for effective delivery of genetic loads to hundreds of thousands of cells simultaneously [23, 84].
As an emerging method, nanoinjection shows promise in regards to CRISPR-Cas9 chronic wound
applications, given the high efficiency of transfection and high cell survival rates [24].

7.3

Conclusion
Given the present nature of how widespread chronic wounds are and that they are com-

plicated, multi-faceted conditions, it is important that research continue to explore alternatives to
traditional approaches. This review provides a context to technologies that view healing chronic
wounds from the inside-out. Genetically engineering chronic wounds for enhanced healing outcomes is not yet fully realize; however, it is clear that there are viable approaches and that new
combinations of tools can help overcome current shortcomings.
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CHAPTER 8.
CRISPR-CAS9 TRANSCRIPTIONAL UP-REGULATION OF PDGFR-β
IN PRIMARY NEONATAL FIBROBLASTS

The following chapter comes from a journal article under review by PLoS ONE and is entitled
“CRISPR-Cas9 Transcriptional Up-Regulation of PDGFR-β in Primary Neonatal Fibroblasts following Lance Array Nanoinjection”.1 As a result, there may be some material that is contained
elsewhere in this dissertation but is presented here as a representation of this original journal article.

8.1

Introduction
Chronic wounds represent a health crisis that affects an estimated 50 million patients and

carries high costs in terms of human suffering, quality of life, and health care [223, 224]. To give
perspective to how quickly this global crisis is growing in terms of cases caused by diabetes alone,
in 2016 it is reported by the International Diabetes Federation that 415 million adults are diabetic.
By 2040, the diabetic population is projected to increase by an additional 227 million people [225].
When juxtaposed with the fact that 25% of these patients will have at least one diabetic ulcer
within their lifetime, it is clear that the current chronic wound challenges will become much larger
in the near future making it of paramount importance to have effective therapies to combat this
surge [226].
The key to preventing an escalation of complications related to chronic wounds is to get
wound closure quickly. Many of the traditional treatment approaches (i.e. surgical debridement,
moisture correction dressings, tissue-engineered human skin grafts, etc.) attempt to kickstart native
healing by trying to control environmental factors in the wound in order to over-come this stalled
state. Essentially this approach is seeking wound closure from the outside-in.
1 This

work has also been accepted as part of an oral presentation at the 2016 International Society for Transgenic
Technologies (ISTT) annual meeting (Prague, Czech Republic) and as a poster presentation at the Kaiser Permenante
Foot and Ankle Summit (Oakland, CA).
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Regrettably, traditional wound care methods can take long periods of time before wound
closure occurs and in some cases, traditional care fails completely necessitating amputation [231].
In an effort to create a second front for wound treatment, researchers have focused on creating
technologies that can genetically modify native wound cells in order to facilitate healing. Essentially this approach is seeking wound closure from the inside-out. Attempted wound healing
transfection methods using this model include: recombinant viral vectors [236, 243], liposomal
reagents [253], particle bombardment with gold- or tungsten- conjugated to DNA [254], and electroporation [67, 256, 257].
Unfortunately, these efforts have had mixed results for two major reasons. First, current
gene modifying technologies experience trade-offs between efficient modification and safety. Viral transduction can be effective at targeting skin cells but can also have inherent safety issues (i.e.
viral induced immune responses) [29, 32, 239]. Non-viral transfection can be moderately effective
in the skin but frequently causes cell cytotoxicity or survivability concerns (i.e. liposomal reagents,
particle bombardment, electroporation) [37]. Second, nearly all animal experimentation with genetic wound healing has focused on increasing production of ligands important to healing but not
the surface receptors upon which these ligands must act. Demidova-Rice et al. [284] discusses
the incompleteness of this approach by commenting on the disappointing clinical trial results with
topically applied becaplermin, a platelet derived growth factor ligand (PDGF-BB) that is critical
for healing [285]. The attributed cause to less than desired healing results has to do with the fact
that resident cells in chronic wounds have dramatically fewer surface receptors due to excessive
extracellular protease action, therefore preventing ligand-initiated healing even in the presence of
elevated ligand levels (see Figure 8.1).
The purpose of this work is to present an alternative, non-viral transfection method that uses
a micro-electromechanical system (MEMS-based), known as Lance Array Nanoinjection (LAN),
in conjunction with a platelet derived growth factor receptor-β (PDGFR-β ) CRISPR-Cas9 transcriptional activation plasmid. In contrast to previous works, this work demonstrates a method that
can both efficiently and safely modify primary neonatal fibroblasts and demonstrates its utility in
terms of increasing the surface receptor PDGFR-β on fibroblasts.
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Figure 8.1: Illustrates the interaction between PDGF growth factor isoforms (-AA, -AB, -BB, and
-DD) with PDGFR-beta in both normal (left) and chronic (right) wound healing conditions

8.2
8.2.1

Materials and Methods
Lance Array Nanoinjection Device
Figure 8.2 shows a schematic view of the Lance Array Nanoinjection (LAN) device with

the inserted silicon lance array. The LAN device has four major components, which include the:
stepper motor, orthoplanar spring, silicon lance array, and cell culture platform. At the top end,
a stepper motor, which is used to control vertical motion of the silicon lance array, is attached
to an orthoplanar spring, which facilitates vertical displacement by preventing unwanted torsion
motions [84]. As the stepper motor moves the silicon lance array downward, the lance array is able
to interact with the fibroblast cell culture (as detailed in Figure 8.2). To help align this process, the

113

fibroblasts are seeded on a glass slide, which is locked into place by the cell culture platform. For
reference, the silicon lance array is a microfabricated-etched array of 4 million lances, measuring
10 µm in length and spaced in a grid pattern every 10 µm. [23] describes the fabrication process
required for the silicon lance array construction.

8.2.2

Lance Array Nanoinjection Process

LAN occurs in a series of three steps shown in Figure 8.2. These steps include:
Step 1: Staging
Step 1 involves staging of the silicon lance array in the solution containing the cell culture.
For electrically stimulated samples, cell cultures experience extracellular current control exposure
of either 3.0 mA or 4.5 mA for 20 seconds. For treatment samples that have the CRISPR-Cas9
plasmid added, this step facilitates the attachment of the negatively charged DNA onto the silicon
lance structures in preparation for physical injection of target cell membranes.
Step 2: Injection
Step 2 consists of the lance arrays being lowered towards the cell culture until the lances
have penetrated the cell membranes of the fibroblasts and contacted the glass slide substrate to
which the fibroblasts are adhered. There is no electrical exposure at the time the lances penetrate
the cell membrane. For samples that have CRISPR-Cas9 plasmid added, this step allows the DNA
to cross the cell membrane.
Step 3: Electrical Delivery
Once the lance array is lowered into the cell cultures penetrating the cell membranes, all
electrically treated samples were given an application of 10 square-wave pulses with an amplitude of 0 to -7V applied for 20 ms. Following the pulses, a 5 second period of -1.5V DC is
applied and then the lance array is removed from the cell culture. For treatment samples that have
CRISPR-Cas9 plasmid added, this step helps to release the DNA into the intracellular space of the
fibroblasts.
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Figure 8.2: Illustrates Lance Array Nanoinjection Device (a) and Process (b). a) LAN device in
a cross-sectional view consists of four major parts, which include: (top to bottom) stepper motor,
orthoplanar spring, silicon lance array, and cell culture platform. Shown in isometric view on the
lower left is a view of the cell culture platform, illustrating how the glass slide containing the
fibroblast culture locks into place for injection. Shown in isometric view on the lower right is a
SEM image of the lances on the silicon-etched array. Lances are spaced every 10 µm in a grid
pattern, measuring 10 µm in length and 1-2.5 µm in diameter. b) Displays the LAN process in
three major steps which include: Staging, Injection, and Electrical Delivery (refer to Lance Array
Nanoinjection Process for details on activities that occur during each step)
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8.2.3

Biologic Testing
Primary neonatal fibroblasts BJ ATTC CRL-2522 were prepared for injection by being

plated on glass slides at 37C and 5% carbon dioxide in Dulbeccos Modified Eagles Medium
(DMEM, Gibco) containing 10% Fetal Bovine Serum (FBS, Denville Scientific) and
penicillin/streptomyocin 24 hrs. prior to injection. Because it was anticipated that the fibroblasts
would proliferate following treatment, cells were plated with a cell confluency or cell density of
50% to 60% across a 1 cm diameter area in order to provide space for cell division to occur.
Following the 24 hr. incubation in growth media, the cell culture plates were removed
from the incubator. Cell cultures were visualized under a light microscope to ensure consistency
in cell confluency and then had growth media removed and replaced with 2 mL of phosphate
buffered solution (PBS, Gibco) in each well. Sample wells that were treated with DNA received 2
µg of CRISPR-Cas9 transcriptional activation plasmid mixture (per manufacturer protocol; Santa
Cruz Biotechnology Inc., sc-400187). This DNA mixture contained information to encode for a
deactivated Cas9 nuclease fused to a VP64 domain (used to activate transcription) and a gRNA
sequence for targeting the PDGFR- gene.
The following describe the different controls and treatments used for experimentation:
• Non-Treated Control (NTC): Received no injection, no electrical exposure, and no DNA.
• Lance Only, Injected 1 Time (LO,x1): Samples were injected one time without electrical
exposure and no DNA.
• Lance Only, Injected 2 Times (LO,x2): Samples were injected twice, with a one hour rest
period between injections. Both injection events were done without electrical exposure and
no DNA.
• Background Control, 3.0 mA, Injected 1 Time (BC3,x1): Samples were injected one time
with electrical exposure and no DNA. Specifically, these samples received 3.0 mA during
Step 1 of the injection process (refer to Figure 8.2).
• Background Control, 3.0 mA, Injected 2 Times (BC3,x2): Samples were injected twice,
with a one hour rest period between injections. Both injection events were done with electri116

cal exposure and no DNA. Specifically, these samples received 3.0 mA during Step 1 of the
injection process (refer to Figure 8.2)
• Background Control, 4.5 mA, Injected 1 Time (BC4.5,x1): Samples were injected one
time with electrical exposure and no DNA. Specifically, these samples received 4.5 mA
during Step 1 of the injection process (refer to Figure 8.2).
• Background Control LAN, 4.5 mA, Injected 2 Times (BC4.5,x2): Samples were injected
twice, with a one hour rest period between injections. Both injection events were done with
electrical exposure and no DNA. Specifically, these samples received 4.5 mA during Step 1
of the injection process (refer to Figure 8.2).
• Diffusion Treatment, Injected 2 Times (DT,x2): Samples were injected twice with 2 µg
of CRISPR-DNA mixture in each sample, with a one hour rest period between injections.
Both injection events were done without electrical exposure.
• LAN Treatment, 3.0 mA, Injected 2 Times (LAN 3.0,x2): Samples were injected twice
with 2 µg of CRISPR-DNA mixture in each sample, with a one hour rest period between
injections. Both injection events were done with electrical exposure. Specifically, these
samples received 3.0 mA during Step 1 of the injection process (refer to Figure 8.2).
• LAN Treatment, 4.5 mA, Injected 2 Times (LAN 4.5,x2): Samples were injected twice
with 2 µg of CRISPR-DNA mixture in each sample, with a one hour rest period between
injections. Both injection events were done with electrical exposure. Specifically, these
samples received 4.5 mA during Step 1 of the injection process (refer to Figure 8.2).

8.2.4

Flow Cytometry Preparation
Prior to running flow cytometry for test samples, calibration of FITC as a marker and the

baseline activity of native PDGFR-β was performed. For FITC calibration, a FITC-CD90 conjugated antibody (BioLegend, 328107) was applied to the fibroblasts and flowed, matching expression levels previously recorded for fibroblasts [286, 287]. For PDGFR-β baseline measurement
of pre-treated cells, cells were labelled with a FITC-PDGFR-β conjugated antibody (Santa Cruz
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Biotechnology Inc., sc-19995). Results showed PDGFR-β levels in living cells to be <1% prior
to testing, which indicated that increases due to treatment could be measured.
All samples were returned to the incubator for 48 hrs. post-injection before preparing the
samples for flow cytometry (per CRISPR Activation Plasmid Transfection Protocol, Santa Cruz
Biotechnology Inc.). After that time, samples were removed from the incubator and cell cultures
were scraped from the glass slides. Each well’s contents were then transferred to a FACS tube and
centrifuged at 2000 rpm for 10 min. Samples were then decanted and rinsed with 1 mL of PBS
and centrifuged again at 2000 rpm for 5 minutes. Samples were decanted again and then given 100
µL of ice cooled PBS and 20 µL of FITC-PDFGR-β conjugated label (Santa Cruz Biotechnology
Inc., sc-19995). After incubating on ice for 12-15 minutes, samples were then rinsed in 2 mL of
PBS and centrifuged at 2000 rpm for 5 min. Samples were decanted again, re-suspended in 250
µL of ice cooled PBS and 40 µL of propidium iodide (PI, Sigma Aldrich). PI was added to all
samples as a cell viability stain because it is impermeable to living cells membranes.

8.2.5

Flow Cytometry and Statistical Analysis
Characterization of the samples was performed using flow cytometry (Attune Acoustic

Focusing Flow Cytometer, Life Technologies). For each sample well, 20,000 events were captured.
Post-flow analysis was conducted using Attune Cytometric 2.1 software (Applied Biosystems, Life
Technologies). Gating of the data occurred to two steps. First, the samples were evaluated for cell
viability using gating for PI signals. Second, living cells were then gated for the relative FITCPDGFR-β signal, thus establishing the relative level of living, PDGFR-β positive cells in each
sample.
Once primary level data was generated for each sample, data was statistically analyzed in
JMP by first screening for the presence of statistical significance using ANOVA testing followed
by further testing using student t-tests to determine relative significance between sample types (α
= 0.05).
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Table 8.1: P-values for sample comparison of the Number of Living Cells
Comparison
LO,x1
BC3,x1
BC4.5,x1
LO,x2
BC3,x2
BC4.5,x2

8.3

NTC
LO,x1
LO,x2
0.2258
–
–
0.2416 0.0176
–
0.0043 <0.0001 0.0778
0.0011 <0.0001 0.0269
0.0246 0.0009 0.2236
0.0013 <0.0001 0.0250

BC3,x1
–
–
–
0.6291
0.6898
0.5199

BC3,x2
–
–
–
–
0.4032
0.8451

BC4.5,x1
–
–
–
–
–
0.3351

Results
In an effort to compartmentalize the effects of LAN with and without the PDGFR- CRISPR-

Cas9 plasmid, the Results and Discussion sections will be divided into two sub-sections. The
Electro-Mechanical effects of LAN will examine the controls and treatment samples that had no
plasmid added. Treatment samples that had the PDGFR-β CRISPR-Cas9 plasmid added will be
examined in a second group, where all samples injected twice (with or without DNA) will be
examined to show the difference between those samples given the CRISPR-Cas9 plasmid.

8.3.1

Electro-Mechanical Effects
Figure 8.3 shows box plot results for the number of Living Cells and the Number of

Living/PDGFR-β Cells for the seven types that did not receive DNA during injection. Detailed in
Table 8.1 and Table 8.2 are the p-values for the student t-test comparisons of the different samples
within this group and shown in Table 8.5 is a statistical summary for all samples. Of particular
note, samples that were injected twice had a significantly higher number of Living Fibroblasts
and Living/PDGFR-β Fibroblasts compared to NTC. Statistical comparison between one and two
times injected samples for analogously treated sample types also have significant differences (i.e.
LO,x1 vs LO,x2 and BC3,x1 vs BC,x2), except for the BC4.5,x1 vs BC4.5,x2 comparison. This
trend is further illustrated in Table 8.5.
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LO,x1

BC3,x1

BC4.5,x1

LO,x2

BC3,x2 BC4.5,x2

Number of Living/PDGFR-beta+ Cells

Number of Living Cells

NTC

NTC

LO,x1

BC3,x1

BC4.5,x1

LO,x2

BC3,x2 BC4.5,x2

Figure 8.3: Shows box plot results for the Number of Living Cells (left) and the Number of
Living/PDGFR-β + Cells (right), with outliers removed. For convenience, see Table 1 to see
statistically significant relationships between the different sample types for Electro-mechanical
experimentation

Table 8.2: P-values for sample comparison of the Number of
Living/PDGFR-β + cells
Comparison
NTC
LO,x1
0.3927
BC3,x1
0.1001
BC4.5,x1
0.0003
LO,x2
<0.0001
BC3,x2
0.0002
BC4.5,x2
<0.0001

8.3.2

LO,x1
LO,x2
–
–
0.4518
–
0.0560 0.0338
0.0002 0.0014
0.0036 0.0203
<0.0001 0.0006

BC3,x1
–
–
–
0.2538
0.6956
0.1236

BC3,x2
–
–
–
–
0.5101
0.6287

BC4.5,x1
–
–
–
–
–
0.2861

CRISPR-Cas9 Effects
Figure 8.4 shows box plot results for the number of Living Cells and the Number of

Living/PDGFR-β Cells for the comparisons of the NTC relative to the twice injected sample types.
Shown in Table 8.3 and Table 8.4 are the p-values for the student t-test comparisons of the different
samples within this group. Table 3 provides a statistical summary for these samples types. Seen in
these comparisons is that the three DNA injected samples (i.e. DC,x2; LAN3,x2; and LAN4.5,x2)
were significantly higher than the NTC for both the number of Living Cells and the number of
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LO,x2

BC3,x2

BC4.5,x2

DC,x2

LAN3,x2 LAN4.5,x2

Number of Living/PDGFR-beta+ Cells

Number of Living Cells

NTC

NTC

LO,x2

BC3,x2

BC4.5,x2

DC,x2

LAN3,x2 LAN4.5,x2

Figure 8.4: Shows box plot results for the Number of Living Cells (left) and the Number of
Living/PDGFR-β + Cells (right), with outliers removed. For convenience, see Table 2 to see statistically significant relationships between the different sample types for CRISPR-Cas9 experimentation

Table 8.3: P-values for comparison of the Number of Living Cells
Comparison NTC LO,x2 BC3,x2
DC,x2
0.0233 0.1819 0.1383
LAN3,x2
0.0034 0.0434 0.0343
LAN4.5,x2 0.0002 0.0040 0.0035

BC4.5,x2 DC,x2 LAN3,x2
0.2361
–
–
0.0683
0.4971
–
0.0085
0.1221
0.3827

Living/PDGFR-β Cells, with the exception of the number of Living/PDGFR-β Cells in the NTC
vs. DC,x2 comparison.
Comparison of the DNA treated samples to the non-DNA treated samples reveal that there
is only a consistently significant difference between LAN4.5,x2 and the non-DNA treated samples
(i.e. LO,x2; BC3,x2; and BC4.5,x2) for both the number of Living Cells and the number of
Living/PDGFR-β Cells. There is an increase in the mean fold cell counts in both categories for all
DNA treated samples compared to non-DNA treated samples.
As a group, LAN4.5,x2 performed the best in both measures but was not significantly
different from other DNA treated samples (i.e. DC,x2 or LAN3,x2). Table 8.5 highlights the fold
increases among the DNA sample types, indicating large mean fold increases over the NTC in the
Number of Living/PDGFR-β with LAN4.5,x2 having an increase of 15.29-fold.
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Table 8.4: P-Values for sample comparison of the Number of
Living/PDGFR-β + cells
Comparison NTC LO,x2 BC3,x2
DC,x2
0.1694 0.2900 0.3035
LAN3,x2
0.0338 0.0686 0.0821
LAN4.5,x2 0.0057 0.0134 0.0189

BC4.5,x2 DC,x2 LAN3,x2
0.3419
–
–
0.0967
0.4515
–
0.0232
0.1604
0.5124

Table 8.5: Statistical summary for all sample types in PDGFR-β Experimentation
Sample Type
NTC
LO,x1
LO,x2
BC3,x1
BC3,x2
BC4.5,x1
BC4.5,x2
DC,x2
LAN3,x2
LAN4.5,x2

8.4
8.4.1

Sample Size
(n)
19
18
20
21
15
21
15
18
18
18

Mean Living Fold Increase in Living
Mean Living /
Cell Counts Cell Counts over NTC PDGFR-β Cell Counts
44,730
–
2311
35,580
0.80
3023
69,243
1.55
6213
53,245
1.19
3635
62,696
1.40
5643
65,786
1.47
5308
70,772
1.58
6631
102,666
2.30
18,532
120,059
2.68
27,514
142,435
3.18
35,327

Fold Increase in Living /
PDGFR-β Cell Counts over NTC
–
1.31
2.69
1.57
2.44
2.30
2.87
8.02
11.91
15.29

Discussion
Electro-Mechanical Stimulation
To the authors’ knowledge, the effect of electro-mechanical stimulation (EMS) of mam-

malian cells through direct interaction with the intracellular space of the target cell has not been
previously observed, particularly in the context of its effects on PDGFR-β and cell proliferation
of fibroblasts. Other researchers have investigated the effects of mixed mechanical conditions
that can stimulate cellular gene expression and/or biochemical behavior. For instance, Hu et al.
used direct magneto-mechanical actuation of PDGFR-β surface receptors on human mesenchymal stem cells using magnetic nano-particles to demonstrate that higher osteogenic gene marker
expression could occur after 7 and 12 days of stimulation [222]. Similar concepts of actuating
mechano-sensitive surface receptors on mammalian cells have been reported in other works as
well [288–290]. In addition to magneto-mechanical stimulation, researchers have also reported results of indirect or external stimulation using either high or low electric fields to generate biochemical response [291, 292]. Nevertheless, no previous work has shown that with brief intracellular
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electro-mechanical stimulation, such as that experienced during LAN, that increases in PDGFRexpression and cell count can be observed.
An explanation of the mechanism(s) generating both the receptor and proliferation response
in the fibroblasts following LAN induced EMS are not understood. Bonazzi et al. [293] reviews
much of what is currently known about the biophysics of galvanotactic effects on mammalian
cells in response to external electric fields. In his work, it is suggested that the general thought
is that electric fields cause an intracellular response that involves a complex signal transduction
cascade that eventually leads to the reorganization of the cytoskeleton and directed cell growth.
Furthermore, Bonazzi et al. hypothesized that by virtue of gradients in the transmembrane potential
values in the target cells, imbalances in ion fluxes via voltage gated ion channels may be disrupted
during electric field exposure and thereby signal up-regulation of biologic intermediates, citing
other researchers who have observed this behavior with electric field exposure on GTPase cdc42p,
Rho/Rac pathway, integrin signaling, and phophatidylinositol signaling pathways [294–298].
In terms of LAN, these previous works involving galvanotactic stimulation and its effect
on mammalian cells provide only a partial explanation of what is observed in this work. For LO,x1
and LO,x2 samples types, electrical stimulation is not used, meaning the increases in both the
PDGFR-β and the cell count are only due to the mechanical response of lancing with the lance
array. Noted in Table 8.5 is that the fold increase for the number of Living/PDGFR-β + cells for the
LO,x2 sample group is between the BC3,x2 and BC4.5,x2 groups. Also, in Table 8.1 and Table 8.2
it can be seen that there is no statistical difference between any of the twice injected, non-DNA
treated sample types. Examination of Table 8.1 and Table 8.2 in regards to the same comparisons
for the single injected samples reveal that BC4.5,x1 is significantly higher than BC3,x1 and nearly
significantly higher than LO,x1.
How do these LAN results relate to the galvanotactic hypothesis? It is possible that the
physical lancing of the target cell membranes during LAN mimics partially the external electrical
field effects observed in works cited by Bonazzi et al. During the transient membrane openings
following LAN, it is probable that ion imbalances are created across the membrane. As ions travel
across the membrane to re-establish the transmembrane potential, it is possible that these ions
could trigger intracellular cascades related to growth and receptor production a mechanism similar
to the one Bonazzi et al. discuses for transmembrane ion disturbances observed with external
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electric fields exposure. Furthermore, for samples that use electrical application, it is possible
that past a certain threshold (i.e. like that used for 4.5 mA samples) in LAN samples, that using
electrical stimulation in combination with the physical lancing action can increase this intracellular
molecular cascade activity and thereby increase PDGFR- and cell counts. This hypothesis, while
suggested by other’s findings, requires further investigation.

8.4.2

CRISPR-Cas9 Effects
One of the key elements of this experiment is that it shows that EMS by itself can cause

increases in cell growth and the number of living/PDGFR-β + cells. The CRISPR-Cas9 portion
of the experimentation, in addition to these EMS findings, illustrates an improved biologic response mainly for LAN4.5,x2 sample types. The increased efficacy in regards to the higher EMS
conditions relative to the LAN4.5,x2 have been discussed above.
As far as the CRISPR-Cas9 effects in regards to skin targets, experimentation of this kind
has not yet been conducted and represents a key finding for wound healing applications. Basic
science related to CRISPR-Cas9 is rapidly expanding both in terms of functionality of the Cas9
component [97, 133, 299] and the gRNA (guide RNA) sequences that facilitate the action of the
Cas9 [209]. Nevertheless, the application of CRISPR-Cas9 in the realm of wound healing is still
in its infancy.
The implications of both the EMS effect unique to LAN and the enhanced effect noted
with CRISPR-Cas9 in these primary neonatal fibroblasts is significant in terms of wound healing
therapy for four reasons. First, the combination of LAN with CRISPR-Cas9 shown in this work
has achieved high modification rates, reaching between 8 and 15 fold increases in the number of
living/PDGFR-β + cells. As noted earlier, many non-viral transfection technologies have historically struggled to obtain rates this high [178, 245].
Second, LAN in conjunction with CRISPR-Cas9 modification of a surface receptor is a
relatively safe method of cutaneous modification. The use of a transcriptional activating CRISPRCas9 plasmid is transient, meaning specifically that there are no structural changes to the host
genome. Furthermore, by modifying the receptor, a level of cellular control can occur by regulating
the amount of PDGF ligand available to bind to the receptor.
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Third, PDGFR-β is an essential element for wound healing and without it significant
wound healing delays occur [285]. As noted earlier, chronic wounds have excessive protease
action, which degrades the extracellular portion of the PDGFR-β making the receptor inoperable.
As a result, lack of PDGFR-β signaling results in dramatic reductions in recruitment of immune
and stromal cells to the wound, decreased proliferation of resident wound bed cells, and functional
inactivity of fibroblasts and pericytes. Thus by improving PDGFR-β presence, treated wounds can
initiate healing sooner.
Lastly, these findings are particularly useful because it demonstrates that molecular effectors (i.e. DNA, RNA, protein, etc.) are not necessarily required in order to alter cellular receptor
expression, which could be useful for current wound healing applications. For instance, commonly
used artificial skin grafts, which consist of primary neonatal fibroblasts seeded on a matrix, could
be pre-treated with LAN induced EMS prior to placement into chronic wounds. Theoretically,
these artificial skin grafts could experience marked increases in fibroblast growth and PDGFR-β
expression, thereby decreasing healing times – a critical element to preventing wound complications.
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CHAPTER 9.

SUMMARY OF FINDINGS AND POTENTIAL FUTURE WORK

Several key discoveries have been discussed in this research in regards to Lance Array Nanoinjection (LAN) and its ability to transfect both culture cells and primary human cells. Categorically,
these findings have been segregated into three main objectives.

9.1

Key Findings Review
The first objective focussed on several enironomental variables related to the LAN process,

highlighting the impact that they make on cell transfection rates and survival post-injection. The
following provides a brief summary of key findings related to the investigation of environmental
factors impacting LAN outcomes.
• Chapter 2: Saline Solution Effects on Propidium Iodide Uptake Experimentation with
three different saline solution types revealed that PBS with potassium performs slightly better than HBSS and PBS without potassium in regards to PI uptake but makes no impact on
cell survival.
• Chapter 3: The Effects of Lance Geometry and Carbon Coating of Silicon Lances Experimentation with three different lance geometries demonstrated that Flat, Narrow shaped
lances have a slightly better cell viability rate than Flat, Wide and Pointed, but Pointed lances
had the best PI uptake. Carbon coating of lances made little difference on cell viability or PI
uptake.
• Chapter 4: Transient Low Temperature This work demonstrated that transient low temperatures around 3C were sufficient to increase PI uptake into HeLa cells 8.3 times higher
than controls and 173% higher than samples at 23C (given the same injection parameter).
Furthermore, between 3 and 6 minutes post-injection, many of the induced pores close – a
behavior that was observed at different magnitudes for all samples regardless of temperature.
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• Chapter 5: Injection Speed and Serial Injection Investigation with five different injection
speeds showed that slower injection speeds with HeLa cells (0.08 mm/sec) allow nearly all
cells to remain adherent, thus making serial injections (multiple injections into the same
cell culture) possible. These results allowed further exploration into slow, serial injection
experiments with both HeLa cells and primary neonatal fibroblast using PI as an indicator.
Results showed an injection dose response, meaning more PI delivery with more injections.
The second objective focussed on genetic modification of cultured HeLa cells using an
indicator marker. For this work, an isogenic GFP+ HeLa cell line was created that constitutively
expressed the GFP protein. In order to measure the degree with which LAN could successfully
genetically modify these cells, a CRISPR-Cas9 plasmid was created which targeted just up-stream
of the promoter for the GFP gene. Using LAN to deliver the plasmid containing information for
both the gRNA sequence required to target the GFP promoter region and the Cas9 which could
induce a non-homologous end joining (NHEJ) knock-out when guided with the gRNA, it was
observed that high levels of GFP negative cells could be generated (median GFP knock-out rates
of 93.22% in samples injected three times). Similar to earlier work as well, it was observed in
this work that the degree of GFP knock-out correlated to the number of times the samples were
injected.
The third objective investigated the ability of LAN to genetically modify primary, neonatal
fibroblasts, a historically difficult cell line to modify, using a clinically useful target – PDGFR-β .
Similar to the GFP-Knock-Out project, this work also used a CRISPR-Cas9 plasmid system. The
main difference with this system and the knock-out system was that this CRISPR-Cas9 construct
was designed to activate transient up-regulation of an existing gene instead of knock-out of an
engineered gene. Results showed that levels higher than 15-fold could be observed 48 hrs. posttreatment using the combination of both the CRISPR-Cas9 system and LAN.

9.2

Research Impact
The discoveries made during this research have been significant. LAN represents a viable

transfection technology that satisfies many of the key criteria required for robust transfection which
include: high transfection efficiency, high cell survival rates, effective in clinically useful cell lines,
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flexible pay load capacity, and no insertional mutagenesis. Prior to this work, to the authors’
knowledge, such an accomplishment by a viral transduction or non-viral transfection system has
not yet been achieved.

9.3

Future Work
The success with the latter portions of the research in regards to CRISPR-Cas9 and LAN

are particularly exciting. Chronic wounds are discussed and demonstrated to be a viable direction
for LAN clinical application – a direction that would require additional investigation for clinical
trial. However, because of the broad range of capabilities associated with CRISPR-Cas9, using
CRISPR-Cas9 in conjunction with LAN make the list of potential applications compelling and the
number of potential future directions for LAN broad.
Within the context of current research areas, there are two logical directions for further research investigation regarding LAN (in addition to what has been discussed with chronic wounds).
The first direction would be extending LAN to be able to work with non-adherent induced pluripotent stem cells (iPSCs). iPSCs represent an exciting frontier in being able to re-program hostderived, fully-differentiated cells into stem cells [75, 76, 300, 301]. Once in stem cell state, these
cells can be used to remedy a large number of disease states, particularly if coupled with CRISPRCas9 [92, 180]. Leveraging the ability of LAN to either initially deliver genes to initiate the transformative process to the stem cell state or facilitating modification of these stem cells in en masse
could be tremendously useful.
A second logical direction for future LAN research involves combining the scope of the
first generation single nanoinjection system with the advances made in the second generation with
LAN. Specifically this means using the Lance Array Nanoinjection system presented in this work,
in conjunction with CRISPR-Cas9, to create a high-through-put transgenic organism generation
system. Transgenic animals are difficult still to create, particularly with the need to visualize the
pro-nuclei during micro-injection. Nanoinjection does not have that requirement [27]. Moreover,
being able to generate large numbers of modified cells quickly, can facilitate basic research investigation into critical mechanisms related to the genome for both animals and plants [279, 302–306].
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APPENDIX A.

MATERIALS AND PROTOCOLS

The following appendix was constructed to serve as a resource for important material preparations
and protocols used in the lab.

A.1

Calcium Phosphate Transfection Protocol

The following protocol was originally obtained from Caleb Cornaby and modified as better
techniques were identified through experimentation. It is worth noting, this protocol is designed to
transfect several different cell lines. In my experimentation, HeLa cells have been the target cell of
choice. While this is not an optimized protocol for HeLa cells, it is very effective in transfecting
HeLa cells both in terms of modification rate and cell survival.
As an aside, calcium phosphate transfection operates on the basis of getting a salt to precipitate around DNA molecules. These conjugates then are taken into the cell (through an unknown
mechanism but it is believed to be pinocytosis-like) where the salt is dissolved away and the DNA
can then be incorporated into the host’s genome.

A.1.1

Cell Preparation: Materials List

• 6-Well Plate
• DMEM

A.1.2

Cell Preparation (-1 Day)

• Prepare 6 Well-Plate by placing approximately 30 ∗ 106 cells into each well. Recommended
method: Using cells from cell passaging after 4 days growth in flask, 100-120 µL per well.
• Add 1 mL of DMEM media to each well.
• Incubate for 24 hours at 37C, 5% carbon dioxide.

A.1.3

Transfection: Materials List

This protocol makes enough solution for 8 total treatment wells on 6 Well-Plate (Makes it
convenient so that you can have non-treated wells next to treated wells.)
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• 7.5 mL DMEM (warmed to 37C)
• Chloroquine (25 mM stock)
• 50 mL conical tube
• 1.5 mL Eppendorf Tube
• HBS (Hepes Buffered Solution) (2x, pH 7.0): Note pH is critical.
• Sodium Phosphate (75 µM, 100x)
• Calcium Chloride (2.5 M)
• DNA
• dH20 (de-ionized water)
• 10 mL serological pipet
• 5 mL serological pipet
For material preparation for this section, refer to the end of the Calcium Phosphate Transfection protocol.

A.1.4

Transfection Prep (0 Day)

Prior to transfection, remove the 6 Well Plate from the incubator to examine cells under the
microscope to determine the degree of cell confluency (how much space exists between cells). Approximately 40-60% confluency is desired. If there are too many cells, the transfection efficiency
will be lower than desired because successful Calcium Phosphate transfection requires cell division for the DNA to enter the intermittently dis-assembled cell nuclear membrane. Cell division
requires available space for the cells to grow.

A.1.5

Transfection (0 Day)
Performed under a Hood

1. Put 7.5 mL of DMEM into the 37 C water bath so it is warm by Step 9.
2. Remove 6 Well Plate from the incubator, remove old media from the day before and replace
with 1 mL of DMEM in each well (this is not the warmed DMEM).
3. Treat each well in 6 Well Plate with: 2 µL of Chloroquine (that is 2 µL of chloroquine per
1 mL of media). (This is a critical step because the Chloroquine acts to transiently inhibit
lysosomes from degrading the DNA introduced through the transfection.)
Once Chloroquine placed, let it sit for at least 5-10 minutes (up to 3 hrs is fine) while preparing transfection reagents. Swirl gently and put the plates back in the incubator while performing the next steps.
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4. Mix the following using 50 mL conical tube and 1.5 mL Eppendorf Tube:
In the 50 mL Conical Tube: 500 µL HBS (2x, pH 7.0) + 10 µL Sodium Phosphate (100x).
In the 1.5 mL Eppendorf Tube: 62.5 µL Calcium Chloride (2.5 M) + 12500 ng of DNA +
dH20 (enough dH20 to make the total volume of fluid in the Eppendorf Tube to equal 500
µL total)
Note: To clarify the mass of DNA added, consider the following example:
Given a DNA concentration of: 2497 ng/µL, in order to have 12500 ng of DNA, it requires
5 µL of DNA [ ie (12500 ng)*(2497 ng/µL) ] Thus adding 5 mL of DNA to the 1.5 mL
Eppendorf Tube is enough for transfecting the 8 total wells.
Intermediate Transfection Mix
5. Take the 50 mL Conical Tube and place the 5 mL serological pipet tip into the fluid and
begin blowing a constant stream of air into the fluid creating bubbles. THIS IS CRITICAL – IF THERE IS NOT A CONSISTENT STREAM OF BUBBLES THE ENTIRE
PROCEDURE WILL FAIL.
6. In the other hand, pull all of the fluid of the 1.5 Eppendorf Tube into a micro-pipet tip
and slowly, drop-wise add to the bubbling fluid in the 50 mL Conical Tube – this is the
Intermediate Transfection Mix.
7. Following mixture of the solutions, wait for 15 minutes (up to 30 minutes is fine).
8. Remove 6 Well-Plates from the incubator and remove the chloroquine-containing media
from each well in the 6 Well Plate.
Final Transfection Mix
9. Take the 7.5 mL of warmed DMEM and invert the container several times to mix solution.
Add 1 mL of the Intermediate Transfection Mix to the warmed DMEM, creating a total of
8.5 mL of solution creating the Final Transfection Mix.
10. Add 1 mL of the Final Transfection Mix to each treatment well of the 6 Well-Plate. Use all
of the transfection mix if there is extra.
11. Incubate at 37 C, 5% CO2 for 1 day. Check for expression on inverted fluorescent microscope.

A.1.6

Material Preparation Appendix

HBS (HEPES Buffered Solution, 2x)
1. Weigh out the following ingredients: 8.0 g NaCl, 0.37 g KCl, 0.099 g Na2HPO, 1.0 Dextrose
(D-glucose), and 5.0 g HEPES.
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2. Dissolve the dry ingredients into 450 mL of H20, adjust the pH to 7.04 to 7.06. Note: This
is a critical balancing step for transfection to work.
3. Fill the container with 50 mL more of H20, bringing the total fluid content to 500 mL.
Recheck the pH to make sure it is still 7.04 to 7.06.
4. Autoclave.
5. Store at Room Temperature.

Calcium Chloride (2.5 M, CaCl2)
1. Weigh out the following ingredients: 0.238 g HEPES, 27.75 g CaCl2.
2. Dissolve the dry ingredients in 90 mL of H20, adjust the pH to 7.2.
3. Fill the container with 10 mL more of H20, bringing the total fluid content to 100 mL.
Recheck the pH to make sure it is still 7.2.
4. Autoclave.
5. Store at Room Temperature.

Sodium Phosphate (75 µM)
1. Take stock solution and dilute to 75 µM.
2. Autoclave.
3. Store at Room Temperature.

Chloroquine
1. Order 25mM solution.
2. Aliquot if desired.
3. Store in fridge.

A.2

Cell Passaging and Plate Prep for Injections

Several different cell types have been used in the lab recently (i.e. HeLa 229, RPE, HEK,
and BJ Fibroblasts). The following protocol is a general process for passaging these cells and pearls
fo wisdom for getting good growth results. It should be noted that for good results with any cell
culture, a consistent pattern for passaging in terms of days since the previous passaging, cell
confulency at the time of passaging, and the quality of cell growth media are critical. (Note:
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Most failures for good growth of cell cultures is directly related to one of these three items. True
cell culture contamination is rare if a researcher uses sterile technique.)
In order to provide these details concisely, a simple list of important materials (Note: Some
items will not be listed for convenience sake. It is assumed that the reader is aware of sterile
technique in a cell culture hood and basic lab procedures.) and a detailed list of procedural steps
are provided below.

A.2.1

Materials

• Sterile Dulbeccos Modified Eagle Medium (DMEM)(with 10% FBS and penicillin/streptomycin).
Note: If you are working with RPE (retinal pigmented epithelial) cells, then F12 FBS must
be used. Also, for all FBS solutions mixed with DMEM used for cell culturing, the FBS must
undergo heat inactivation of the complement, otherwise it can be problematic for proper cell
growth. Heat Inactivation will be covered in this appendix.)
• Sterile Phosphate Buffered Solution (PBS)
• Sterile 5x Trypsin (≈ 2.5 mL)
• T75 Flask of cells to be passaged
• Pipette-aid
• Waste beaker
• serological pipettes for fluid transfer
• 6-Well Plate with 18mm x 18mm glass slides placed into each well

A.2.2

Protocol

The following protocol should be performed in a cell culture hood using sterile technique.
Prior to every passage event, you must look at the cell cultures under a microscope to access two
major items. First, you want to see if how many of the cells are living. If it has been several days
since the last passaging event, the cells may begin to die, which means they will shrink and darken.
Depending on how many cells are dead, it may not be worth the time and expense to passage the
cells. It is absolutely critical, particularly if you are in an experimental stage of research, to be
consistently passaging the cells (i.e 3-4 days). Otherwise, the cells can go into a quiescent state –
and once there, they are super hard to transfect. Second, you want to see how confluent or densely
spaced the cells are. This will provide key incite into how much to dilute cells during the passaging
or plating process. I my experience, cell confluency during plate prep is critical – too much and the
transfection efficiencies are low because the cells aren’t able to grow; and too little, and the cells
typically died.
1. Spray hands and all materials use for passaging with ethanol before placing into the hood.
Prior to opening sterile containers or handling cell cultures, items in the hood need to be
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UV sterilized, so Place all items (except liquids and flask of cells) into the clean hood and
turn on the UV for at least 15 minutes. For proper material handling, have a place for sterile
solution containers on one side and disposeable items and waste containers on the other.
2. Once items are sterilized, place fluid solutions and cell culture in the hood, having sprayed
them with ethanol before placing in the hood.
3. Using a 25mL pipette, remove the old media from the flask and discard into waste beaker
4. Using a new 10mL pipette, add 10 mL PBS solution to the flask to help rinse unbound or
loosely bound cells into solution. Depending on the cell type you are working with, different
levels of care must be taken at this step. For HeLa, RPE, and BJ Fibroblasts, a gentle rinse
is perfectly fine for the cell cultures. For HEK cells, you must be very careful to not rinse
the entire culture into solution because there are much more loosely bound. Do not do more
than a gentle tilting of the flask with HEK cells.
5. Using the 5 mL pipette, add 2.5 mL Trypsin to the flask. (The trypsin enzymatically cleaves
adhesion proteins between cell cultures and the flask surface.)
6. Place the flask in the incubator for 3-5 minutes. For HeLa and RPE cells, a full five minutes
is required for cells to be trypsinized. For HEK cells, 3 minutes is plenty. For BJ Fibroblasts,
4 minutes is enough – however, if the cells are overgrown a great deal, it can be difficult to
get good cell separation because fibroblasts love to cluster.
Note: It should be recognized that trypsin is indiscriminate as far as what proteins it cleaves,
so depending on what kind of experiment you are running, you may elect for cell scraping
rather than trypsin for cell removal from the flask. Also note, over trypsinized some cell
types can kill the cell of interest.
7. Remove flask from incubator.
For HeLa and RPE cells, swirl the solution in the flask until all cells are no longer adhered.
HeLa cells in particular are very adherent cells and may require you to hit the flask against
the work-surface to break the cells up. After that, use a pipette to and pipette up and down a
portion of the fluid to ensure break up of the cell clusters.
For HEK cells and BJ Fibroblasts, once you remove the flask from the incubator, gently swirl
the cells. That should be enough to break the cells loose. Then slowly pipette up and down
a portion of the fluid to ensure break up of the cell clusters. If you hit the flask containing
BJ Fibroblasts against the work-surface like you would a HeLa flask, you will kill the
cell culture – BE VERY CAREFUL WITH BJ FIBROBLASTS AT THIS STAGE.
Note: An excellent trypsinized cell culture has a cloudy, white appearances, with no visable
cell clumps.
IMPORTANT: This step is a vulnerable step for the cell’s survival, rapidly finish this step
and move to the next step.
8. Using a 10 mL pipette, add 7.5 mL DMEM media to the flask. Note: The DMEM media
contains FBS, which serves to de-activate the trypsin. Once the DMEM is placed into the
159

flask, use the same pipette to thoroughly mix the solution to ensure proper mixture and deactivation of the trypsin.
9. Pull all the cell solution back into the 10 mL pipette. At this point, you can use the 10 mL
solution containing your cell culture for plate prep for Nanoinjection or for freezing back
cells for later use.
10. Add desired amount of cell solution back to the flask (i.e. for a 1:20 ratio, put 0.5 mL back;
for a 1:2 ratio, put 5 mL back)
11. Discard remaining cell solution into waste beaker if not using any cells for injection or
freezing cell back.
12. Once the desired amount of cell solution is added back to the flask, use a 25 mL pipette and
add enough DMEM to the flask to bring the total amount of solution to ≈ 20 mL.
13. Label the flask with the date and amount returned to the flask. Place flask back into incubator,
being sure to loosen the lid to allow CO2 access.
14. Clean up materials and wipe down hood with ethanol

A.2.3

Plate Preparation

For proper plate preparation prior to injection, the following steps should be taken the day
before injections are planned.
1. Follow the cell passage protocol up to the point where you have cells in solution. At this
point, transfer roughly 1.5 to 2 mL of cell solution (per 6-well plate) to a 10 mL conical
tube. Depending on how concentrated the cells are and how confluent you need your cells
for injection, you will need to add DMEM to the conical tube to get the proper concentration
of cells for proper plate prep. This step cannot be over-emphasized. Knowing exactly
how much to dilute the cells for this step takes experience and serial testing. Simply
guess how much to dilute the cells is not a great use of time.
2. Once proper dilution of the cells in the 10 mL conical tube is achieved, take 120 µl of
cell solution from the tube and place in the center of each glass slide in the bottom of the
individual 6-Well Plate.
3. Following completion of seeding each well’s glass slide, place the 6-Well Plate(s) into the
incubator.
4. After 1-2 hours, remove the 6-Well Plates from the incubator and provide 2 mL of DMEM/FBS
growth media to the cells. Return the cells to the incubator for the night. The plates are ready
for injection the next day.
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A.3

Solution Material Preparation

All media preparation must be performed in the sterile hood. Non-fluid supplies
should be UV sterilized for 15 minutes prior to the aliquoting of fluids.

A.3.1

Trypsin Preparation

Trypsin is frequently used in the lab in the context of 6-Well-based experimentation. The
following is a protocol used to aliquot trypsin for those uses.

Materials
• New 100 mL bottle of 10X Trypsin (thawed)(Sigma brand, Chem Stockroom)
• Phosphate Buffered Solution (PBS, Chem Stockroom)
• (x17) 15 mL conical tubes
• (x1) 10 mL serological pipettes
• (x3) 25 mL serological pipettes

Protocol
1. Using the 10 mL pipette, add 6 mL 10X Trypsin to 16 of the tubes
2. Using the same 10 mL pipette, add remaining 10X Trypsin to the final tube
3. Using a 25 mL pipette, add 6 mL PBS solution to each tube already containing 6 mL Trypsin
(use a new 25 mL pipette each time PBS is needed and always fill to the 35 mL line)
4. Add PBS solution to the final tube until the Trypsin is diluted 1:1
5. Label tubes: Date of Preparation, 5x Trypsin, and Initials of Person that Prepared
6. Place tubes in -20C Freezer

A.3.2

Fetal Bovine Serum (FBS) Preparation

FBS can contain complement proteins that can be damaging to cell cultures and requires
heat inactivation to prevent that from happening. The followin protocol provides details on how to
do that and aliquot the solutions in preparation for DMEM growth media prep.
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Materials
• New 500 mL bottle of FBS (thawed, Chem Stockroom)
• (x9) 50 mL conical tubes
• (x8) 15 mL conical tubes

Protocol
1. Heat in-activate the FBS (FBS) by warming FBS is 57C water bath for 1 hour. Be aware that
the FBS will come in a frozen bottle. It takes time to just de-frost the bottle and then heat it
to 57C. Do not let the FBS sit at 57C more than 4 hours – it will cause the proteins to
become gelatinous – a big problem for testing. Since FBS is expensive, you must watch
this carefully.
2. Allow FBS to cool to room temperature. This can take a couple hours.
3. In the hood, pipette 50 mL FBS to 8 of the 50 mL tubes and 5 mL FBS to the eight 15 mL
tubes.
4. Label tubes and place tubes in -20C Freezer.

A.3.3

DMEM Growth Media Preparation

Materials
• Un-opened 500 mL bottle of DMEM (Chem Stockroom)
• 55 mL thawed fetal bovine serum (FBS, Chem Stockroom): (1) 50 mL tube* + (1) 5 mL
tube aliquots*
• Penicillin/Streptomyocin (Chem stockroom): (1) 5 mL aliquot of 10,000 U/mL
penicillin/streptomyocin
• **L-Glutamine (200 mM, online order): (1) 5 mL aliquot (Sigma G7513, 100 mL)
NOTES:
*Indicate supplies that were pre-prepared following protocols specific to their preparation
**L-Glutamine needs to be added to media solutions if the media is not being used quickly;
L-Glutamine is an essential amino acid and degrades over time, by providing extra, the cells are
able to have nutrition to continue growth
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Protocol
1. Thaw heat inactivated FBS (total 55 mL) to Room Temperature.
2. Thaw Penicillin/Streptomyocin and L-Glutamine aliquots to room temperature.
3. Spray containers with alcohol (70%) and place in hood
4. Under the hood, combine the FBS (55 mL), Penicillin/Streptomyocin, and L-Glutamine to
the 500 mL of DMEM.
5. Secure media container cap, slightly agitate the media solution, label, and remove from hood
6. Place media container in refrigerator for storage.
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APPENDIX B.

ATTEMPTED EXPERIMENTS THAT YIELDED NO CONCLUSIONS

The following details experiments that were attempted but produced no conclusions for various
reasons. These details are presented here merely as a cataloging of the attempts and results.

B.1

The Effects of Cell Synchronization on the Efficiency of Lance Array Nanoinjection on
HeLa Cells

Introducing exogenous genetic material into target cells and getting a prescribed expression is the core principle of gene therapy. In effort to facilitate delivery of these loads, several
mechanisms have been developed and include a technology previously described as Lance Array
Nanoinjection (LAN). In brief, LAN utilizes a combination of physical penetration of the cell
membrane with micron-sized silicon etched lances and electrical release of the desired molecular
load (i.e. DNA) off of these lances.
In prior research, it was demonstrated with a single lance injector that during the electrical
release procedural step that localized electroporation occurs at the nuclear membrane, allowing
transient access of the molecular load to the nucleus and consequently causing genetic transformation of the target cell [27].
In this work, it is hypothesized that LAN uses a similar localized, nuclear electroporative
mechanism as the single lance nanoinjector and that by using a CAG/GFP plasmid, non-dividing
HeLa cells can be successfully transfected to become GFP positive. In order to demonstrate this
mechanism, target HeLa cells will be stalled in G0/G1 phase as a way to have target cells in a
non-dividing state and fully intact nuclear membrane. This aspect of investigating the capabilities
of LAN is considered of value because of the intent to demonstrate LAN as a viable technology in
the in situ context where cells may not be dividing quickly.
Secondarily, it is hypothesized that HeLa cells synchronized via thymidine to S and G2
phases will have different transfection efficiencies from G0/G1 for two reasons. First, in S-phase,
the cell is actively undergoing DNA replication and as such more likely to incorporate exogenous
DNA due to inconsistency that arise during replication. The nuclear membrane is still intact during
S-phase and therefore, relative transfection efficiencies discovered for S-phase when compared to
G0/G1-phase will elucidate potential transfection events required/occurring with LAN. Second, in
late G2-phase, nuclear membranes will breakdown right prior to cell division and act as a window
of opportunity for exogenous DNA to enter and later be incorporated into the genome. During
late G2-phase, DNA replication has stopped such that cell division can occur. As noted with S-
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Table B.1: Cell Cycle and Transfection Rate Predictions
Phase
G1/GO
S
Late G2

Nuclear Membrane
Intact
Intact
Dissolved

DNA Replication
Inactive
Active
Inactive

phase, relative transfection efficiency discovered with G2-phase will indicate transfection events
required/occurring with LAN.

B.1.1

Design of Experiment
The experiment will be divided into three sections as follows:

• Stage 1: Characterizing the Cell Cycle of Sample Population following Synchronization
(Calibration Curve Creation)
The intent is to synchronize HeLa cell samples using proximity growth inhibition (G1/G0)
and thymidine (other phases) to determine the time required to get the cells to reach S-phase
and Late G2-phase after release from being stalled. To help establish this calibration curve,
the cells will be fixed and stained with propidium iodide every 2 hours for tens hours. Based
on prior research, ten hours should be long enough to have the cells go through a complete
cell division (4).
Outcome: Stage 1 is anticipated to give us an idea of what stage the cells should be in at a
specific time post-release from having their growth stalled. This will serve as a calibration
curve for the LAN treatment samples.
• Stage 2: Lance Array Nanoinjection at specific Synchronized Cell Cycles The intent in
Stage 2 is to test both hypotheses noted above in regards to LAN and the cell cycle using a
CAG/GFP plasmid.
Consideration: A potential direction that could be added to this stage is performing a similar
test using a CRISPR to see if cell cycle stage is a factor in transfection rate.

B.1.2

Methods

• Stage 1: Calibration Curve
As noted previously, it is anticipated that samples taken every 2 hours following release from
two different growth stalling techniques will be used.
Step 1: G1/G0 Stall
Proximity Growth Inhibition or Density Arrest keeps the cells in G1. Once cells have been
stalled, cells will be fixed, treated with RNAse A, stained with Propidium Iodide, and run
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Table B.2: Stage 1: Cell Synchronization
Well
Type
Purpose
1
Non-treated Control
Normalized Cell Viability
2-6
Treated Samples
Determine cell cycle stage after x hrs post-release

through flow cytometry. The results will be analyzed in a third-party software call Flowjo to
determine relative amounts of cells in respective phases. Once a clear determination of what
protocol is required to achieve the desired G1/G0 stall, Stage 2 will be ready to perform on
these non-dividing cells.
Protocols: Proximity Growth Inhibition: Contain below, Fixation: Contain below, Staining:
Contain below, Flow: Samples will be run on the Attune flow cytometer, Post-Flow Analysis:
Requires the FCS files from Flow. Dr. Weber has offered the use of Flowjo for this step.
It is anticipated that we will need approximately 15 samples per cell cycle time.
• Step 2: G1/S Phase Synchronization and Calibration
Using excess thymidine, cells will be stalled at the beginning of S-phase. Following release
from this point, cells will be fixed and prepared for flow cytometry at 2 hour intervals. The
intent is to correlate time elapsed from growth cycle stall release to DNA content via PI
intensity signal. Once a clear determination of time required to achieve desired cell growth
of a sample population is known, Stage 2 will be ready to perform.
Protocols: Thymidine Growth Inhibition: Contain below, Fixation: Contain below, Staining:
Contain below, Flow: Samples will be run on the Attune flow cytometer, Post-Flow Analysis:
Requires the FCS files from Flow. Dr. Weber has offered the use of Flowjo for this step.
It is anticipated that we will need approximately 15 samples per cell cycle time.
Total samples required for Stage 1: 150 samples
The following protocol is an outline of how to prepare a 6-well plate for testing in Stage 1.

B.1.3

Protocols: Thymidine Growth Inhibition from (Yoshizawa2014)

In this protocol, HeLa cells are treated with thymidine twice sequentially with an interval
in between the treatments. Highly synchronous cell cycle populations can be obtained with this
method. For tips on the release from the first block and optimization of the protocol for other cells
lines, see Notes 2 and 3.
(Prep Day 1: 4 PM) Cell Preparation and First Thymidine Block (0 to 16 hrs)
• Culture HeLa cells in a 10-cm dish until 2530% confluency is achieved.
• Add thymidine to a final concentration of 2.5 mM and incubate at 37 C for 16 h.
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(Prep Day 2: 8 AM) First Release (16 hrs to 25 hrs)
• Wash cells twice with 3 mL of pre-warmed PBS or serum-free DMEM.
• Add pre-warmed medium with serum and release cells into cell cycle at 37 C for 9 h. Note:
For better synchronization, keep cells warm during the wash and handle only a small number
of dishes at one time (at most 45 dishes).

(Prep Day 2: 5 PM) Second Thymidine Block (25 hrs to 39/41 hrs)
• Add thymidine to a final concentration of 2.5 mM and incubate at 37 C for 1416 h.
(Prep Day 3: 7 AM) Second Release (39/41 hrs to Desired Time Post-Release starting from
Early S-Phase)
• Wash cells twice with 3 mL of pre-warmed PBS or serum-free DMEM.
• Release cells at 37 C as in step 4 and harvest cells at Desired Time Post-Release starting
from Early S-Phase.

Cell Preparation (Treatment: Day 1)
• Synchronize cells to the desired stage of growth.
• Seed 106 HeLa cell/ml in 2 mL of DMEM of 6-well plate. Incubate for 24 h (For monolayers;
no need to incubate for suspension cells).

Fixation (Treatment: Day 2)
• Remove DMEM from each well and rinse wells with 1.5 mL of PBS and discard PBS.
• Harvest the cells by trypsinizing (for monolayers) by adding 0.5 mL trypsin per well and
then incubate for 5 minutes.
• After incubation, add 1 mL of DMEM to each well to de-activate the trypsin.
• Place cell solution ( 1.5 mL) in Eppendorf tube. Centrifuge the cells at 200 x g for 5 minutes
at 4 0C. (If Desired, count the cells to find out total number of cells.)
• Following centrifugation, remove supernant.
• Wash cells by centrifugation (200 x g, 5 min, 4C) in 1 mL PBS in each Eppendorf Tube.
• Remove PBS supernant.
• Resuspend at 2 x 106 cells in 1 ml ICE COLD PBS.
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• Take 9 mL of 70% Ethanol (in a 15 ml polypropylene centrifuge tube) and Vortex gently
while slowly adding dropwise the ICE COLD PBS cell suspension.
• Store at 4C for AT LEAST 2 hours, 12 - 24 hours is best.
(Treatment: Day 2 or Day 3) Staining with Propidium Iodide (PI)
• Centrifuge the tube at 200 x g, 10 min, 4C to pellet the cells.
• Wash cells at least once with COLD PBS. Cells may form a diffuse ring-shaped pellet, so
centrifuge longer ( e.g. 200 x g, 10 min, 4C )
• Resuspend cells in 400 µl of Staining Solution and transfer to FACS tube.
• Incubate at 37C for 15 minutes, cover in aluminum to limit light exposure.
• Acquire data on flow cytometer
FlowJo (Post-Analysis)
Utilize FlowJo software from Dr. Webber to determine percentage of cells in each phase.

Material Preparation
DNAse free RNAse-A
RNAse A comes in a powder form and may not actually be purified. In the case of the experiments performed with Cell Synchronization, the RNAse A needs to be free of DNAse that would
potentially break down chromosomal DNA, and thereby confounding the flow cytometry results.
• Prepare a 10 mg/mL stock solution of RNAse A powder in 10 mM sodium acetate buffer,
pH 5.2.
• Heat to 100C (boiling) for 15 minutes, allow to cool to room temperature.
• Adjust pH to 7.4 using 0.1 volume of 1 M Tris-HCl, pH 7.4.
• Aliquot and store at -20C.
Note: If RNase A is boiled at a neutral pH, precipitation will occur. When boiled at the
lower pH, some precipitation may occur because of protein impurities that are present. When
Sigma tests the activity of RNAse A, a stock solution is prepared in water at 1 mg/ml.
Storage Instructions
• Store at RNase A at 20 C. Stock solutions stored in frozen aliquots remain active for at least
6 months.
• RNase A is a very stable enzyme and solutions have been reported to withstand temperatures
up to 100 C.
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• At 100 C, an RNase A solution is most stable between pH 2.0 and 4.5.9
• A major application for RNase A is the removal of RNA from preparations of plasmid DNA.
For this application, DNase free RNase A is used at a final concentration of 10 (g/ml).10
• Note: RNase A is stable to both heat and detergents. In addition, it adsorbs strongly to glass.
Scrupulous precautions are necessary to ensure RNase A residue does not cause artifacts in
processes requiring intact RNA.

B.1.4

Materials

• DMEM
• PBS
• Trypsin
• Eppendorf Tubes
• ICE COLD PBS
• Triton X-100
• Staining Solution: To 10 ml of 0. 1% (v/v) Triton X-100 (Sigma) in PBS (meaning 10 µl of
Triton X in 10 mL of PBS); Add 2 mg DNAse-free RNAse A (Sigma) and 0.40 ml of 500
µg/ml PI; Store the left over at -20C covering the tube with tin foil.
Stalling and Cell Cycle Characterization
Double Thymidine Block Protocol
1. Tips on the release from the first block: For better synchronization, keep cells warm during
the wash and handle only a small number of dishes at one time (at most 45 dishes or wells).
2. Culture cells in a 6-well plate until 25-30% confluency is achieved on 22mm glass slide with
2mL of DMEM included in each well
3. Add thymidine to a final concentration of 2.5 mM and incubate at 37 C for 16 h.
• Use the following formula to determine the amount of thymidine stock solution to be
added where T(mL) is the amount of thymidine stock solution to be added to Y(mL)
amount of media in the well.
• 0.0025((mg/mL))=(0.100((mg/mL)) * T(mL))/(Y(mL)+ T(mL) )
• Solving for T yields: T(mL)= ((0.0025*Y)/0.0975)
4. Wash cells twice with 0.4 mL of pre-warmed PBS or serum-free DMEM.
5. Add pre-warmed medium with serum and release cells into cell cycle at 37 C for 9 h.
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Table B.3: Phase Injections
Well
Type
1
Negative
2
Block
3
Positive
4-6 Injected Sample

Purpose
No treatment
Double Thymidine Block
Blocked, DNA added
Blocked, DNA, Injected

6. Add thymidine to a final concentration of 2.5 mM as explained in Step (4c) and incubate at
37C for 1416 h.
7. Wash cells twice with 3 mL of pre-warmed PBS or serum-free DMEM.
8. Release cells at 37C as in Step 4
Cell Cycle Characterization
Use the cell cycle staining protocol above to determine the results of the stalling as well
as track the cells as they progress through the cell cycle. Based upon previous research, HeLa
cells released following a double thymidine block will progress through the cycles after the hours
specified: S phase 0-4 hours, Enter G2 phase 5-6 hours, Mitosis 7-8 hours, Re-enter S Phase
14-16 hours. This data may be verified by performing the cell cycle staining procedure at various
time intervals following release from the double thymidine block.
Phase Injection
Variables will be: Voltages 3, 5, 7, 9; Cell Cycle Phase
Plates
• Utilize 4 plates per experiment run
• Repeat each plate with the same sample types as described above, producing approximately
12 samples per experiment run.
• Repeat experiment twice per voltage setting for each cell cycle phase: Phases (4) S, G2, M,
G1/G0; Voltages (4) 3, 5, 7, 9; If two trials of each combination, 32 trials are needed.

B.1.5

Reasons for Experiment Abandonment

In conjunction with an undergraduate researcher, we proposed this work and received an ORCA
grant to pursue the work. At the time, I had just begun my research into using CRISPR-Cas9
plasmids and it was proposed once we had started this work to implement CRISPR into this project,
thereby investigated when in the cell cycle cells are most likely to incorporate exogenous DNA.
The challenge with this project was about a month and a half into it, in conducting a literature search, I discovered that another group was conducting the same research and published
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while we were still in the middle of this project [307]. At that point, it was determined that other
research questions were of value and this project was abandoned.

B.2

Electrostatic Attraction of DNA

An important element of the Lance Array Nanoinjection (LAN) process is described as
electrostatically attracting DNA from solution onto a series of micron-sized lances, most commonly etched from silicon. This step is of particular interest because the relative factors that affect
the amount of DNA that can be accumulated onto the lance array is largely unknown. Recently,
Nick Gregory (Nick2015) demonstrated that using LAN and radio-tagged DNA strands, that approximately 50,000 DNA strands are delivered to each target cell during LAN (using a linearized
plasmid of 5551 bp at 250 ng/mL of injection solution). These findings strongly suggest that LAN
is electrically attracting the DNA onto the lances, however, these findings are not definitive. Because this step is critical to the process of introducing exogenous DNA into the cell, it is imperative
that this area of LAN is explored more completely.

B.2.1

Previous Work

In previous work done with the Single Lance Nanoinjector (SLN) [26], it was shown that
in an attraction period of 5 minutes 46 seconds, that over 32,000 DNA plasmids of 4700 bp was
accumulated onto the single lance (DNA concentration: 1-2µL of 306 ng/µL). In order to get
this outcome, +1.5 VDC was applied to the solution with the understanding that by keeping the
electrical attraction below decomposition voltage that oxidative damage cannot occur to the MEMS
device.
Unfortunately, after having a conversation with Quentin Aten about his testing, it was discovered that the results of the testing making up this paper to be suspect. Dr. Aten could not
replicate the results of this paper following experimentation at Nanoinjection LLC. The problem
with previous experimentation is believed to be a result of a couple factors. First, during voltage
application to an ionic solution, the electrode immediately following the application of a voltage
collected oppositely charged ions. As these ions collect, the current in the solution diminishes
exponentially. Because the current drops off so quickly, the ability to actually pull DNA out of
the ion-rich solution is reduced significantly. Second, the use of voltages above the decomposition voltage results in electrolysis or separation of water into hydrogen and oxygen. This becomes
problematic because the bubble formation on the electrodes causes disruption to potentially accumulating DNA molecules. Therefore, a way needs to be created to construct a barrier between
the electrode and bubble formation events (particularly on the negatively charged electrode) to
diminish this effect.
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B.2.2

Hypothesis:

It is hypothesized that DNA can be attracted from an aqueous solution using current controlled application to a metal electrode using DAPI as an indicator stain for the DNA (at DNA
concentrations appropriate to standard transfection protocols: 250 to 750 ng/mL of injection solution)
• If that is true, it is further hypothesized that the larger the attraction current, the greater the
amount of DNA attraction to the associated electrode.
• If that is true, it is further hypothesized that attraction can occur in a variety of solution types
(particularly biologically relevant solutions) including: PBS and DMEM.
• If that is true, it is further hypothesized that DNA transfer can occur following a successful
attraction event to a new DNA-free solution and quantified.

B.2.3

Methods

Equipment:
• Zeiss Imager A.1 Fluorescence Microscope
• Settings: Exposure time, saturation, linear brightness scaleo
• Light filter: blue
• Image capture: only at imaging times, helps reduce photo-beaching of the DAPI
• DAQ 1: LabView VI measures the current and voltage in time, helps to characterize the
behavior of the voltage as the current is maintained.

DAPI Prep (Adapted from Sigma-Aldrich Counterstaining Protocol)
Main DAPI Supply:
• Take 0.25 mL of H20 and add to the 5 mg DAPI powder inside the provided bottle. Heat
or sonication may be required and make sure that the solution is fully dissolved. (Conc: 20
mg/mL)
• Solution stored in the dark at room temperature or 4C, should be stable for 2 to 3 weeks.
Store all solutions in foil in the fridge, solution only useful for up to 3 weeks.
DAPI Dilution for Sample Testing
• Intermediate DAPI Supply: Take 50 L of Main DAPI Supply (contains 1 mg of DAPI) and
place into a 10 mL conical tube labelled 300 M Intermediate DAPI Supply; Add to the
conical tube 9.5 mL of PBS, shake the tube to mix the DAPI.
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• Sample Testing: Take 600 µL from the Intermediate DAPI Supply and add to each sample
well, which already contains 2 mL of PBS.
Controls
• Negative Control: Test in 2 mL solution (H2O, PBS, and DMEM) with no DAPI or DNA in
solution and monitor appearance without voltage application.
• Positive Control: Test in 2 mL solution (H2O, PBS, and DMEM) with DAPI and no DNA in
solution and monitor appearance with and without current application; Test in 2 mL solution
(H2O, PBS, and DMEM) with no DAPI but with DNA present in solution and monitor
appearance with and without current application.

Test Sample Procedure:
1. Place glass slip into well with the electrodes.
2. Add 2 mL of H20 to treatment sample well.
3. Add DNA to well (250 to 750 ng per mL of injection fluid, 500 to 1500 ng in 2 mL solution,
roughly 5kbp in size): Note: Nano-drop confirm the concentration of the DNA concentration
4. Add DAPI solution as outlined in the DAPI Dilution for Sample Testing: Sample Testing.
5. Set-up DAQ1 to capture voltage, current, and resistance through time.
6. Apply current control and capture images at specific time intervals.
7. Variables to consider: Current Magnitude, Duration of Current Exposure, DNA to DAPI
Concentration by verifying DNA mass added, Fluid Type, Transfer Hypothesis

B.2.4

Reasons for Experiment Abandonment

Many experiment parameters were attempted in regards to electrostatic attraction of DAPI-labelled
DNA onto tungsten tipped micro-manipulator electrodes in PBS solution with no success. Occassionally, it would appear for brief moments that DAPI-stained DNA was collecting on the electrodes. However, these events could not be repeated. After visiting with Dr. Quentin Aten, a
former graduate student from the lab that did similar work in regards to the single lance nanoinjection, it was noted that he too experienced similar problems and had not been able to resolve them.

In short, what appears to be the problem is that when the electrode is placed in the ionic
solution, as soon as a voltage is applied across the electrode, ions are attracted to the electrode and
quickly diminish the voltage potential of the electrode. Without the voltage potential, the DNA in
the solution is not attracted to the electrode.
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In effort to overcome this, I tried reversing the voltage across the electrode to more or
less help remove the collection of ions. This did not work to improve DAPI-DNA collection
results. Furthermore, I also tried simply increasing the voltage across the electrode. This lead to
localized electrophoresis. The resulting bubble formations helped with bulk fluid motion but failed
to improve DAPI-DNA collection on the electrode. Ultimately, this project was dropped from the
research.

B.3

Increasing Lenti-Viral Titers in Phoenix HEK cells using Lance Array Nanoinjection

Virology research often requires the production of high titers of engineered viruses. Typically,
transfection of Phoenix HEK cell lines for lenti-viral production is performed using calciumphosphate (Ca-Pho) transfection, achieving transfection rates of approximately 30%. From the
HEK cells that are successfully transfected, researchers are able to harvest lenti-viruses produced
by these modified HEK cells, where the goal is to have as high as possible viral counts.
In effort to achieve greater transfection rates, it is hypothesized that a non-viral transfection
method called Lance Array Nanoinjection can facilitate better transfection and expression rates
when compared to Ca-Pho in the context of modifying Phoenix HEK cells to producing lentivirus. Specifically, the following hypotheses are proposed in the context of comparing LAN to
Ca-Pho for Phoenix HEK cell transfection:
• LAN can transfect with greater than or equal efficiency as Ca-Pho in terms of GFP expression.
• LAN transfection efficiency will follow an injection-dose response, meaning the more times
the target cells are injected, the greater the transfection rate will be.
• LAN will reach a 10% settling time sooner than Ca-Pho because the injection process can
insert viral particles immediately into the cell whereas Ca-Pho takes a day before transfection
occurs.
• The rate at which GFP expression is measured post-treatment will correlate to the number of
infectious units, meaning the greater the transfection rate with GFP, the greater the number
of infectious units measured.

B.3.1

Reasons for Experiment Abandonment

After a series of Lance Array Nanoinjection (LAN) experiments, it was shown that the
LAN treated cells were dying in massive numbers when transfecting Phoenix HEK cells with
these Lenti-viruses. This was not an expected outcome.
It was hypothesized that the reason for the massive cell death was due to the viral particle
interaction with the HEK cells. With non-aided lenti-viral entry into the cells, part of the proteins
that are required for entry must interact with the host cell membrane. With LAN injections, that
interaction gets by-passed. It is hypothesized that because that interaction does not occur during
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Figure B.1: Fluorescent microscope image of Retinal Pigmented Epithelial cells 1 day post-LAN
with CMV/GFP plasmid

LAN treated experiments, that some capsid proteins remain intact on the Lenti-viral particles and
threaten the target HEK cells. As a last resort effort, the HEK cells induces cell death to prevent
infection.
This hypothesis was not investigated further and remains unknown still. The fact that other
projects were doing well at the time of this project and because this project was outside the scope
of the immediate NSF project, it was abandoned.

B.4

Retinal Pigmented Epithelial Cell Transfection using CMV/GFP Plasmid

One of the experiment types that was tried several times was using Lance Array Nanoinjection
to transfect hard-to-transfect cell lines using plasmids without self-promotional features. This
experiment was one of the most difficult in terms of that scope. Retinal Pigmented Epithelial
(RPE) cells are difficult to transfect with nearly any transfection method available and we sought
to transfect them by inserting a GFP with a CMV promoter.
Initially, our results were promising, showing a fairly high number of transfected cells
(roughly 20%), which was significantly higher than the < 1% results that were reported previously
in the lab. However, repeat experiments could not repeat these results and eventually was discontinued. The reason for failed results is not known.
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Figure B.2: Fluorescent microscope image of Retinal Pigmented Epithelial cells 3 day post-LAN
with CMV/GFP plasmid
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APPENDIX C. ARDUINO CODE USED FOR 3D PRINTED CELL PLATFORM LANCE
ARRAY NANOINJECTIONS

The following code was originally written by Tyler Lewis for Force Injections using a
slower stepper motor (for the entire code see Tyler’s thesis). I modified the initial sections of this
code to operate for most of the injection experimentation completed since the CRISPR-Cas9 GFP
knock-out project (shown below). It operates by causing the stepper motor to vertically travel a
total of 4 mm. The three input delays allow for three different electrical parameters to occur during
this injection process.
Nanoinjection Program
Created by Tyler Lewis Last updated Mar. 6, 2015 by John Sessions
// Distance travel int distance = 4; // Desired travel distance in mm
// Distance at which input 1 turns off double cutoffdistance = 2; // mm
// Input delay times int input1duration = 20000; // ms of constant DC int input2duration
= 20; // ms repel/pulse time int input3duration = 5000; // ms Reverse voltage, withdraw lances
// Pulsed input parameters int pulse = 1; // 0 = no, 1 = yes int periodlength = 2; // period
(ms) of pulse duration
// Time delay between each step // This controls the speed of the motor // (1000 microseconds is the minimum possible) int timedelay = 1200; // microseconds
...
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